0001022079-21-000070.txt : 20210423 0001022079-21-000070.hdr.sgml : 20210423 20210423160221 ACCESSION NUMBER: 0001022079-21-000070 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210423 DATE AS OF CHANGE: 20210423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 21849687 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 10-Q 1 dgx-20210331.htm 10-Q dgx-20210331
000102207912/312021Q1FALSE00010220792021-01-012021-03-31xbrli:shares00010220792021-04-15iso4217:USD00010220792020-01-012020-03-31iso4217:USDxbrli:shares00010220792021-03-3100010220792020-12-3100010220792019-12-3100010220792020-03-310001022079us-gaap:CommonStockMember2020-12-310001022079us-gaap:AdditionalPaidInCapitalMember2020-12-310001022079us-gaap:RetainedEarningsMember2020-12-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001022079us-gaap:TreasuryStockMember2020-12-310001022079us-gaap:NoncontrollingInterestMember2020-12-310001022079us-gaap:RetainedEarningsMember2021-01-012021-03-310001022079us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001022079us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001022079us-gaap:TreasuryStockMember2021-01-012021-03-310001022079us-gaap:CommonStockMember2021-01-012021-03-310001022079us-gaap:CommonStockMember2021-03-310001022079us-gaap:AdditionalPaidInCapitalMember2021-03-310001022079us-gaap:RetainedEarningsMember2021-03-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001022079us-gaap:TreasuryStockMember2021-03-310001022079us-gaap:NoncontrollingInterestMember2021-03-310001022079us-gaap:CommonStockMember2019-12-310001022079us-gaap:AdditionalPaidInCapitalMember2019-12-310001022079us-gaap:RetainedEarningsMember2019-12-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001022079us-gaap:TreasuryStockMember2019-12-310001022079us-gaap:NoncontrollingInterestMember2019-12-310001022079us-gaap:RetainedEarningsMember2020-01-012020-03-310001022079us-gaap:NoncontrollingInterestMember2020-01-012020-03-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001022079us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001022079us-gaap:TreasuryStockMember2020-01-012020-03-310001022079us-gaap:CommonStockMember2020-01-012020-03-310001022079us-gaap:CommonStockMember2020-03-310001022079us-gaap:AdditionalPaidInCapitalMember2020-03-310001022079us-gaap:RetainedEarningsMember2020-03-310001022079us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001022079us-gaap:TreasuryStockMember2020-03-310001022079us-gaap:NoncontrollingInterestMember2020-03-310001022079us-gaap:FairValueMeasurementsRecurringMember2021-03-310001022079us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-03-310001022079us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310001022079us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-03-310001022079us-gaap:FairValueMeasurementsRecurringMember2020-12-310001022079us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001022079us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310001022079us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-31xbrli:pure0001022079dgx:UMassJointVentureMember2015-07-010001022079us-gaap:FairValueInputsLevel3Member2021-01-012021-03-3100010220792020-01-012020-12-310001022079dgx:MidAmericaClinicalLaboratoriesLLCMACLMember2020-12-310001022079us-gaap:CustomerRelationshipsMember2021-01-012021-03-310001022079us-gaap:CustomerRelationshipsMember2021-03-310001022079us-gaap:CustomerRelationshipsMember2020-12-310001022079us-gaap:NoncompeteAgreementsMember2021-01-012021-03-310001022079us-gaap:NoncompeteAgreementsMember2021-03-310001022079us-gaap:NoncompeteAgreementsMember2020-12-310001022079us-gaap:UnpatentedTechnologyMember2021-01-012021-03-310001022079us-gaap:UnpatentedTechnologyMember2021-03-310001022079us-gaap:UnpatentedTechnologyMember2020-12-310001022079us-gaap:OtherIntangibleAssetsMember2021-01-012021-03-310001022079us-gaap:OtherIntangibleAssetsMember2021-03-310001022079us-gaap:OtherIntangibleAssetsMember2020-12-310001022079dgx:TotalAmortizingIntangibleAssetsMember2021-01-012021-03-310001022079dgx:TotalAmortizingIntangibleAssetsMember2021-03-310001022079dgx:TotalAmortizingIntangibleAssetsMember2020-12-310001022079us-gaap:TradeNamesMember2021-03-310001022079us-gaap:TradeNamesMember2020-12-310001022079us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2021-03-310001022079us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2020-12-310001022079us-gaap:CashFlowHedgingMember2020-12-310001022079us-gaap:CashFlowHedgingMember2021-03-310001022079us-gaap:FairValueHedgingMemberus-gaap:LongTermDebtMember2021-03-310001022079us-gaap:FairValueHedgingMemberus-gaap:LongTermDebtMember2020-12-310001022079us-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-03-310001022079us-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-03-310001022079us-gaap:FairValueHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-03-310001022079us-gaap:FairValueHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-03-3100010220792020-04-012020-06-3000010220792020-07-012020-09-3000010220792020-10-012020-12-3100010220792021-03-012021-03-3100010220792021-02-012021-02-280001022079us-gaap:SecuredDebtMemberus-gaap:LetterOfCreditMember2021-03-310001022079us-gaap:SecuredDebtMember2021-03-310001022079us-gaap:LetterOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-03-310001022079dgx:SeniorunsecuredrevolvingcreditfacilityMember2021-03-31dgx:claim00010220792020-10-310001022079dgx:ExcludesgeneralandprofessionalliabilityclaimsMember2021-03-310001022079dgx:ExcludesgeneralandprofessionalliabilityclaimsMember2020-12-310001022079srt:MinimumMemberdgx:DiagnosticInformationServicesBusinessMember2020-01-012020-03-310001022079srt:MinimumMemberdgx:DiagnosticInformationServicesBusinessMember2021-01-012021-03-310001022079dgx:DiagnosticInformationServicesBusinessMember2021-01-012021-03-310001022079dgx:DiagnosticInformationServicesBusinessMember2020-01-012020-03-310001022079us-gaap:AllOtherSegmentsMember2021-01-012021-03-310001022079us-gaap:AllOtherSegmentsMember2020-01-012020-03-310001022079us-gaap:CorporateMember2021-01-012021-03-310001022079us-gaap:CorporateMember2020-01-012020-03-310001022079dgx:RoutineclinicaltestingservicesMember2021-01-012021-03-310001022079dgx:RoutineclinicaltestingservicesMember2020-01-012020-03-310001022079dgx:COVID19TestingServicesMember2021-01-012021-03-310001022079dgx:COVID19TestingServicesMember2020-01-012020-03-310001022079dgx:GenebasedandesoterictestingservicesMember2021-01-012021-03-310001022079dgx:GenebasedandesoterictestingservicesMember2020-01-012020-03-310001022079dgx:AnatomicpathologytestingservicesMember2021-01-012021-03-310001022079dgx:AnatomicpathologytestingservicesMember2020-01-012020-03-310001022079dgx:AllotherservicesMember2021-01-012021-03-310001022079dgx:AllotherservicesMember2020-01-012020-03-310001022079us-gaap:EquityMethodInvesteeMember2021-01-012021-03-310001022079us-gaap:EquityMethodInvesteeMember2020-01-012020-03-310001022079us-gaap:EquityMethodInvesteeMember2021-03-310001022079us-gaap:EquityMethodInvesteeMember2020-12-310001022079us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EquityMethodInvesteeMember2021-01-012021-03-310001022079us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:EquityMethodInvesteeMember2020-01-012020-03-310001022079us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EquityMethodInvesteeMember2021-03-310001022079us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EquityMethodInvesteeMember2020-12-310001022079dgx:HealthcareInsurersMemberdgx:FeeforserviceMemberdgx:DiagnosticInformationServicesBusinessMember2021-01-012021-03-310001022079dgx:HealthcareInsurersMemberdgx:FeeforserviceMemberdgx:DiagnosticInformationServicesBusinessMember2020-01-012020-03-310001022079dgx:HealthcareInsurersMemberdgx:CapitatedMemberdgx:DiagnosticInformationServicesBusinessMember2021-01-012021-03-310001022079dgx:HealthcareInsurersMemberdgx:CapitatedMemberdgx:DiagnosticInformationServicesBusinessMember2020-01-012020-03-310001022079dgx:HealthcareInsurersMemberdgx:DiagnosticInformationServicesBusinessMember2021-01-012021-03-310001022079dgx:HealthcareInsurersMemberdgx:DiagnosticInformationServicesBusinessMember2020-01-012020-03-310001022079dgx:GovernmentPayersMemberdgx:DiagnosticInformationServicesBusinessMember2021-01-012021-03-310001022079dgx:GovernmentPayersMemberdgx:DiagnosticInformationServicesBusinessMember2020-01-012020-03-310001022079dgx:ClientPayersMemberdgx:DiagnosticInformationServicesBusinessMember2021-01-012021-03-310001022079dgx:ClientPayersMemberdgx:DiagnosticInformationServicesBusinessMember2020-01-012020-03-310001022079dgx:PatientsMemberdgx:DiagnosticInformationServicesBusinessMember2021-01-012021-03-310001022079dgx:PatientsMemberdgx:DiagnosticInformationServicesBusinessMember2020-01-012020-03-310001022079dgx:DSBusinessesMemberus-gaap:AllOtherSegmentsMember2021-01-012021-03-310001022079dgx:DSBusinessesMemberus-gaap:AllOtherSegmentsMember2020-01-012020-03-310001022079dgx:HealthcareInsurersMemberdgx:DiagnosticInformationServicesBusinessMember2021-03-310001022079dgx:HealthcareInsurersMemberdgx:DiagnosticInformationServicesBusinessMember2020-12-310001022079dgx:GovernmentPayersMemberdgx:DiagnosticInformationServicesBusinessMember2021-03-310001022079dgx:GovernmentPayersMemberdgx:DiagnosticInformationServicesBusinessMember2020-12-310001022079dgx:ClientPayersMemberdgx:DiagnosticInformationServicesBusinessMember2021-03-310001022079dgx:ClientPayersMemberdgx:DiagnosticInformationServicesBusinessMember2020-12-310001022079dgx:PatientsMemberdgx:DiagnosticInformationServicesBusinessMember2021-03-310001022079dgx:PatientsMemberdgx:DiagnosticInformationServicesBusinessMember2020-12-310001022079dgx:DiagnosticInformationServicesBusinessMember2021-03-310001022079dgx:DiagnosticInformationServicesBusinessMember2020-12-310001022079dgx:DSBusinessesMemberus-gaap:AllOtherSegmentsMember2021-03-310001022079dgx:DSBusinessesMemberus-gaap:AllOtherSegmentsMember2020-12-310001022079dgx:Q2SolutionsMemberus-gaap:SubsequentEventMember2021-04-010001022079srt:ScenarioForecastMemberdgx:Q2SolutionsMember2021-04-012021-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q

(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021

Or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission file number 001-12215

Quest Diagnostics Incorporated
Delaware16-1387862
(State of Incorporation)(I.R.S. Employer Identification Number)
500 Plaza Drive
Secaucus,NJ07094
(973)520-2700
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 Par ValueDGXNew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of April 15, 2021, there were outstanding 130,638,109 shares of the registrant’s common stock, $.01 par value.

PART I - FINANCIAL INFORMATION
 Page
Item 1. Financial Statements (unaudited) 
  
Index to unaudited consolidated financial statements filed as part of this report: 
  
  
  
 
 
  
 
 
  
 
 
  

1
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020
(unaudited)
(in millions, except per share data)

Three Months Ended March 31,
20212020
Net revenues $2,720 $1,822 
Operating costs and expenses and other operating income:  
Cost of services1,626 1,270 
Selling, general and administrative 407 347 
Amortization of intangible assets27 25 
Other operating expense, net— 5 
Total operating costs and expenses, net 2,060 1,647 
Operating income660 175 
Other income (expense):  
Interest expense, net(38)(41)
Other income (expense), net4 (16)
Total non-operating expense, net(34)(57)
Income before income taxes and equity in earnings of equity method investees626 118 
Income tax expense(153)(26)
Equity in earnings of equity method investees, net of taxes17 14 
Net income490 106 
Less: Net income attributable to noncontrolling interests21 7 
Net income attributable to Quest Diagnostics$469 $99 
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic$3.52 $0.74 
Diluted$3.46 $0.73 
Weighted average common shares outstanding:  
Basic133 134 
Diluted135 135 










The accompanying notes are an integral part of these statements.

2
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020
(unaudited)
(in millions)
Three Months Ended March 31,
20212020
Net income$490 $106 
Other comprehensive loss:
Foreign currency translation adjustment(3)(19)
Net change in available-for-sale debt securities, net of taxes(7)— 
Other comprehensive loss(10)(19)
Comprehensive income480 87 
Less: Comprehensive income attributable to noncontrolling interests
21 7 
Comprehensive income attributable to Quest Diagnostics$459 $80 





















The accompanying notes are an integral part of these statements.

3
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2021 AND DECEMBER 31, 2020
(unaudited)
(in millions, except per share data)
March 31,
2021		December 31,
2020
Assets  
Current assets:  
Cash and cash equivalents$1,230 $1,158 
Accounts receivable, net of allowance for credit losses of $29 and $28 as of March 31, 2021 and December 31, 2020, respectively
1,382 1,520 
Inventories223 223 
Prepaid expenses and other current assets164 157 
Total current assets2,999 3,058 
Property, plant and equipment, net1,624 1,627 
Operating lease right-of-use assets600 604 
Goodwill6,870 6,873 
Intangible assets, net1,141 1,167 
Investments in equity method investees527 521 
Other assets170 176 
Total assets$13,931 $14,026 
Liabilities and Stockholders’ Equity  
Current liabilities:  
Accounts payable and accrued expenses$1,559 $1,633 
Current portion of long-term debt2 2 
Current portion of long-term operating lease liabilities146 141 
Total current liabilities1,707 1,776 
Long-term debt4,010 4,013 
Long-term operating lease liabilities503 499 
Other liabilities842 847 
Commitments and contingencies
Redeemable noncontrolling interest79 82 
Stockholders’ equity:  
Quest Diagnostics stockholders’ equity:  
Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2021 and December 31, 2020; 217 shares issued as of both March 31, 2021 and December 31, 2020
2 2 
Additional paid-in capital2,824 2,841 
Retained earnings9,690 9,303 
Accumulated other comprehensive loss(31)(21)
Treasury stock, at cost; 86 and 84 shares as of March 31, 2021 and December 31, 2020, respectively
(5,740)(5,366)
Total Quest Diagnostics stockholders’ equity6,745 6,759 
Noncontrolling interests45 50 
Total stockholders’ equity6,790 6,809 
Total liabilities and stockholders’ equity$13,931 $14,026 


The accompanying notes are an integral part of these statements.

4
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020
(unaudited)
(in millions)
Three Months Ended March 31,
20212020
Cash flows from operating activities:  
Net income$490 $106 
Adjustments to reconcile net income to net cash provided by operating activities:  
Depreciation and amortization101 85 
Provision for credit losses2 7 
Deferred income tax (benefit) provision(17)14 
Stock-based compensation expense18 14 
Other, net(2)(2)
Changes in operating assets and liabilities:  
Accounts receivable138 85 
Accounts payable and accrued expenses(164)(47)
Income taxes payable163 (3)
Other assets and liabilities, net2 (12)
Net cash provided by operating activities731 247 
Cash flows from investing activities:  
Business acquisitions, net of cash acquired— (108)
Capital expenditures(86)(83)
Increase in investments and other assets(7)(15)
Net cash used in investing activities(93)(206)
Cash flows from financing activities:  
Repayments of debt(1)(801)
Purchases of treasury stock(410)(75)
Exercise of stock options17 80 
Employee payroll tax withholdings on stock issued under stock-based compensation plans(21)(13)
Dividends paid(75)(71)
Distributions to noncontrolling interest partners(29)(7)
Other financing activities, net(47)(4)
Net cash used in financing activities(566)(891)
Net change in cash and cash equivalents and restricted cash72 (850)
Cash and cash equivalents and restricted cash, beginning of period1,158 1,192 
Cash and cash equivalents and restricted cash, end of period$1,230 $342 









The accompanying notes are an integral part of these statements.

5
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020
(unaudited)
(in millions)
For the Three Months Ended March 31, 2021Quest Diagnostics Stockholders’ Equity
Shares of
Common Stock
Outstanding		Common
Stock		Additional
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Compre-
hensive Loss		Treasury
Stock, at
Cost		Non-
controlling
Interests		Total
Stock-
holders’
Equity		Redeemable Non-controlling Interest
Balance, December 31, 2020133 $2 $2,841 $9,303 $(21)$(5,366)$50 $6,809 $82 
Net income46917 486 4 
Other comprehensive loss, net of taxes(10)(10)
Dividends declared(82)(82)
Distributions to noncontrolling interest partners
(22)(22)(7)
Issuance of common stock under benefit plans
(29)34 5 
Stock-based compensation expense
18 18 
Exercise of stock options1 3 14 17 
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans
(9)(12)(21)
Purchases of treasury stock
(3)(410)(410)
Balance, March 31, 2021131 $2 $2,824 $9,690 $(31)$(5,740)$45 $6,790 $79 
For the Three Months Ended March 31, 2020Quest Diagnostics Stockholders’ Equity
Shares of
Common Stock
Outstanding		Common
Stock		Additional
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Compre-
hensive Loss		Treasury
Stock, at
Cost		Non-
controlling
Interests		Total
Stock-
holders’
Equity		Redeemable Non-controlling Interest
Balance, December 31, 2019133 $2 $2,722 $8,174 $(39)$(5,218)$46 $5,687 $76 
Net income996 105 1 
Other comprehensive loss, net of taxes(19)(19)
Dividends declared(76)(76)
Distributions to noncontrolling interest partners
(6)(6)(1)
Issuance of common stock under benefit plans
3 3 6 
Stock-based compensation expense
14 14 
Exercise of stock options2 12 68 80 
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans
(13)(13)
Purchases of treasury stock
(1)(75)(75)
Balance, March 31, 2020134 $2 $2,738 $8,197 $(58)$(5,222)$46 $5,703 $76 

The accompanying notes are an integral part of these statements.

6
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(in millions, unless otherwise indicated)

1.    DESCRIPTION OF BUSINESS
    
    Background
    
    Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") empower people to take action to improve health outcomes.  The Company uses its extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.  The Company's diagnostic information services business ("DIS") provides information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The Company provides services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, accountable care organizations ("ACOs"), and direct contract entities ("DCEs"). The Company offers the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers and phlebotomists in physician offices and the Company's connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals. The Company is the world's leading provider of diagnostic information services. The Company provides interpretive consultation with one of the largest medical and scientific staffs in the industry. The Company's Diagnostic Solutions businesses ("DS") are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.

2.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    Basis of Presentation
    
    The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2020 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2020, but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”).

    The accounting policies of the Company are the same as those set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K.

    A novel strain of coronavirus (“COVID-19”) continues to spread and severely impact the economy of the United States and other countries around the world. The Company's testing volume and revenues have been materially impacted by the COVID-19 pandemic, including periods of decline in testing volume in the Company's base business (which excludes COVID-19 testing) compared to historical 2019 levels and periods of significant demand for COVID-19 testing. As a result, operating results for the three months ended March 31, 2021 may not be indicative of the results that may be expected for the full year.

    Use of Estimates
    
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

    Earnings Per Share

    The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings

7
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.

    New Accounting Standards to be Adopted

    In March 2020, the Financial Accounting Standards Board issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The pronouncement is effective immediately and can be applied through December 31, 2022. The adoption of this standard is not expected to have a material impact on the Company’s consolidated results of operations, financial position or cash flows.

3.    EARNINGS PER SHARE

    The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
Three Months Ended March 31,
 20212020
Amounts attributable to Quest Diagnostics’ common stockholders:  
Net income attributable to Quest Diagnostics$469 $99 
Less: Earnings allocated to participating securities1 — 
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted
$468 $99 
Weighted average common shares outstanding – basic133 134 
Effect of dilutive securities:  
Stock options and performance share units2 1 
Weighted average common shares outstanding – diluted135 135 
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic$3.52 $0.74 
Diluted$3.46 $0.73 
    
    The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
Three Months Ended March 31,
20212020
Stock options and performance share units1 2 
    

8
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


4.     BUSINESS ACQUISITIONS

    On March 6, 2021, the Company entered into a definitive agreement to acquire the outreach laboratory services business of Mercy Health, which serves providers and patients in Arkansas, Kansas, Missouri and Oklahoma. The transaction, which is expected to close in mid-2021, remains subject to customary closing conditions.

    For details regarding the Company's 2020 acquisitions, see Note 6 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.    

5.     FAIR VALUE MEASUREMENTS

    Assets and Liabilities Measured at Fair Value on a Recurring Basis

    The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:
Basis of Fair Value Measurements
Quoted Prices in Active Markets for Identical Assets/LiabilitiesSignificant Other Observable InputsSignificant Unobservable Inputs
March 31, 2021TotalLevel 1Level 2Level 3
Assets:    
Trading securities$71 $71 $— $— 
Cash surrender value of life insurance policies52 — 52 — 
Available-for-sale debt securities2 — — 2 
Total$125 $71 $52 $2 
Liabilities:    
Deferred compensation liabilities$132 $— $132 $— 
Redeemable noncontrolling interest$79 $— $— $79 
Basis of Fair Value Measurements
December 31, 2020TotalLevel 1Level 2Level 3
Assets:       
Trading securities$67 $67 $— $— 
Cash surrender value of life insurance policies50 — 50 — 
Available-for-sale debt securities12 — — 12 
Total$129 $67 $50 $12 
Liabilities:    
Deferred compensation liabilities$126 $— $126 $— 
Redeemable noncontrolling interest$82 $— $— $82 
    
    A detailed description regarding the Company's fair value measurements is contained in Note 7 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.    


9
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan. A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities. The trading securities are classified within Level 1 of the fair value hierarchy because the changes in the fair value of these securities are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs. A corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation. The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.

    The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program. A participant's deferrals, together with Company matching credits, are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017.

    The Company's available-for-sale debt securities are measured at fair value based on estimated future cash flows. These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable, including cash flow projections.
        
    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. As of March 31, 2021, the redeemable noncontrolling interest was presented at its fair value. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long term growth rates, and a discount rate commensurate with economic risk.

    During the three months ended March 31, 2021, the Company recorded an $8 million impairment charge, which is included in equity in earnings of equity method investees, net of taxes, in order to adjust to fair value an investment that is accounted for under the equity method of accounting. Following the impairment charge, the carrying value of the investment is not material. The fair value measurement was classified within Level 3 of the fair value hierarchy as it was based on significant inputs that are not observable, including cash flow projections.
    
    The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. As of March 31, 2021 and December 31, 2020, the fair value of the Company’s debt was estimated at $4.4 billion and $4.6 billion, respectively. Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.

6.    GOODWILL AND INTANGIBLE ASSETS

    The changes in goodwill for the three months ended March 31, 2021 and for the year ended December 31, 2020 were as follows:
March 31, 2021December 31, 2020
Balance, beginning of period$6,873 $6,619 
Goodwill acquired during the period— 247 
Adjustments to goodwill(3)7 
Balance, end of period$6,870 $6,873 

10
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    
    Principally all of the Company’s goodwill as of March 31, 2021 and December 31, 2020 was associated with its DIS business.

    For the three months ended March 31, 2021, adjustments to goodwill primarily related to foreign currency translation. For the year ended December 31, 2020, goodwill acquired was principally associated with the acquisitions of Blueprint Genetics Oy, Memorial Hermann Diagnostic Laboratories, the outreach laboratory division of Memorial Hermann Health System; and the remaining 56% interest in Mid America Clinical Laboratories, LLC (see Note 6 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K). For the year ended December 31, 2020, adjustments to goodwill primarily related to foreign currency translation.     

    Intangible assets as of March 31, 2021 and December 31, 2020 consisted of the following:
Weighted
Average
Amortization
Period
(in years)		March 31, 2021December 31, 2020
CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
Amortizing intangible assets:      
Customer-related17$1,481 $(659)$822 $1,479 $(638)$841 
Non-compete agreements93 (2)1 3 (2)1 
Technology15140 (68)72 141 (65)76 
Other5108 (98)10 108 (95)13 
Total171,732 (827)905 1,731 (800)931 
Intangible assets not subject to amortization:     
Trade names 235 — 235 235 — 235 
Other 1 — 1 1 — 1 
Total intangible assets$1,968 $(827)$1,141 $1,967 $(800)$1,167 
    
    The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2021 is as follows:
Year Ending December 31, 
Remainder of 2021$74 
202298 
202396 
202493 
202592 
202686 
Thereafter366 
Total$905 

7.    FINANCIAL INSTRUMENTS

    The Company uses derivative financial instruments to manage its exposure to market risks for changes in interest rates and, from time to time, foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral.

11
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)



    Interest Rate Risk
    
    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements.

    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.

    Interest Rate Derivatives – Cash Flow Hedges

    From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates.

    The total net loss, net of taxes, recognized in accumulated other comprehensive loss, related to the Company's cash flow hedges was $1 million as of both March 31, 2021 and December 31, 2020. The net amount of deferred losses on cash flow hedges that is expected to be reclassified from accumulated other comprehensive loss into interest expense, net within the next twelve months is $1 million.

    Interest Rate Derivatives – Fair Value Hedges

    Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.

    As of March 31, 2021 and December 31, 2020, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:
Hedge Accounting Basis Adjustment (a)
Balance Sheet ClassificationMarch 31, 2021December 31, 2020
Long-term debt$48 $51 

(a) As of both March 31, 2021 and December 31, 2020, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.


12
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
20212020
Other income (expense), netOther income (expense), net
Total for line item in which the effects of fair value hedges are recorded$4 $(16)
Gain (loss) on fair value hedging relationships:
Hedged items (Long-term debt)$— $(69)
Derivatives designated as hedging instruments$— $69 
    
    A detailed description regarding the Company's use of derivative financial instruments is contained in Note 15 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.        

8.    STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
    
    Stockholders' Equity    

    Changes in Accumulated Other Comprehensive Loss by Component

    Comprehensive income (loss) includes:

•Foreign currency translation adjustments;
•Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 7); and
•Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax on available-for-sale debt securities.

    For the three months ended March 31, 2021 and 2020, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material. Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes.

    Dividend Program
    
    During the first quarter of 2021, the Company's Board of Directors declared a quarterly cash dividend of $0.62 per common share. During each of the four quarters of 2020, the Company's Board of Directors declared a quarterly cash dividend of $0.56 per common share.
    
    Share Repurchase Program
    
    In each of February and March 2021, the Company's Board of Directors increased the size of its share repurchase program by $1 billion. As of March 31, 2021, $2.5 billion remained available under the Company’s share repurchase authorization. The share repurchase authorization has no set expiration or termination date.
        
    Share Repurchases

    For the three months ended March 31, 2021, the Company repurchased 3.4 million shares of its common stock for $410 million.


13
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    For the three months ended March 31, 2020, the Company repurchased 0.7 million shares of its common stock for $75 million.

    Shares Reissued from Treasury Stock

    The Company's practice has been to issue shares related to its Employee Stock Purchase Plan ("ESPP") and its stock-based compensation program from shares of its common stock held in treasury or by issuing new shares of its common stock. In January 2021, the Company began to issue shares related to its ESPP and stock-based compensation program solely from common stock held in treasury. For the three months ended March 31, 2021 and 2020, the Company reissued 0.6 million shares and 1.1 million shares, respectively from treasury stock. For details regarding the Company's stock ownership and compensation plans, see Note 17 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.    

    Redeemable Noncontrolling Interest

    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts. Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value. As of March 31, 2021 and December 31, 2020, the redeemable noncontrolling interest was presented at its fair value. For further information regarding the fair value of the redeemable noncontrolling interest, see Note 5.


14
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)



9.    SUPPLEMENTAL CASH FLOW AND OTHER DATA

    Supplemental cash flow and other data for the three months ended March 31, 2021 and 2020 was as follows:
Three Months Ended March 31,
20212020
Depreciation expense$74 $60 
Amortization expense27 25 
Depreciation and amortization expense$101 $85 
Interest expense$(38)$(42)
Interest income— 1 
Interest expense, net$(38)$(41)
Interest paid$32 $48 
Income taxes paid$7 $18 
Accounts payable associated with capital expenditures$30 $11 
Dividends payable$82 $75 
Businesses acquired:  
Fair value of assets acquired$— $131 
Fair value of liabilities assumed— (20)
Fair value of net assets acquired— 111 
Less: Cash acquired— 3 
Business acquisitions, net of cash acquired$— $108 
Leases:
Leased assets obtained in exchange for new operating lease liabilities$36 $32 

    


10.     COMMITMENTS AND CONTINGENCIES

    Letters of Credit

    The Company can issue letters of credit totaling $100 million under its $600 million secured receivables credit facility and $150 million under its $750 million senior unsecured revolving credit facility. For further discussion regarding the Company's secured receivables credit facility and senior unsecured revolving credit facility, see Note 13 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.
    

15
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    In support of its risk management program, to ensure the Company’s performance or payment to third parties, $70 million in letters of credit under the secured receivables credit facility were outstanding as of March 31, 2021. The letters of credit primarily represent collateral for current and future automobile liability and workers’ compensation loss payments.

    Contingent Lease Obligations
    
    The Company remains subject to contingent obligations under certain real estate leases, including leases that were entered into by certain predecessor companies of a subsidiary prior to the Company's acquisition of the subsidiary. No liability has been recorded for any of these potential contingent obligations. For further details, see Note 18 to the audited consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K.

    Certain Legal Matters

    The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues. The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.

401(k) Plan Lawsuit
    
    In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company’s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. In October 2020, the court consolidated the two lawsuits under the caption In re: Quest Diagnostics ERISA Litigation and plaintiffs filed a consolidated amended complaint. The Company plans to vigorously defend this matter and has filed a motion to dismiss the complaint.

AMCA Data Security Incident

    On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (“AMCA”) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019 (the “AMCA Data Security Incident”). Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360. AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019. AMCA’s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included. Neither Optum360’s nor the Company’s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories’ customers was also affected. Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws. The bankruptcy proceeding has been dismissed.

    Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident. The U.S. Judicial Panel on Multidistrict Litigation transferred the cases still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey. In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident. In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss is pending.

    In addition, certain federal and state governmental authorities are investigating, or otherwise seeking information and/or documents from the Company related to the AMCA Data Security Incident and related matters, including the Office for Civil Rights of the U.S. Department of Health and Human Services, Attorneys General offices from numerous states and the District of Columbia, and certain U.S. senators.


16
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    Other Legal Matters

    In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services. These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.

    The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief.

    The federal or state governments may bring claims based on the Company's current practices, which it believes are lawful. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers. The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing practices based on the qui tam provisions of the Civil False Claims Act or other federal and state statutes, regulations or other laws. The Company understands that there may be other pending qui tam claims brought by former employees or other "whistle blowers" as to which the Company cannot determine the extent of any potential liability.

    Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.

    These matters are in different stages. Some of these matters are in their early stages. Matters may involve responding to and cooperating with various government investigations and related subpoenas. As of March 31, 2021, the Company does not believe that material losses related to legal matters are probable.

    Reserves for legal matters totaled $2 million and $1 million as of March 31, 2021 and December 31, 2020, respectively.

    Reserves for General and Professional Liability Claims

    As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims. These suits could involve claims for substantial damages. Any professional liability litigation could also have an adverse impact on the Company's client base and reputation. The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures. The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims. Reserves for such matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience. Such reserves totaled $142 million and $138 million as of March 31, 2021 and December 31, 2020, respectively. Management believes that established reserves and present insurance coverage are sufficient to cover currently estimated exposures.


17
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


11.    BUSINESS SEGMENT INFORMATION

    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, ACOs and DCEs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for greater than 95% of net revenues in 2021 and 2020.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.
        
    As of March 31, 2021, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.

    The following table is a summary of segment information for the three months ended March 31, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended March 31,
20212020
Net revenues:  
DIS business$2,643 $1,744 
All other operating segments77 78 
Total net revenues $2,720 $1,822 
Operating earnings (loss):  
DIS business$712 $205 
All other operating segments9 9 
General corporate activities(61)(39)
Total operating income660 175 
Non-operating expense, net(34)(57)
Income before income taxes and equity in earnings of equity method investees626 118 
Income tax expense(153)(26)
Equity in earnings of equity method investees, net of taxes17 14 
Net income490 106 
Less: Net income attributable to noncontrolling interests21 7 
Net income attributable to Quest Diagnostics$469 $99 

18
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)



    Net revenues by major service were as follows:

Three Months Ended March 31,
20212020
Routine clinical testing services$1,032 $945 
COVID-19 testing services828 24 
Gene-based and esoteric (including advanced diagnostics) testing services653 641 
Anatomic pathology testing services130 134 
All other77 78 
Total net revenues$2,720 $1,822 

12.    RELATED PARTIES

    The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture (see Note 14), a diagnostic information services joint venture, and an investment in a fund that purchases strategic holdings in private companies in the healthcare industry. During the three months ended March 31, 2021 and 2020, the Company recognized net revenues of $5 million and $9 million, respectively, associated with diagnostic information services provided to its equity method investees. As of March 31, 2021 and December 31, 2020, there was $5 million and $3 million, respectively, of accounts receivable from equity method investees related to such services.

    During the three months ended March 31, 2021 and 2020, the Company recognized income of $3 million and $4 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. As of March 31, 2021 and December 31, 2020, there was $1 million and $3 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of both March 31, 2021 and December 31, 2020 included $1 million due to equity method investees.

    During the three months ended March 31, 2021 and 2020, the Company received dividends from its equity method investees of $16 million and $5 million, respectively.

13.    REVENUE RECOGNITION

    DIS

    Net revenues in the Company’s DIS business accounted for over 95% of the Company’s total net revenues for the three months ended March 31, 2021 and 2020 and are primarily comprised of a high volume of relatively low-dollar transactions. The DIS business, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered. The Company estimates the amount of consideration it expects to be entitled to receive from customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions. The portfolios determined using the portfolio approach consist of the following groups of customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.

    For further details regarding revenue recognition in the Company's DIS business, see Note 3 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.

    DS


19
QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED
(unaudited)
(in millions, unless otherwise indicated)


    The Company’s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered.

    The approximate percentage of net revenue by type of customer was as follows:
    
Three Months Ended March 31,
20212020
Healthcare insurers:
Fee-for-service38 %34 %
Capitated2 3 
Total healthcare insurers40 37 
Government payers10 14 
Client payers35 33 
Patients12 12 
Total DIS97 96 
DS3 4 
Net revenues100 %100 %
    
    The approximate percentage of net accounts receivable by type of customer was as follows:
March 31, 2021December 31, 2020
Healthcare Insurers33 %34 %
Government Payers7 6 
Client Payers43 46 
Patients (including coinsurance and deductible responsibilities)13 11 
Total DIS96 97 
DS4 3 
Net accounts receivable100 %100 %

    

14.    SUBSEQUENT EVENTS

    On April 1, 2021, the Company sold its 40% ownership interest in Q2 Solutions® ("Q2 Solutions"), its clinical trials central laboratory services joint venture, to IQVIA Holdings, Inc. ("IQVIA"), its joint venture partner for $760 million in an all-cash transaction. Prior to the transaction, the Company accounted for its minority interest as an equity method investment. As a result of the transaction, the Company expects to record a pre-tax gain during the second quarter of 2021 of approximately $310 million.

    Under a multi-year agreement, the Company will remain the strategic preferred laboratory provider for Q2 Solutions' clients, providing a range of complementary lab testing capabilities to augment Q2 Solutions' core offerings and extend its industry leading suite of services.




20
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

Our Company

    Diagnostic Information Services

    Quest Diagnostics empowers people to take action to improve health outcomes. We use our extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Our diagnostic information services business ("DIS") provides information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. We provide services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, accountable care organizations ("ACOs"), and direct contract entities ("DCEs"). We offer the broadest access in the United States to diagnostic information services through our nationwide network of laboratories, patient service centers and phlebotomists in physician offices and our connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals. We are the world's leading provider of diagnostic information services. We provide interpretive consultation with one of the largest medical and scientific staffs in the industry. Our DIS business makes up greater than 95% of our consolidated net revenues.

    We assess our revenue performance for the DIS business based upon, among other factors, volume (measured by test requisitions) and revenue per requisition.

    Each requisition accompanies patient specimens, indicating the test(s) to be performed and the party to be billed for the test(s).

    Revenue per requisition is impacted by various factors, including, among other items, the impact of fee schedule changes (i.e., unit price), test mix, payer mix, and the number of tests per requisition. Management uses number of requisitions and revenue per requisition data to assist with assessing the growth and performance of the business, including understanding trends affecting number of requisitions, pricing and test mix. Therefore, we believe that information related to changes in these metrics from period to period are useful information for investors as it allows them to assess the performance of the business.

    Diagnostic Solutions

    In our Diagnostic Solutions ("DS") businesses, which represent the balance of our consolidated net revenues, we offer a variety of solutions for life insurers and healthcare organizations and clinicians. We are the leading provider of risk assessment services for the life insurance industry. In addition, we offer healthcare organizations and clinicians robust information technology solutions.

First Quarter Highlights
    
Three Months Ended March 31,
20212020
(dollars in millions, except per share data)
Net revenues$2,720$1,822
DIS revenues$2,643$1,744
Revenue per requisition change20.5%(1.2)%
Requisition volume change25.6%(2.4)%
Organic requisition volume change21.6%(2.7)%
DS revenues$77$78
Net income attributable to Quest Diagnostics$469$99
Diluted earnings per share$3.46$0.73
Net cash provided by operating activities$731$247

    For further discussion of the year-over-year changes for the three months ended March 31, 2021 compared to the three months ended March 31, 2020, see Results of Operations below.


21

Impact of COVID - 19

    As a novel strain of coronavirus (COVID-19) continues to spread and severely impact the economy of the United States and other countries around the world, we are committed to being a part of the coordinated public and private sector response to this unprecedented challenge. We have made substantial investments to expand the amount of COVID-19 testing available to the country and are currently capable of performing approximately 300,000 COVID-19 molecular diagnostic tests per day to aid in the diagnosis of COVID-19 and approximately 350,000 COVID-19 antibody tests per day to aid in the detection of immune response. We have been effectively managing challenges in the global supply chain; and, at this point, we have sufficient supplies to conduct our business.

    During 2020 and the first quarter of 2021, our testing volume and revenues were materially impacted by the COVID-19 pandemic.

    During January and February 2020, we experienced growth in DIS revenues and volume compared to the prior year period. However, in March 2020, we experienced a material decline in testing volume due to the COVID-19 pandemic. During May and June 2020, we began to experience a recovery in base testing volume (which excludes COVID-19 testing), which continued in the second half of 2020 and the first quarter of 2021. For the first quarter of 2021, our base testing volume, excluding volume associated with recent acquisitions and recent agreements associated with our Professional Laboratory Services offerings, was 7.9% below our historical first quarter of 2019 levels. We estimate that the impact of weather negatively impacted the comparison by 1%.

    The decrease in base testing volume was driven by federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home policies, all of which have had, and may continue to have, an impact on our operating results, financial position and cash flows, including base testing volume.

    Beginning during the second quarter of 2020, we experienced growing demand for COVID-19 testing services and we expanded our capacity throughout 2020 in order to satisfy the demand, which has had a significant impact on our testing volumes. Since the fourth quarter of 2020, demand for COVID-19 testing has decreased reflecting an industry-wide trend. Compared to the fourth quarter of 2020, our net revenues associated with COVID-19 testing in the first quarter of 2021 declined by 27.9%. We expect demand for COVID-19 testing to continue to decline throughout 2021 as more people become vaccinated.

    Additionally, our revenue per requisition has been positively impacted by favorable mix, driven in large part by COVID-19 molecular testing. In April 2020 the Centers for Medicare and Medicaid Services ("CMS") announced that it would increase the reimbursement for certain COVID-19 molecular tests making use of high-throughput technologies developed by the private sector that allow for increased testing capacity, faster results, and more effective means of combating the spread of the virus to $100 per test, effective April 14, 2020. Beginning January 1, 2021, Medicare changed the base reimbursement rate for COVID-19 diagnostic tests run on high-throughput technologies to $75 per test with an additional payment of $25 per test if the laboratory (1) completes the test in two calendar days or less and (2) completes the majority of its COVID-19 tests that use high throughput technology in two calendar days or less for all of its patients in the previous month. Certain healthcare insurers have now moved to a similar reimbursement model for COVID-19 molecular tests.

    We believe the COVID-19 pandemic’s impact on our consolidated results of operations, financial position and cash flows will be primarily driven by: the severity and duration of the COVID-19 pandemic; healthcare insurer, government, and client payer reimbursement rates for COVID-19 molecular testing; the COVID-19 pandemic’s impact on the U.S. healthcare system and the U.S. economy; and the timing, scope and effectiveness of federal, state and local governmental responses to the COVID-19 pandemic. We may also be impacted by changes in the severity of the COVID-19 pandemic at different times in the various cities and regions where we operate and offer services. Even after the COVID-19 pandemic has moderated and the business and social distancing restrictions have eased, we may continue to experience similar effects to our businesses, consolidated results of operations, financial position and cash flows. In the longer term, given the many challenges that hospitals will face, we may have more opportunities to partner with hospitals to help achieve their laboratory strategies, and the COVID-19 pandemic may also be a further catalyst for consolidation in the laboratory testing industry.


22
Agreement to Acquire the Outreach Laboratory Services Business of Mercy Health

    On March 6, 2021, we entered into a definitive agreement to acquire the outreach laboratory services business of Mercy Health, which serves providers and patients in Arkansas, Kansas, Missouri and Oklahoma. The transaction, which is expected to close in mid-2021, remains subject to customary closing conditions.

Sale of Ownership Interest in Q2 Solutions® ("Q2 Solutions") to IQVIA Holdings, Inc. ("IQVIA")

    On April 1, 2021, we sold our 40% ownership interest in Q2 Solutions, our clinical trials central laboratory services joint venture, to IQVIA, our joint venture partner for $760 million in an all-cash transaction. Prior to the transaction, we accounted for our minority interest as an equity method investment. As a result of the transaction, we expect to record a pre-tax gain during the second quarter of 2021 of approximately $310 million.

    Under a multi-year agreement, we will remain the strategic preferred laboratory provider for Q2 Solutions' clients, providing a range of complementary lab testing capabilities to augment Q2 Solutions' core offerings and extend its industry leading suite of services.

Medicare Sequestration

    In April 2021, the suspension of Medicare sequestration, which has resulted in a small benefit to us in the form of higher reimbursement rates for diagnostic testing services performed on behalf of Medicare beneficiaries, was extended through the end of 2021.

Invigorate Program
        
    We are engaged in a multi-year program called Invigorate, which is designed to reduce our cost structure and improve our performance. We currently aim annually to deliver savings of approximately 3% of our costs.

    Invigorate has consisted of several flagship programs, with structured plans in each, to drive savings and improve performance across the customer value chain. These flagship programs include: organization excellence; information technology excellence; procurement excellence; field and customer service excellence; lab excellence; and revenue services excellence. In addition to these programs, we have identified key themes to change how we operate including reducing denials and patient price concessions; further digitizing our business; standardization and automation; and optimization initiatives in our lab network and patient service center network. We believe that our efforts to standardize our information technology systems, equipment and data also foster our efforts to strengthen our foundation for growth and support the value creation initiatives of our clinical franchises by enhancing our operational flexibility, empowering and enhancing the customer experience, facilitating the delivery of actionable insights and bolstering our large data platform.

    For the three months ended March 31, 2021, we incurred $15 million of pre-tax charges under our Invigorate program primarily consisting of systems conversion and integration costs, all of which result in cash expenditures. Additional restructuring charges may be incurred in future periods as we identify additional opportunities to achieve further cost savings.
    
Critical Accounting Policies
    
    There have been no significant changes to our critical accounting policies from those disclosed in our 2020 Annual Report on Form 10-K.
    
Impact of New Accounting Standards

    The adoption of new accounting standards, if any, is discussed in Note 2 to the interim unaudited consolidated financial statements.

    The impact of recent accounting pronouncements not yet effective on our consolidated financial statements is also discussed in Note 2 to the interim unaudited consolidated financial statements.

23
Results of Operations    

    The following tables set forth certain results of operations data for the periods presented:
Three Months Ended March 31,
20212020$ Change% Change
(dollars in millions, except per share amounts)
Net revenues:
DIS business $2,643 $1,744 $899 51.5 %
DS businesses77 78 (1)(1.0)
Total net revenues$2,720 $1,822 $898 49.3 %
Operating costs and expenses and other operating income:  
Cost of services$1,626 $1,270 $356 28.0 %
Selling, general and administrative 407 347 60 17.1 
Amortization of intangible assets27 25 2 8.2 
Other operating expense, net— 5 (5)NM
Total operating costs and expenses, net $2,060 $1,647 $413 25.1 %
Operating income$660 $175 $485 277.2 %
Other income (expense):
Interest expense, net$(38)$(41)$3 (8.1)%
Other income (expense), net4 (16)20 NM
Total non-operating expense, net$(34)$(57)$23 NM
Income tax expense$(153)$(26)$(127)493.3 %
Effective income tax rate
24.6 %22.0 %
Equity in earnings of equity method investees, net of taxes$17 $14 $3 22.3 %
Net income attributable to Quest Diagnostics$469 $99 $370 374.3 %
Diluted earnings per common share attributable to Quest Diagnostics' common stockholders$3.46 $0.73 $2.73 375.8 %
NM - Not Meaningful

















24
    The following table sets forth certain results of operations data as a percentage of net revenues for the periods presented:
Three Months Ended March 31,
20212020
Net revenues:
DIS business 97.2 %95.7 %
DS businesses 2.8 4.3 
Total net revenues100.0 %100.0 %
Operating costs and expenses and other operating income:
  
Cost of services59.8 %69.7 %
Selling, general and administrative 14.9 19.0 
Amortization of intangible assets1.0 1.4 
Other operating expense, net— 0.3 
Total operating costs and expenses, net 75.7 %90.4 %
Operating income24.3 %9.6 %
    
    Operating Results
    
    Results for the three months ended March 31, 2021 were affected by certain items that on a net basis reduced diluted earnings per share by $0.30 as follows:

•pre-tax amortization expense of $29 million ($27 million in amortization of intangible assets and $2 million in equity in earnings of equity method investees, net of taxes) or $0.16 per diluted share;
•pre-tax charges of $17 million ($7 million in cost of services and $10 million in selling, general and administrative expenses), or $0.10 per diluted share, primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business;
•pre-tax charges of $4 million in cost of services, or $0.03 per diluted share, representing the impact of certain items resulting from the COVID-19 pandemic including incremental costs incurred primarily to protect the health and safety of our employees and customers; and
•a pre-tax non-cash impairment to the carrying value of an equity method investment of $8 million, or $0.04 per diluted share, recorded in equity in earnings of equity method investees, net of taxes; partially offset by
•excess tax benefits associated with stock-based compensation arrangements of $4 million, or $0.03 per diluted share, recorded in income tax expense.
        
    Results for the three months ended March 31, 2020 were affected by certain items that on a net basis reduced diluted earnings per share by $0.21 as follows:

•pre-tax amortization expense of $28 million ($25 million in amortization of intangible assets and $3 million in equity in earnings of equity method investees, net of taxes) or $0.15 per diluted share;
•pre-tax charges of $16 million ($7 million in cost of services and $9 million in selling, general and administrative expenses), or $0.09 per diluted share, primarily associated with systems conversions and integration incurred in connection with further restructuring and integrating our business; and
•pre-tax charges of $9 million ($1 million in cost of services, $3 million in selling, general and administrative expenses and $5 million in other operating expense, net), or $0.03 per diluted share, representing the impact of certain items resulting from the COVID-19 pandemic including certain asset impairment charges, and incremental costs incurred primarily to protect the health and safety of our employees and customers and to transition certain employees to a remote work environment; partially offset by
•excess tax benefits associated with stock-based compensation arrangements of $8 million, or $0.06 per diluted share, recorded in income tax expense.

    Net Revenues

    Net revenues for the three months ended March 31, 2021 increased by 49.3% compared to the prior year period.

25

    DIS revenues for the three months ended March 31, 2021 increased by 51.5% compared to the prior year period. For the three months ended March 31, 2021:

•Organic revenue and acquisitions contributed approximately 48.5% and 3.0%, respectively, to DIS revenue growth compared to the prior year period. Organic revenue growth was driven by demand for COVID-19 molecular testing and, to a lesser extent, growth in the base business.
•Revenues in the base business (including the impact of recent acquisitions) increased by 5.1% compared to the prior year period, which was negatively impacted in March 2020 as a result of the COVID-19 pandemic. Compared to historical levels in the first quarter of 2019, revenues in the base business, excluding revenue associated with recent acquisitions and recent agreements associated with our Professional Laboratory Services offerings, decreased by 5.5%. We estimate that the impact of weather negatively impacted the comparison by 0.8%.
•DIS volume increased by 25.6% with organic volume and acquisitions contributing approximately 21.6% and 4.0%, respectively. Organic volume growth was driven by demand for COVID-19 molecular testing and, to a lesser extent, growth in the base business.
•Testing volume in the base business (including the impact of recent acquisitions) continued to recover and was up 5.0% compared to the prior year period, which was negatively impacted in March 2020 as a result of the COVID-19 pandemic. Compared to historical levels in the first quarter of 2019, testing volume in the base business, excluding volume associated with recent acquisitions and recent agreements associated with our Professional Laboratory Services offerings, decreased by 7.9%. We estimate that the impact of weather negatively impacted the comparison by 1%.
•Revenue per requisition increased by 20.5% compared to the prior year period primarily due to favorable mix, driven in large part by COVID-19 molecular testing.
    
    Cost of Services

    Cost of services consists principally of costs for obtaining, transporting and testing specimens as well as facility costs used for the delivery of our services.

    For the three months ended March 31, 2021, cost of services increased by $356 million compared to the prior year period. The increase was primarily driven by higher variable expenses related to increased testing volumes as well as test mix and a higher supply cost associated with COVID-19 testing, and, to a lesser extent, additional operating costs associated with our acquisitions.
    
    Selling, General and Administrative Expenses ("SG&A")
    
    SG&A consist principally of the costs associated with our sales and marketing efforts, billing operations, credit loss expense and general management and administrative support as well as administrative facility costs.
    
    SG&A increased by $60 million for the three months ended March 31, 2021, compared to the prior year period, primarily driven by higher variable expenses to support our increase in testing volumes as well as higher costs associated with changes in the value of our deferred compensation obligations.
    
    The change in the value of our deferred compensation obligations is largely offset by gains or losses due to the changes in the value of the associated investments, which are recorded in other income (expense), net. For further details regarding our deferred compensation plans, see Note 17 to the audited consolidated financial statements in our 2020 Annual Report on Form 10-K.
    
    Amortization Expense

    For the three months ended March 31, 2021, amortization expense increased by $2 million compared to the prior year period as a result of recent acquisitions.

    Other operating expense, net
    
    Other operating expense, net includes miscellaneous income and expense items and other charges related to operating activities.    


26
    For the three months ended March 31, 2020, other operating expense, net primarily represents certain costs incurred as a result of the COVID-19 pandemic and resulting impact on the economy including certain asset impairment charges.

    Interest Expense, Net

    Interest expense, net decreased for the three months ended March 31, 2021 compared to the prior year period, primarily driven by lower interest rates due to recent refinancing transactions, including the termination of our interest rate swap agreements in April 2020, which resulted in a deferred gain that is being amortized as a reduction of interest expense, net over the remaining term of the associated debt.

    Other Income (Expense), Net

    Other income (expense), net represents miscellaneous income and expense items related to non-operating activities, such as gains and losses associated with investments and other non-operating assets.

    For the three months ended March 31, 2021, other income (expense), net increased by $20 million compared to the prior year period primarily due to changes in the value of investments in our deferred compensation plans.

    Income Tax Expense

    Income tax expense for the three months ended March 31, 2021 and 2020 was $153 million and $26 million, respectively. The increase in income tax expense for the three months ended March 31, 2021 compared to the prior year period was primarily driven by an increase in income before income taxes and equity in earnings of equity method investees.

    For the three months ended March 31, 2021 and 2020, the effective income tax rate was 24.6% and 22.0%, respectively. The effective income tax rate benefited from $4 million and $8 million of excess tax benefits associated with stock-based compensation arrangements for the three months ended March 31, 2021 and 2020, respectively.

    Equity in Earnings of Equity Method Investees, Net of Taxes

    Equity in earnings of equity method investees, net of taxes increased for the three months ended March 31, 2021 by $3 million compared to the prior year period primarily due to the demand for COVID-19 testing services, partially offset by an $8 million non-cash impairment to the carrying value of an equity method investment.
    

Quantitative and Qualitative Disclosures About Market Risk

    We address our exposure to market risks, principally the risk of changes in interest rates, through a controlled program of risk management that includes the use of derivative financial instruments. We do not hold or issue derivative financial instruments for speculative purposes. We seek to mitigate the variability in cash outflows that result from changes in interest rates by maintaining a balanced mix of fixed-rate and variable-rate debt obligations. In order to achieve this objective, we have historically entered into interest rate swap agreements. Interest rate swap agreements involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements are recognized as an adjustment to interest expense, net. We believe that our exposures to foreign exchange impacts and changes in commodity prices are not material to our consolidated results of operations, financial position or cash flows.
    
    As of March 31, 2021 and December 31, 2020, the fair value of our debt was estimated at approximately $4.4 billion and $4.6 billion, respectively, principally using quoted prices in active markets and yields for the same or similar types of borrowings, taking into account the underlying terms of the debt instruments. As of March 31, 2021 and December 31, 2020, the estimated fair value exceeded the carrying value of the debt by $378 million and $597 million, respectively. A hypothetical 10% increase in interest rates (representing 23 basis points as of March 31, 2021 and 17 basis points as of December 31, 2020) would potentially reduce the estimated fair value of our debt by approximately $94 million and $82 million as of March 31, 2021 and December 31, 2020, respectively.

    Borrowings under our secured receivables credit facility and our senior unsecured revolving credit facility are subject to variable interest rates. Interest on our secured receivables credit facility is based on either commercial paper rates for highly rated issuers, or LIBOR, plus a spread. As of March 31, 2021, interest on our senior unsecured revolving credit facility is based on certain published rates plus an applicable margin based on changes in our public debt ratings and our leverage ratio. As such, our borrowing cost under this credit arrangement is subject to fluctuations in interest rates, our leverage ratio and changes in our

27
public debt ratings. As of March 31, 2021, the borrowing rates under these debt instruments were: for our secured receivables credit facility, commercial paper rates for highly-rated issuers or LIBOR, plus a spread of 0.825% to 0.950%; and for our senior unsecured revolving credit facility, LIBOR plus 1.125%. As of March 31, 2021, there were no borrowings outstanding under either our $600 million secured receivables credit facility or our $750 million senior unsecured revolving credit facility.

    A hypothetical 10% change to the variable rate component of our variable rate indebtedness would not materially change our annual interest expense.     

    For further details regarding our outstanding debt, see Note 13 to the audited consolidated financial statements included in our 2020 Annual Report on Form 10-K. For details regarding our financial instruments and hedging activities, see Note 7 to the interim unaudited consolidated financial statements and Note 15 to the audited consolidated financial statements included in our 2020 Annual Report on Form 10-K.

    Risk Associated with Investment Portfolio

    Our investment portfolio primarily includes equity investments comprised mostly of strategic holdings in privately and publicly held companies. These securities are exposed to price fluctuations and are generally concentrated in the life sciences and healthcare industries. Equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) with readily determinable fair values are measured at fair value with changes in fair value recognized in net income. Equity investments that do not have readily determinable fair values are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes. We regularly evaluate these equity investments to determine if there are any indicators that the investment is impaired. The carrying value of our equity investments that do not have readily determinable fair values was $25 million as of March 31, 2021.
    
    We do not hedge our equity price risk. The impact of an adverse movement in equity prices on our holdings in privately held companies cannot be easily quantified, as our ability to realize returns on investments depends on, among other things, the enterprises’ ability to raise additional capital or derive cash inflows from continuing operations or through liquidity events such as initial public offerings, mergers or private sales.

    In conjunction with the preparation of our March 31, 2021 financial statements, we considered whether the carrying values of our investments were impaired and concluded that no such impairment existed. However, should the impact of the COVID-19 pandemic be worse than currently expected, it is possible that we could incur impairment charges in the future.

Liquidity and Capital Resources
Three Months Ended March 31,Change
20212020
(dollars in millions)
Net cash provided by operating activities$731 $247 $484 
Net cash used in investing activities(93)(206)113 
Net cash used in financing activities(566)(891)325 
Net change in cash and cash equivalents and restricted cash$72 $(850)$922 
    
    Cash and Cash Equivalents

    Cash and cash equivalents consist of cash and highly-liquid short-term investments. Cash and cash equivalents as of March 31, 2021 totaled $1,230 million, compared to $1,158 million as of December 31, 2020.

    As of March 31, 2021, approximately 3% of our $1,230 million of consolidated cash and cash equivalents were held outside of the United States.

    Cash Flows from Operating Activities

    Net cash provided by operating activities for the three months ended March 31, 2021 and 2020 was $731 million and $247 million, respectively. The $484 million increase in net cash provided by operating activities for the three months ended March 31, 2021, compared to the prior year period was primarily a result of:


28
•higher operating income in 2021 as compared to 2020; and, to a lesser extent,
•the timing of movements in our working capital accounts; partially offset by
•higher performance-based compensation payments in 2021 compared to 2020.
    
    Days sales outstanding ("DSO"), a measure of billing and collection efficiency, was 46 days as of both March 31, 2021 and December 31, 2020 and 51 days as of March 31, 2020. The changes in our DSO is partially due to recent fluctuations in our monthly revenue due to the impact of the COVID-19 pandemic.

    Cash Flows from Investing Activities

    Net cash used in investing activities for the three months ended March 31, 2021 and 2020 was $93 million and $206 million, respectively. This $113 million decrease in cash used in investing activities for the three months ended March 31, 2021, compared to the prior year period was primarily a result of a $108 million decrease in net cash paid for business acquisitions.

    Cash Flows from Financing Activities

    Net cash used in financing activities for the three months ended March 31, 2021 and 2020 was $566 million and $891 million, respectively. This $325 million decrease in cash used in financing activities for the three months ended March 31, 2021, compared to the prior year period was primarily a result of:

•an $800 million decrease in repayments of debt; partially offset by
•a $335 million increase in repurchases of our common stock (see "Share Repurchase Program" for further details);
•a $63 million decrease in proceeds from the exercise of stock options, which was a result of a decrease in the volume of stock options exercised compared to the prior year; and
•a $46 million change in bank overdrafts, which are generally settled in cash the following day.

    During the three months ended March 31, 2020, we redeemed in full the outstanding indebtedness under our senior notes due January 2020 and senior notes due March 2020 using proceeds from the issuance, in December 2019, of the 2.95% senior notes due June 2030, along with cash on hand. During both the three months ended March 31, 2021 and 2020, there were no borrowings or repayments under our secured receivables credit facility or senior unsecured revolving credit facility.

    Dividend Program
    
    During the first quarter of 2021, our Board of Directors declared a quarterly cash dividend of $0.62 per common share. During each of the four quarters of 2020, our Board of Directors declared a quarterly cash dividend of $0.56 per common share.
    
    Share Repurchase Program

    In each of February and March 2021, our Board of Directors increased the size of our share repurchase program by $1 billion. As of March 31, 2021, $2.5 billion remained available under our share repurchase authorization. The share repurchase authorization has no set expiration or termination date.

    Share Repurchases

    For the three months ended March 31, 2021, we repurchased 3.4 million shares of our common stock for $410 million.

    For the three months ended March 31, 2020, we repurchased 0.7 million shares of our common stock for $75 million.

    Equity Method Investees

    Our equity method investees primarily consist of our clinical trials central laboratory services joint venture (which we sold our ownership interest in during April 2021), a diagnostic information services joint venture, and an investment in a fund that purchases strategic holdings in private companies in the healthcare industry. Such investees are accounted for under the equity method of accounting. Our investment in equity method investees is less than 5% of our consolidated total assets. Our proportionate share of income before income taxes associated with our equity method investees is less than 5% of our consolidated income before income taxes and equity in earnings of equity method investees. We have no material unconditional obligations or guarantees to, or in support of, our equity method investees and their operations.

29

    In conjunction with the preparation of our March 31, 2021 financial statements, we considered whether the carrying values of our equity method investments were impaired and, during the three months ended March 31, 2021, we recorded an $8 million impairment charge for one of the investments. Should the impact of the COVID-19 pandemic be worse than currently expected, it is possible that we could incur additional impairment charges in the future.

    For further details regarding related party transactions with our equity method investees, see Note 12 to the interim unaudited consolidated financial statements and Note 20 to the audited consolidated financial statements in our 2020 Annual Report on Form 10-K.
    
    Requirements and Capital Resources

    We estimate that we will invest approximately $350 million to $400 million during 2021 for capital expenditures, to support and grow our existing operations, principally related to investments in information technology, laboratory equipment and facilities, including COVID-19 testing equipment and completion of our new multi-year laboratory construction in New Jersey, and investments in our advanced diagnostics and consumer growth strategies.

    During the second quarter of 2021, we expect to launch an accelerated share repurchase in the amount of approximately $1.5 billion.

    Together with the Quest Diagnostics Foundation, during 2020 we launched a multi-year initiative to reduce health disparities in underserved communities, including those impacted by the COVID-19 pandemic. As part of this initiative, we plan to offer testing services and fund a range of initiatives estimated to total more than $100 million aimed at improving access to testing and awareness of the value of diagnostic insights in managing overall health, a significant portion of which will occur in 2021.

    As of March 31, 2021, we had $1.3 billion of borrowing capacity available under our existing credit facilities, including $530 million available under our secured receivables credit facility and $750 million available under our senior unsecured revolving credit facility. There were no borrowings under these credit facilities as of March 31, 2021. In support of our risk management program, to ensure our performance or payment to third parties, $70 million in letters of credit under the secured receivables credit facility were outstanding as of March 31, 2021. The secured receivables credit facility includes a $250 million loan commitment which matures in October 2021, and a $250 million loan commitment and a $100 million letter of credit facility which mature in October 2022. The senior unsecured revolving credit facility matures in March 2023. For further details regarding the credit facilities, see Note 13 to the audited consolidated financial statements in our 2020 Annual Report on Form 10-K.

    Our secured receivables credit facility is subject to customary affirmative and negative covenants, and certain financial covenants with respect to the receivables that comprise the borrowing base and secure the borrowings under the facility. Our senior unsecured revolving credit facility is also subject to certain financial covenants and limitations on indebtedness. As of March 31, 2021, we were in compliance with all such applicable financial covenants.

    We believe that our cash and cash equivalents and cash from operations, together with our borrowing capacity under our credit facilities, will provide sufficient financial flexibility to fund seasonal and other working capital requirements, capital expenditures, debt service requirements and other obligations, cash dividends on common shares, share repurchases and additional growth opportunities for the foreseeable future. However, should it become necessary, we believe that our credit profile should provide us with access to additional financing in order to fund normal business operations, make interest payments, fund growth opportunities and satisfy upcoming debt maturities.


30
Forward-Looking Statements
    
    Some statements and disclosures in this document are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements. Risks and uncertainties that may affect our future results include, but are not limited to, impacts of the COVID-19 pandemic and measures taken in response, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in our most recently filed Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the “Business,” “Risk Factors,” “Cautionary Factors that May Affect Future Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of those reports.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
      
    See Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations."

Item 4.    Controls and Procedures

    Management, including our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended). Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report.

    During the first quarter of 2021, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.




PART II - OTHER INFORMATION

Item 1.    Legal Proceedings
    
    See Note 10 to the interim unaudited consolidated financial statements for information regarding the status of legal proceedings involving the Company.

Item 1A. Risk Factors

    Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2020 includes a discussion of our risk factors. There have been no material changes in the risk factors described in such report.


31
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

    The table below sets forth the information with respect to purchases made by or on behalf of the Company of its common stock during the first quarter of 2021.
ISSUER PURCHASES OF EQUITY SECURITIES
PeriodTotal Number of
Shares
Purchased		Average Price
Paid per Share		Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs
 (in thousands)
January 1, 2021 – January 31, 2021    
Share Repurchase Program (A)— $— — $917,139 
Employee Transactions (B)2,815 $119.45 N/AN/A
February 1, 2021 – February 28, 2021   
Share Repurchase Program (A)1,383,227 $120.11 1,383,227 $1,751,000 
Employee Transactions (B)78,541 $121.25 N/AN/A
March 1, 2021 – March 31, 2021  
Share Repurchase Program (A)1,994,788 $122.57 1,994,788 $2,506,502 
Employee Transactions (B)102,538 $115.42 N/AN/A
Total    
Share Repurchase Program (A)3,378,015 $121.56 3,378,015 $2,506,502 
Employee Transactions (B)183,894 $117.97 N/AN/A

(A)Since the share repurchase program’s inception in May 2003, our Board of Directors has authorized $11 billion of share repurchases of our common stock through March 31, 2021. The share repurchase authorization has no set expiration or termination date. In each of February and March 2021, the Company's Board of Directors increased the size of its share repurchase program by $1 billion.

(B)Includes: (1) shares delivered or attested to in satisfaction of the exercise price and/or tax withholding obligations by holders of stock options (granted under the Company’s Amended and Restated Employee Long-Term Incentive Plan) who exercised options; and (2) shares withheld (under the terms of grants under the Amended and Restated Employee Long-Term Incentive Plan) to offset tax withholding obligations that occur upon the delivery of outstanding common shares underlying restricted stock units and performance share units.




32
Item 6.Exhibits

    Exhibits:
31.1
  
31.2
  
32.1
  
32.2
  
10.1
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
  
101.SCHInline XBRL Taxonomy Extension Schema Document - dgx-20210331.xsd
  
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document - dgx-20210331_cal.xml
  
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document - dgx-20210331_def.xml
  
101.LABInline XBRL Taxonomy Extension Label Linkbase Document - dgx-20210331_lab.xml
  
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document - dgx-20210331_pre.xml
104Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

33
Signatures
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
April 23, 2021
Quest Diagnostics Incorporated
By /s/ Stephen H. Rusckowski
 Stephen H. Rusckowski
 Chairman, Chief Executive Officer
and President
 
  
By/s/ Mark J. Guinan
 Mark J. Guinan
 Executive Vice President and
Chief Financial Officer


34
 EX-10.1 2 dgx03312021ex101.htm EX-10.1 Document
Exhibit 10.1
Quest Diagnostics Incorporated
2021 Equity Award Agreement
This Equity Award Agreement (the “Agreement”) dated as of [Grant Date] (the “Grant Date”) between Quest Diagnostics Incorporated, 500 Plaza Drive, Secaucus, NJ 07094 (the “Company”) and the employee to whom the awards described herein are made (the “Employee”) is subject in all respects to the Company’s Amended and Restated Employee Long-Term Incentive Plan (the “Plan”). All references to “Shares” mean shares of the Company’s Common Stock.
This Agreement and the awards described herein are effective as of the grant date but shall be canceled if the Employee fails to complete, not later than thirty (30) days after such awards are communicated electronically to the Employee, all the steps to accept the Options (as hereinafter defined) electronically at the Fidelity Net Benefits website (https://nb.fidelity.com) (the “Site”), including without limitation acknowledging that the Employee has read all of the documentation provided at the Site and confirming acceptance of the Options.
If the Site does not reflect confirmation of acceptance of the Options by Midnight on the thirtieth (30th) day after the awards described herein are communicated electronically to the Employee, this Agreement, and the awards described herein, shall be cancelled.
The Employee’s taking the necessary steps so that the Site reflects confirmation of acceptance for the Options will suffice to reflect the Employee’s acceptance of the RSUs (as hereinafter defined) and the Performance Shares (as hereinafter defined) as well as the Options. Thus, it is not necessary for the Employee to make a separate electronic acceptance of the RSUs or the Performance Shares.
If you are not a United States citizen or resident as such term is defined by the Internal Revenue Code and you are employed outside the United States, please consult the “International Supplement” attached as Appendix B to this Agreement. The International Supplement amends certain terms and conditions of this Agreement as they apply to individuals employed outside the United States.
AWARDS COVERED BY THIS AGREEMENT
SECTION 1.    Award of Stock Options. The Company hereby awards stock options (each, an “Option”) to the Employee under the Plan. The number of Options awarded to the Employee is indicated at the Site. Each Option entitles the Employee, subject to the terms and conditions of this Agreement and the Plan, to purchase from the Company at the exercise price set forth for the Options at the Site (the “Exercise Price”) one Share (an “Option Share”). The Options shall vest and become exercisable on the terms set forth in Section 4. The Options shall expire on, and no Option Shares may be purchased pursuant to this Agreement after, the
1
Exhibit 10.1
tenth anniversary of the Grant Date (such tenth anniversary is referred to as the “Option Expiration Date”). The Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) may, in its sole discretion, convert any or all of the Options at any time to a stock-settled stock appreciation grant. The Options are not intended to be “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), and this Agreement shall be construed and interpreted in accordance with such intention.
SECTION 2.    Restricted Share Units. The Company hereby awards restricted share units (each, an “RSU”) to the Employee under the Plan. The number of RSUs awarded to the Employee is indicated at the Site. Each RSU corresponds to one Share and constitutes a contingent and unsecured promise of the Company to pay the Employee one Share for each vested RSU, subject to the terms and conditions set forth in the Plan and this Agreement. The RSUs shall vest and convert to Shares on the terms set forth in Section 4. For purposes of this Agreement, an “RSU Share” means a Share delivered upon conversion of an RSU.
SECTION 3.    Performance Shares. Capitalized terms used in this Section 3 without definition have the meanings set forth in Appendix A. The Employee shall be eligible to receive and vest in Shares as provided in this Section 3 and Section 7 based on (a) the number of target performance shares indicated for the Employee at the Site (“Target Performance Shares”) and (b) the Company’s performance during the Performance Period. Performance will be measured as of the end of the performance period that began on January 1, 2021 and will continue through December 31, 2023 (the “Performance Period”). 35% of the Target Performance Shares will be earned based on the annual compounded growth of Base Business Net Revenues (“Base Business Revenue Growth”) during the Performance Period, determined by comparing the Company’s Base Business Net Revenues for the Final Year of the Performance Period (as reported by the Company for the relevant year) with the Company’s Base Business Net Revenues for the Baseline Year (as reported by Company for the year). After the Performance Period, Base Business Revenue Growth will be calculated and the number of Shares to be issued (subject to vesting under Section 7 and withholding of taxes under Section 14) in respect of the Base Business Revenue Growth performance measure shall be based upon the following formula (such Shares, and the Shares determined using the COVID-19 Net Revenue, Average ROIC, and Relative TSR performance measures described below in this Section 3 being “Earned Performance Shares”):
Annual Compounded Base Business Revenue Growth*“Earnings Multiple”* multiplied by 35% of Target Performance Shares = Earned Performance Shares
Greater Than or Equal to %    
Greater Than or Equal to % but Less Than or Equal to %…………………………………...
2 x 35% x Target Performance Shares
1 x 35% x Target Performance Shares
Equal to %0.25 x 35% x Target Performance Shares
Less Than %0 x 35% x Target Performance Shares
*The Earnings Multiple for Base Business Revenue Growth between the percentages designated in the above table will be interpolated.
2
Exhibit 10.1
15% of the Target Performance Shares will be earned based on the Company’s cumulative COVID-19 Net Revenue (as defined in Appendix A) during the Performance Period. After the Performance Period, the COVID-19 Net Revenue will be calculated and the number of Earned Performance Shares to be issued (subject to vesting under Section 7 and withholding of taxes under Section 14) in respect of the COVID-19 Net Revenue performance measure shall be based upon the following formula:
COVID-19 Net Revenue (mm)*“Earnings Multiple”* multiplied by 15% of Target Performance Shares = Earned Performance Shares
Greater Than or Equal to $    
Equal to $…………………………………
2 x 15% x Target Performance Shares
1 x 15% x Target Performance Shares
Equal to $0.25 x 15% x Target Performance Shares
Less Than $0 x 15% x Target Performance Shares
*The Earnings Multiple for COVID-19 Net Revenue between the percentages designated in the above table will be interpolated.
30% of the Target Performance Shares will be earned based on the Company’s Average ROIC (as defined in Appendix A) during the Performance Period. After the Performance Period, the Average ROIC will be calculated and the number of Earned Performance Shares to be issued (subject to vesting under Section 7 and withholding of taxes under Section 14) in respect of the Average ROIC performance measure shall be based upon the following formula:
Average ROIC*“Earnings Multiple”* multiplied by 30% of Target Performance Shares = Earned Performance Shares
Greater Than or Equal to %    
Greater Than or Equal to % but Less Than or Equal to %…………………………...
2 x 30% x Target Performance Shares
1 x 30% x Target Performance Shares
Equal to %0.25 x 30% x Target Performance Shares
Less Than %0 x 30% x Target Performance Shares

*The Earnings Multiple for Average ROIC between the percentages designated in the above table will be interpolated.
The remaining 20% of the Target Performance Shares will be earned based on the Company’s Relative TSR (as defined in Appendix A) during the Performance Period. After the Performance Period, the Relative TSR will be calculated and the number of Earned Performance Shares to be issued (subject to vesting under Section 7 and withholding of taxes under Section 14) in respect of the Relative TSR performance measure shall be based upon the following formula:
Relative TSR*“Earnings Multiple”* multiplied by 20% of Target Performance Shares = Earned Performance Shares
Greater Than or Equal to Percentile2 x 20% x Target Performance Shares
Equal to Percentile1 x 20% x Target Performance Shares
Equal to Percentile0.5 x 20% x Target Performance Shares
Less Than Percentile0 x 20% x Target Performance Shares

3
Exhibit 10.1
*The Earnings Multiple for Relative TSR between the percentiles designated in the above table will be interpolated.
The aggregate number of Earned Performance Shares will equal the sum of the number of Performance Shares earned in respect of the Base Business Revenue Growth performance measure, the number of Performance Shares earned in respect of the COVID-19 Net Revenue performance measure, the number of Earned Performance Shares earned in respect of the Average ROIC performance measure and the number of Earned Performance Shares earned in respect of the Relative TSR performance measure. The maximum number of Earned Performance Shares is 2x the number of Target Performance Shares.
STOCK OPTIONS AND RESTRICTED SHARE UNITS
SECTION 4.    Vesting of Options and RSUs.
(a)    General Vesting Requirements for Options. Except as otherwise provided below, the Options shall vest and become exercisable on the vesting dates set forth below (the “Option Vesting Dates”), provided that the Employee remains in continuous employment with the Company Group (as defined in Section 23) through the applicable Option Vesting Date. Options shall be exercisable only to the extent vested.
Option Vesting Dates            Vesting Percent        Cumulative
First anniversary of Grant Date        33.3%            33.3%
Second anniversary of Grant Date        33.3%            66.6%
Third anniversary of Grant Date        33.4%            100%

4
Exhibit 10.1
(b)    General Vesting Requirements and Conversion Rules for RSUs. Except as otherwise provided in this Agreement, the RSUs shall vest on the vesting dates set forth below (the “RSU Vesting Dates”), provided that the Employee remains in continuous employment with the Company Group through the applicable RSU Vesting Date.
RSU Vesting Dates            Vesting Percent        Cumulative
First anniversary of Grant Date        33.3%            33.3%
Second anniversary of Grant Date        33.3%            66.6%
Third anniversary of Grant Date        33.4%            100%
In the case of an Employee who continues in employment through an RSU Vesting Date, the RSUs that vest on that RSU Vesting Date will convert to Shares as soon as practicable, and in all cases within fourteen (14) days, after the RSU Vesting Date. In the case of RSUs that vest as provided in Sections 4(d) through 4(f), the RSUs, although vested, will not convert to shares by virtue of having vested and instead will convert to Shares as soon as practical, and in all cases within fourteen (14) days, after each remaining RSU Vesting Date following the relevant vesting event specified in Sections 4(d) through 4(f); in other words, the RSUs will convert to Shares as though the Employee’s employment had continued through the applicable RSU Vesting Date. In all cases, upon conversion, the RSU Shares, net of required tax withholding as described in Section 14 below, shall be transferred into the Employee’s account at the Company’s dedicated broker.
(c)    Termination of Employment Generally. If the Employee’s employment terminates for any reason other than those described in Section 4(d) through 4(f) prior to the third anniversary of the Grant Date, any Options and any RSUs that have not vested as of the date of termination of employment (the Employee’s “Termination Date”) will be canceled.
(d)    Death and Disability. If the Employee’s employment terminates due to death or Disability (as defined in Section 23), all Options and all RSUs shall immediately vest.
(e)    Change in Control. If within two years following the date of a Change in Control (as defined in the Plan), the Employee’s employment is terminated by the Company Group (or its successor) without Cause (as defined in Section 23) or the Employee resigns from his or her employment for Good Reason (as defined in Section 23), then all Options and all RSUs shall immediately vest on the Employee’s Termination Date. Notwithstanding the preceding sentence, in the event of a Change in Control in which the Company is not the surviving entity, and the surviving entity or successor to the Company does not agree to assume the Company’s obligations with respect to the Options under this Equity Award Agreement or to grant the Employee a Replacement Award (as defined in Section 23), then all Options and all RSUs shall vest immediately prior to the Change in Control in such a manner that will enable the Employee to participate in the Change in Control with respect to the Shares issuable upon exercise of the Options and conversion of the RSUs on the same basis as other holders of the Company’s outstanding Common Stock.
(f)    Retirement. If on or after the first anniversary of the Grant Date, the Employee’s employment with the Company Group terminates due to Retirement (as defined in
5
Exhibit 10.1
Section 23), the Employee will immediately vest in any Options and any RSUs that have not vested as of the Termination Date.
SECTION 5.    Exercise of Options.     The Employee may exercise Options in accordance with the procedures specified by the Company from time to time. The Exercise Price of Options shall be paid in full with, or in a combination of: (a) cash; (b) Shares that are owned by the Employee and are fully vested and freely transferable by the Employee, duly endorsed or accompanied by stock powers executed in blank; (c) a net share settlement procedure; or (d) through the withholding of Shares subject to the Options. The Company in its discretion may permit the Employee (if the Employee owns Shares that are fully vested and fully transferable by the Employee) to “attest” to his/her ownership of the number of Shares required to pay all or part of the purchase price (and not require delivery of the Shares), in which case the Company will deliver to the Employee the number of Shares to which the Employee is entitled, net of the “attested” Shares. If payment is made in whole or in part with Shares (including through the withholding of Shares subject to Options), the value of such Shares shall be the mean of its high and low prices on the New York Stock Exchange Composite list (or such other stock exchange as shall be the principal public trading market for the Shares) on the day of exercise. No “reload” or other option will be granted by reason of any such exercise.
SECTION 6.    Exercise of Option After Termination of Employment, Death, Disability or Retirement. The provisions covering the exercise of the Options following termination of employment are as follows, provided that in no event may any Options be exercised after the Option Expiration Date:
(a)    Termination in General. If the Employee’s employment terminates for any reason other than those described in Section 6(b) through 6(d), the Options that have vested simultaneously with or before the Employee’s termination of employment may be exercised for ninety (90) days following such termination (but not beyond the Option Expiration Date) and such vested Options shall thereafter expire and cease to be exercisable.
(b)    Death. If the Employee shall die while employed, then any Options that are vested and exercisable (including any Options that become vested and exercisable under Section 4(d)) may be exercised through the fifth anniversary of the date of termination (but not beyond the Option Expiration Date) and shall thereafter expire. If the Employee shall die after termination of employment but while all or any portion of the Options are still exercisable, they shall remain exercisable through the first anniversary of the date of death but not beyond the Option Expiration Date.
(c)    Disability. If the Employee’s employment shall terminate due to Disability, then any Options that are vested and exercisable (including any Options that become vested and exercisable under Section 4(d)), may be exercised through the fifth anniversary of the date of termination (but not beyond the Option Expiration Date) and shall thereafter expire.
(d)    Retirement. If the Employee’s employment with the Company Group terminates due to Retirement, then any Options that are vested and exercisable (including any Options that become vested and exercisable under Section 4(f)) may be exercised through the
6
Exhibit 10.1
fifth anniversary of the date of termination (but not beyond the Option Expiration Date) and shall thereafter expire.
PERFORMANCE SHARES
SECTION 7.    Vesting of Performance Shares.
(a)    Performance Share Vesting Period. Except as otherwise provided in this Agreement, Earned Performance Shares will vest at the end of the vesting period beginning on the Grant Date and continuing through February 18, 2024 (the “Performance Share Vesting Period”), provided that the Employee remains in continuous employment with the Company Group through the end of the Performance Share Vesting Period. Earned Performance Shares, net of required tax withholding as described in Section 14 below, will be transferred into the Employee’s account at the Company’s dedicated broker as soon as practicable after the final calculation of the number of Earned Performance Shares but in any event on or prior to March 15, 2024.
(b)    Change in Control. If a Change in Control occurs prior to the end of the Performance Share Vesting Period then a number of Earned Performance Shares shall be calculated as of the Change in Control and shall be equal to the greater of:
(i)    the number of Earned Performance Shares that would be awarded if the calculation under Section 3 were based on the most recent fiscal year end results of the Company (rather than the Final Year of the Performance Period); and
(ii)    the number of Target Performance Shares.
Such Earned Performance Shares shall not vest solely by virtue of the occurrence of the Change in Control but shall instead remain subject to vesting, and shall be transferred into the Employee’s account at the Company’s dedicated broker, as provided in Section 7(a); provided, however, that in the event of a Change in Control in which the Company is not the surviving entity, and the surviving entity or successor to the Company does not agree to assume the Company’s obligations with respect to the Performance Shares under this Equity Award Agreement or to grant the Employee a Replacement Award, such Earned Performance Shares, net of required tax withholding as described in Section 14 below, will be transferred to the Employee’s account at the Company’s dedicated broker within five business days after the consummation of the Change in Control. If within two years following the date of a Change in Control, the Employee’s employment is terminated by the Company Group (or successor to the Employee’s employer within the Company Group) without Cause or the Employee resigns from his or her employment for Good Reason, the Employee shall immediately vest in the number of Earned Performance Shares calculated in accordance with the first sentence of this Section 7(b), and (to the extent not previously transferred pursuant to the preceding sentence) such Earned Performance Shares, net of required tax withholding as described in Section 14 below, will be transferred to the Employee’s account at the Company’s dedicated broker within five business days after the Employee’s Termination Date. If (and only if) the Company continues to file annual reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as
7
Exhibit 10.1
amended, following the Change in Control, including for the Final Year of the Performance Period, then following the end of the Performance Period, to the extent that the number of Earned Performance Shares calculated pursuant to Section 3 exceeds the number of Earned Performance Shares calculated pursuant to the first sentence of this Section 7(b), the full amount of Earned Performance Shares resulting from the calculation in accordance with Section 3 (net of the number of Earned Performance Shares, if any, previously delivered or withheld for taxes under the preceding two sentences) will be so transferred as provided in Section 7(a). If the Employee terminates employment prior to the Change in Control, the Earned Performance Shares will vest, be pro-rated or be canceled, as applicable, in accordance with Section 7(c).
(c)    Adjustments to Earned Performance Shares and Vesting of Earned Performance Shares on Termination of Employment. The Employee (or, in the case of death, the Employee’s beneficiary or estate) shall be entitled to receive 100% of the Earned Performance Shares calculated pursuant to Section 3, and such Earned Performance Shares shall not be subject to a service-based vesting requirement, if prior to the end of the Performance Share Vesting Period (x) the Employee’s employment terminates by reason of death or Disability or (y) the Employee’s employment terminates by reason of Retirement on or after the first anniversary of the Grant Date. Such Earned Performance Shares (if any) will be delivered as provided in Section 7(a) or Section 7(b), if applicable. The number of Earned Performance Shares calculated pursuant to Section 3 to which the Employee is entitled will be adjusted in the following circumstances:
(i)    Termination of Employment Generally. If the Employee’s employment terminates prior to the end of the Performance Share Vesting Period for any reason other than death, Disability, Retirement on or after the first anniversary of the Grant Date or the circumstances described in Section 7(b) or 7(c)(ii), all of the Target Performance Shares will be canceled and none of the Earned Performance Shares will vest.
(ii)    Involuntary Termination without Cause or Divestiture. If prior to the end of the Performance Share Vesting Period the Employee’s employment is terminated by the Company Group without Cause or as a result of a divestiture and the Employee is employed by the divested or purchasing entity, then, notwithstanding the provision of Section 7(c)(i), the Employee shall vest in the number of Earned Performance Shares determined by multiplying the Earned Performance Shares by a fraction (A) the numerator of which is the number of full months that the Employee was employed by the Company Group during the Performance Share Vesting Period and (B) the denominator of which is the number of months in the Performance Share Vesting Period; and the balance of the Earned Performance Shares will be canceled.
TERMS AND CONDITIONS APPLICABLE TO ALL AWARDS
SECTION 8.    Cancellation. The Employee acknowledges and agrees that, in consideration for the Employee’s being granted the award covered by this Agreement, the Employee shall abide by the terms and conditions of the restrictive covenant agreement attached hereto as Appendix C (the “Restrictive Covenant Agreement”), which terms and conditions are
8
Exhibit 10.1
incorporated herein by reference. Notwithstanding anything to the contrary contained herein, this Agreement shall expire and be canceled, the Employee will not vest in any additional Options, the Employee may not exercise any Options, whether or not vested, and all RSUs, RSU Shares, Target Performance Shares (whether or not vested or earned) and Earned Performance Shares shall be canceled if:
(a)    the Employee shall cause the Company or any other member of the Company Group to suffer financial harm or damage to its reputation (either before or after termination of employment) through (x) dishonesty, (y) violation of law in the course of the Employee’s employment or violation of the Company’s Corporate Compliance Manual and compliance bulletins or other written policies or (z) material deviation from the duties owed the Company Group by the Employee; or
(b)    the Employee is subject to the Executive Share Ownership Policy, as such policy may be amended from time to time (the “Ownership Policy”), and the Employee makes any false attestation under the Ownership Policy; or
(c)    the Employee violates the terms of the Restrictive Covenant Agreement or any other confidentiality, non-solicit or non-compete obligation, or any other restrictive covenant set forth in any agreement between the Employee and the Company or any other member of the Company Group, or otherwise pursuant to any written policy of the Company or any other member of the Company Group (each, a “Restrictive Covenant”).
The Company may require the Employee to provide a written certification or other evidence, from time to time in the Company’s sole discretion, to confirm that no cancellation event identified in clauses (a), (b) or (c) above has occurred, including upon or following a termination of employment for any reason and/or during a specified period of time prior to the exercise of any Options or the scheduled delivery of any Option Shares, RSU Shares or Earned Performance Shares. If the Employee fails to provide any required certification or other evidence by the specified deadline, the Company shall have the right to cancel the Employee’s awards and/or, as discussed in the next paragraph, to cause the exercise of any Option and the delivery of any Option Shares, RSU Shares or Earned Performance Shares under this Agreement to be rescinded (and if the Employee has previously sold the Shares issued pursuant to this Agreement, the Employee would be required to pay back to the Company the pre-tax proceeds received from the sale of such Shares).
The Employee understands that the cancellation of any awards or rights under this Agreement is only one of the remedies that potentially may be asserted against the Employee for injuries or damages sustained by the Company or any other member of the Company Group as a result of any action described in this Section 8 or a violation of any Restrictive Covenant. Such cancellation shall be in addition to any equitable and legal rights the Company or any other member of the Company Group has or may have and shall not constitute a release of any claim that the Company or any other member of the Company Group may have for damages, past, present, or future. In addition, a breach by the Employee of any provisions of any Restrictive Covenant that occurs after any exercise of any Option or delivery of Shares pursuant to this Agreement (including any breach occurring after termination of employment) shall cause the
9
Exhibit 10.1
exercise of the Option and the delivery of any Option Shares, RSU Shares or Earned Performance Shares under this Agreement to be rescinded (and if the Employee has previously sold the Shares issued pursuant to this Agreement, the Employee would be required to pay back to the Company the pre-tax proceeds received from the sale of such Shares).
SECTION 9.    Executive Share Ownership Policy.
(a)    Employees Subject to Ownership Policy. In consideration of the grant of the awards under this Agreement, the Employee agrees that, if the Employee is or becomes subject to the Ownership Policy, the Options and all Option Shares, the RSUs and all RSU Shares, the Target Performance Shares and all Earned Performance Shares shall be subject to cancellation pursuant to Section (8)(b) of this Agreement and all Options, Option Shares, RSUs, RSU Shares, Target Performance Shares, Earned Performance Shares and shares of restricted stock granted to the Employee by the Company prior to the date hereof (the “Prior Awards”) shall be subject to cancellation pursuant to Section 8(b) of this Agreement (for false attestation under the Ownership Policy), the Shares obtained on exercise of such Prior Awards after the date hereof shall be subject to the Ownership Policy pursuant to Section 9(b) of this Agreement and the terms of Sections 8 and 9(b) hereof are made a part of the terms of each of the Prior Awards.
(b)    Shares Subject to Ownership Policy. If the Employee is subject to the Ownership Policy, any Shares issued under this Agreement or pursuant to any Prior Award (in each case net of tax withholdings) are subject to such Policy. The Employee hereby acknowledges and agrees that the investment risk associated with the retention of any Shares, whether pursuant to the Ownership Policy or otherwise, is the sole responsibility of the Employee and the Employee hereby holds the Company and each other member of the Company Group harmless against any claim of loss related to the retention of the Shares.
SECTION 10.    Non-Transferability; Voting Rights and Dividends.
(a)    Non-Transferability. The awards and rights under this Agreement shall not be transferable other than by will or the laws of descent and distribution. The Options may be exercised during the lifetime of the Employee only by the Employee except in the case of the Employee’s Disability, in which case the Options may be exercised by the Employee’s legal representative.
(b)    Voting and Dividend Rights. The Employee will not have any voting, dividend or other rights as a stockholder with respect to any Option Shares, RSUs, RSU Shares, Target Performance Shares or Earned Performance Shares prior to the date on which he/she is recorded as the holder of such Option Shares, RSU Shares or Earned Performance Shares on the records of the Company; provided, however, that until RSUs convert to Shares, if the Company declares and pays a regular or ordinary dividend on its Common Stock, the Employee will be paid a dividend equivalent for vested and unvested RSUs, but no dividend equivalents will be paid on any RSUs that are canceled. The Employee understands that the Option Shares will not be issued to the Employee until after (and to the extent that) Options are exercised, that Shares will not be issued to the Employee in respect of RSUs until after (and to the extent that) RSUs convert to Shares and that, except as provided in Section 7(b), Earned Performance Shares will
10
Exhibit 10.1
not be issued to the Employee until after the final calculation of the Earnings Multiple as contemplated by Section 3 and any adjustment under Section 7, it being understood that such issuance shall occur in any event on or prior to March 15, 2024. The Employee further understands that all deliveries of Shares under this Agreement shall be net of required tax withholding as described in Section 14 below. Until Shares have been delivered to or on behalf of the Employee in respect of any RSUs or Earned Performance Shares, the Employee shall have only the rights of a general unsecured creditor.
(c)    Assignment. Until Shares are transferred to the Employee’s account at the Company’s dedicated broker or the Employee otherwise receives possession of any such Shares, the Employee shall have no right to sell, assign, transfer, pledge or otherwise encumber Shares in any manner. Any purported attempt to sell, assign, transfer, pledge or otherwise encumber any award under this Agreement will be void and shall result in the cancellation of such award. Unless otherwise provided at the time of such transfer or delivery to the Employee of any Shares issued in respect of vested RSUs or Earned Performance Shares or Shares issued upon full or partial exercise of the Options, upon such transfer or delivery to the Employee the Shares will not be subject to any restrictions on transfer other than those that may arise under the securities laws or the Company’s policies, but the Shares shall remain subject to cancellation as provided in Section 8.
SECTION 11.    Consideration. In consideration for the awards under this Agreement, the Employee hereby agrees to be bound by the Restrictive Covenant Agreement and all other Restrictive Covenants applicable to the Employee.
SECTION 12.    Clawback. By accepting the awards under this Agreement the Employee agrees that all awards hereunder, and any other awards granted to the Employee under the Plan or any other equity or cash incentive plan of the Company (whether before or after the date of this Agreement), shall be subject to cancellation and recoupment by the Company, and shall be repaid by the Employee to the Company, to the extent required by law, regulation or listing requirement, or as determined in accordance with any Company incentive compensation recoupment policy, in each case, as in effect from time to time.
SECTION 13.    The Plan. The Plan is incorporated herein by reference. The Employee acknowledges that he/she has read the terms of the Plan and that those terms shall govern in the event of any conflict with the terms of this Agreement.
SECTION 14.    Taxes. The partial or full exercise of any Option, the transfer of Shares upon conversion of any vested RSUs and the delivery of any Earned Performance Shares under this Agreement will result in the Employee’s recognition of income for U.S. federal income tax purposes and shall be subject to tax and tax withholdings as appropriate. The Company or any other member of the Company Group that employs the Employee may make such provisions and take such steps as it may deem necessary or appropriate for the withholding of all federal, state, local and other taxes required or permitted by law to be withheld with respect to the exercise of any Options. On the delivery of Shares upon conversion of any RSUs and upon payment of any Earned Performance Shares, the Company will reduce the number of Shares to be delivered to the Employee by the amount of the taxes due (with the Shares valued at
11
Exhibit 10.1
the mean of its high and low prices on the New York Stock Exchange Composite list (or such other stock exchange as shall be the principal public trading market for the Shares) on the date that the Shares are valued for purposes of reporting compensation for Federal income tax purposes). The Company or any other member of the Company Group that employs the Employee shall have the authority to make arrangements for payment of the Employee’s share of any employment/payroll taxes (including Federal Insurance Contributions Act taxes), whether imposition of such taxes occurs upon exercise of Options, conversion of RSUs, transfer of Earned Performance Shares or at some other time. In particular, the Employee authorizes his or her employer to withhold such taxes from any payroll or other payment or compensation owed to the Employee, subject to the limitations imposed under Section 409A of the Code.
SECTION 15    Consent Requirement. If the Company shall at any time determine that any consent (as hereinafter defined) is necessary or desirable as a condition of, or in connection with, the granting of the Options, the issuance or purchase of Shares or other rights hereunder, or the taking of any other action hereunder (a “Plan Action”), then no such Plan Action shall be taken, in whole or in part, unless and until such consent shall have been effected or obtained to the full satisfaction of the Company. The term “consent” as used herein with respect to any action referred to in this Section 15 means (a) any and all listings, registrations or qualifications in respect thereof upon any securities exchange or under any federal, state or local law, rule or regulation, (b) any and all written agreements and representations by the Employee with respect to the disposition of Shares, or with respect to any other matter, which the Company shall deem necessary or desirable to comply with the terms of any such listing, registration or qualification or to obtain an exemption from the requirement that any such listing, qualification or registration be made, (c) any and all consents, clearances and approvals in respect of a Plan Action by any governmental or other regulatory bodies, and (d) any and all consents or authorizations required to comply with, or required to be obtained under, applicable local law or otherwise required by the Company. Nothing herein shall require the Company to list, register or qualify the Shares on any securities exchange.
SECTION 16.    Invalidity and Enforcement. If any provision of this Agreement is deemed invalid or unenforceable, either in whole or in part, this Agreement shall be deemed amended to delete or to modify, as set forth in this Section, the offending provision or provisions and to alter the bounds of this Agreement in order to render it valid and enforceable. The Company and the Employee specifically request that any court having jurisdiction over any dispute relating to this Agreement modify, if possible, any offending provision so that such provision will be enforceable to the maximum extent permitted by law.
SECTION 17.    No Entitlements. This Agreement is not an employment agreement, and nothing in this Agreement or the Plan shall alter an Employee’s status as an “at-will” employee of the Company Group subject to the rights (if any) that the Employee may have under any employment agreement existing between any member of the Company Group and the Employee.
SECTION 18.    Enforcement by Successors and Assigns. The Company and any of its successors or assignees may enforce the Company’s rights under this Agreement.
12
Exhibit 10.1
SECTION 19.    Entire Agreement. Other than with respect to any Restrictive Covenant and the Ownership Policy, this Agreement constitutes the entire agreement between the Company and the Employee regarding the Options, the RSUs and the Performance Shares. No modification of this Agreement will have any force or effect unless such modification is in writing, signed by the Chief Executive Officer (or by the Senior Vice President, Chief Human Resources Officer or successor officer) of the Company and the Employee, and expressly indicates an intent to modify this Agreement.
SECTION 20.    Interpretation. Any dispute, disagreement or matter of interpretation which shall arise under the Agreement shall be finally determined by the Compensation Committee in its absolute discretion.
SECTION 21.    Governing Law. This Agreement and all rights hereunder shall be governed by, and construed and interpreted in accordance with, the laws of the state of New York applicable to contracts made and to be performed entirely within such state (without reference to its principles of conflicts of law). Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of any New York state court or federal court of the United States of America sitting in New York City, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in any such New York state court or, to the extent permitted by law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Each of the parties hereto irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in state or federal court in New York City. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.
SECTION 22.    Section 409A. It is the intention and understanding of the parties that the RSUs are either exempt from or comply with the provisions of Section 409A of the Code, and that none of the Options or the Performance Shares provide for a deferral of compensation subject to Section 409A of the Code. This Agreement shall be interpreted and administered to give effect to such intention and understanding and to avoid the imposition on the Employee of any tax, interest or penalty under Section 409A of the Code in respect of any Options, RSUs or Performance Shares. Notwithstanding any other provision of this Agreement, the Employee’s consent shall not be required for any amendment to this Agreement which, in the reasonable, good faith judgment of the Company, is necessary or appropriate to avoid the imposition on the Employee of any tax, interest or penalty under Section 409A of the Code.
SECTION 23.    Defined Terms. As used in this Equity Award Agreement, the following terms have the meanings indicated below:
13
Exhibit 10.1
(a)    Cause. “Cause” means
(i)    as to any Employee who is a party to an employment agreement with the Company or any other member of the Company Group which contains a definition of “cause,” the definition set forth in such employment agreement;
(ii)    as to any Employee who is not a party to such an employment agreement but who is eligible to receive severance under a severance plan of the Company or any other member of the Company Group (other than the Quest Diagnostics Incorporated Severance Pay Plan) which contains a definition of “cause”, the definition set forth in such severance plan; and
(iii)    as to any other Employee:
(A)    repeated failure or refusal to perform duties and responsibilities of his or her job as required by the Employee’s employer (other than any such failure resulting from the Employee’s incapacity due to physical or mental illness);
(B)    violation of any fiduciary duty or duty of loyalty owed to the Company or any other member of the Company Group, including without limitation any acts of theft or dishonesty;
(C)    conduct or misconduct that is or threatens to be injurious to the Company or any other member of the Company Group or that harms or threatens to harm the reputation or financial position of the Company or any other member of the Company Group;
(D)    the commission of conduct that meets the definition of any felony under state or federal law, or conviction of, or plea of nolo contendere to, any other criminal charge that is or threatens to be injurious to the Company or any member of the Company Group;
(E)    willful conduct that violates the Company’s Corporate Compliance Manual, compliance bulletins or other written policies;
(F)    (x) obstructing or impeding, (y) endeavoring to influence, obstruct or impede or (z) failing to cooperate with a Company investigation, whether or not related to the Employee’s employment, or the willful destruction of or willful failure to preserve documents or other material known to be relevant to any such investigation;
(G)    being found liable in any Securities and Exchange Commission or other civil or criminal securities law action; or
14
Exhibit 10.1
(H)    other egregious conduct that has or could have a serious and detrimental impact on the Company or any other member of the Company Group.
(b)    Company Group. The “Company Group” means (i) the Company, (ii) any company or other entity in which the Company owns at least a 50% interest within the meaning of Section 424(f) of the Code, and (iii) any company or other entity in which the Company owns at least a 20% interest within the meaning of Section 424(f) of the Code and which the Administrator has designated as a member of the Company Group for purposes of awards under the Plan. References to employment by or with the Company Group shall be understood to refer to employment by or with the Company or any other member of the Company Group.
(c)    Disability. “Disability” means permanent and total disability as determined under the Company’s long-term disability program for employees then in effect.
(d)    Good Reason. “Good Reason” means:
(i)    as to any Employee who is a party to an employment agreement with the Company or any other member of the Company Group which contains a definition of “good reason,” the definition set forth in such employment agreement;
(ii)    as to any Employee who is not a party to such an employment agreement but who is eligible to receive severance under a severance plan of the Company or any member of the Company Group which contains a definition of “good reason,” the definition set forth in such severance plan; and
(iii)    as to any other Employee, the termination of the Employee’s employment by the Employee after one of the following events, provided that the Employee’s termination of employment occurs within sixty (60) days after the occurrence of any such event:
(A)    any material change in the duties, responsibilities or status (including reporting responsibilities) of the Employee that is inconsistent in any material and adverse respect with the Employee’s position(s), duties, responsibilities or authority with his or her employer immediately prior to such Change in Control (including any material and adverse diminution of such duties or responsibilities); provided, however, that Good Reason shall not be deemed to occur upon a change in duties, responsibilities (other than reporting responsibilities) or status that is solely and directly a result of the Company no longer being a publicly traded entity and does not involve any other event set forth in this paragraph (d);
(B)    a material reduction in the Employee’s aggregate rate of annual base salary, annual bonus opportunity and equity incentive
15
Exhibit 10.1
compensation target opportunity (including any material and adverse change in the formula for such targets) as in effect immediately prior to such Change in Control;
(C)    the Employee’s employer requiring the Employee to be based at any office or location more than fifty (50) miles from the office where the Employee is located at the time of the Change in Control and as a result causing the Employee’s commute from his residence at the time of the Change in Control to the new location to increase by more than fifty (50) miles; or
(D)    a material reduction in the Employee’s retirement, welfare, perquisite (if any) and other benefits taken as a whole, unless the Employee is permitted to participate in other plans providing the Employee with materially equivalent benefits in the aggregate (at materially equivalent or lower cost with respect to welfare benefit plans);
provided, however, that an event described in (A) through (D) above shall permit an Employee to terminate his or her employment for Good Reason only if written notice of such event has been provided by the Employee to his or her employer and the employer failed to cure such action within thirty (30) days following receipt of such notice.
(e)    Replacement Award. “Replacement Award” means an equity award that is made by the surviving entity in a Change in Control in substitution for Options, RSUs or Performance Shares covered by this Equity Award Agreement and that, in the sole judgment of the Compensation Committee, affords the Employee economic opportunity and protections in the event of termination of employment that are at least as favorable to the Employee in the aggregate as the economic opportunity and protections afforded by the terms of the Options, RSUs or Performance Shares, as the case may be, set forth in this Equity Award Agreement.
(f)    Retirement. “Retirement” means the voluntary cessation of employment by the Employee upon the attainment of age sixty (60) and the completion of not less than five (5) completed years of service with the Company or any other member of the Company Group; provided, however, that there is no basis for the Company or any member of the Company Group to terminate the employment of the Employee for Cause at the time of the Employee’s voluntary cessation of employment.
SECTION 24.    Leave of Absence and Transfer.
(a)    Leave of Absence. Unless the Administrator expressly provides otherwise, the Employee’s employment with the Company Group will be deemed to have terminated when the Employee is no longer employed by or in a service relationship with the Company or another member of the Company Group (including by reason of a member of the Company Group ceasing to be such a member); provided, however, that the Employee’s employment will not be deemed to have terminated during a bona fide leave of absence approved by the Employee’s direct employer for medical, personal, educational and/or other permissible
16
Exhibit 10.1
purposes pursuant to policies of the Company Group as in effect from time to time if such absence does not exceed six months or, if longer, so long as the Participant retains a right by statute or by contract to return to employment or other service relationship with the Company Group. The Employee’s leave of absence shall be considered “bona fide” only if there is a reasonable expectation that the Employee will return to perform services for the employer.
(b)    Transfers. If the Employee shall be transferred from the Company to another member of the Company Group or vice versa or from one member of the Company Group to another, the Employee’s employment shall not be deemed to have terminated for purposes of this Equity Award Agreement. If, while the Employee is employed by a member of the Company Group, such entity shall cease to be a member of the Company Group (whether by virtue of a sale, spin-off or other disposition or otherwise) and the Employee is not thereupon transferred to and employed by the Company or another member of the Company Group, then the Employee’s employment will be treated as a termination due to a divestiture on the date that the Employee’s employer ceases to be a member of the Company Group, and the provisions of Section 7(c)(ii) (Performance Shares) shall govern, as applicable.
SECTION 25.    Acknowledgements. By accepting this Equity Award Agreement, the Employee agrees that he/she has received and reviewed a copy of:
(a)    the Prospectus (link to Prospectus) relating to the Company’s Employee Equity Participation Program;
(b)    the Quest Diagnostics Incorporated 2020 Annual Report on Form 10-K (link to 2020 Annual Report);
(c)    the Company’s Policy for Purchasing and Selling Securities (the “Policy”) (link to Trading Policy). The Employee further agrees to fully comply with the terms of the Policy; and
(d)    the Eligibility Policy.

17
Exhibit 10.1
Appendix A
Quest Diagnostics Incorporated
Performance Shares Award Terms
2021 – 2023 Performance Period

Base Business Net Revenues – The net revenues of the Company’s business excluding COVID-19 revenues.
Base Business Net Revenues for the Baseline Year – The Company’s net revenues during the Baseline Year were $6,714.5 million.
Baseline Year – 2020.
COVID-19 Net Revenue: – The Company’s net revenues during the Performance Period that are related to the Company’s COVID-19 testing products and services, including, without limitation, revenues related to COVID-19 testing, including Nuclear Acid Amplification (including PCR), serology, antigen, viral sequencing, genotyping and other immunological testing solutions.
Final Year – The Company’s Fiscal Year ended December 31, 2023.
Performance Period – January 1, 2021 through December 31, 2023.
ROIC – NOPAT/Invested Capital.
NOPAT – (Income from continuing operations – net income attributable to non-controlling interests) + (gross interest expense x (1 – statutory tax rate)).
Invested Capital – Average total Quest Diagnostics stockholders equity + average total debt.
Average ROIC – Average of the Annual Average ROIC for each year in the Performance Period.
Annual Average ROIC – For a given year within the Performance Period, NOPAT/Invested Capital.
Peer Index – The companies listed in the S&P 500 Health Care Industry Index at the start of the Performance Period. The Compensation Committee may, in its sole discretion, adjust the Peer Index in the event of: (i) the merger of two members of the Peer Index; (ii) the acquisition of a member of the Peer Index by another member of the Peer Index; (iii) the acquisition of a member of the Peer Index by a company that is not a member of the Peer Index; and (iv) a split of a member of the Peer Index (in which case the Compensation Committee may, in its sole discretion, include both companies in the Peer Index). A Peer Company shall remain in the Peer Index following its bankruptcy or delisting (and shall be listed at the bottom of the Peer Index).
Relative TSR – The percentile rank of the Company’s TSR as compared to the TSR of each member of the Peer Index, determined by dividing the number of members of the Peer Index
18
Exhibit 10.1
with TSR equal to or lower than the Company’s TSR for the Performance Period by the total number of members of the Peer Index minus 1.
Total Shareholder Return or TSR – The change in a company’s stock price over the Performance Period (counting any dividends paid as if such dividends were reinvested at the time of issuance) divided by that company’s stock price at the beginning of the Performance Period, expressed as a percentage. The stock price at the beginning of the Performance Period shall be calculated using the relevant company’s 20 trading-day average closing stock price leading up to, but not including, January 1, 2021. The stock price at the end of the Performance Period shall be calculated using the relevant company’s 20 trading-day average closing stock price leading up to, and including, December 31, 2023.
Performance Share Vesting Period – February 18, 2021 through February 18, 2024.
19
Exhibit 10.1
Appendix B
International Supplement

This International Supplement amends certain terms and conditions of, and is made a part of, the Quest Diagnostics Incorporated Equity Award Agreement dated as of [Grant Date], 2021 (the “Agreement”) to which this International Supplement is attached as Appendix B. This International Supplement applies to awards made to individuals who are not United States citizens or residents, as such term is defined by the Internal Revenue Code, and who are employed outside the United States. Capitalized terms that are used without definition in this International Supplement have the meanings set forth in the Agreement.
A.    Provisions applicable to all individuals who are not United States citizens or residents.
1.    Disability. Section 4(d) is amended to provide that if the Employee’s employment shall terminate as a result of a medical condition for which the Employee receives disability income benefits from a governmental program, all Options and all RSUs shall vest. All references in the Agreement to Section 4(d), including without limitation the reference to Section 4(d) set forth in Section 6(c), shall be understood as referring to Section 4(d) as so amended.
2.    Taxes. The first two sentences of Section 14 are replaced in their entirety to read as follows: “Depending on applicable tax rules, the Employee may recognize income for income tax purposes upon the grant, vesting, exercise or settlement of the awards covered by this Agreement, and the Employee shall be subject to tax and tax withholdings as appropriate.” References in Section 14 to Federal income tax and Federal Insurance Contribution Act taxes shall be understood as references to the comparable taxes in the jurisdiction in which the Employee is employed.
B.    Provisions applicable to individuals who are citizens or residents of Finland.

1.Definition of Termination Date. The definition of “Termination Date” in Section 4(c) is replaced in its entirety with the defined term “Expiry Date”, which shall mean the date of the Employee’s expiry of employment. All references in the Agreement to Termination Date shall be understood as referring to Expiry Date.

2.Leave of Absence and Transfer. Each use of the term “terminated” in Section 24 is replaced with the term “expired.” Section 24 is amended to provide that, in addition to the enumerated permissible bona fide leaves of absence, an Employee’s employment will not be deemed to have expired as a result of a bona fide leave of absence permitted pursuant to statute.

3.Definition of Good Reason. Section 23(d)(iii) is amended to provide that the events set forth in Sections 23(d)(iii)(A) through (D) shall provide grounds for a termination by the Employee with Good Reason if the Employee serves notice of Employee’s termination of employment within sixty (60) days of the occurrence of any such event and the employer fails to
20
Exhibit 10.1
cure the event giving rise to Good Reason within thirty (30) days following receipt of such notice.


21
Exhibit 10.1
Appendix C

RESTRICTIVE COVENANT AGREEMENT
22
 EX-31.1 3 dgx03312021ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen H. Rusckowski, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Quest Diagnostics Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

April 23, 2021
By/s/ Stephen H. Rusckowski
Stephen H. Rusckowski
Chairman, Chief Executive Officer and
President



 EX-31.2 4 dgx03312021ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Mark J. Guinan, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Quest Diagnostics Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

April 23, 2021
By/s/ Mark J. Guinan
Mark J. Guinan
Executive Vice President and
Chief Financial Officer


 EX-32.1 5 dgx03312021ex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. § 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended March 31, 2021 of Quest Diagnostics Incorporated, as being filed with the Securities and Exchange Commission concurrently herewith, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. § 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Quest Diagnostics Incorporated.
Dated:April 23, 2021/s/ Stephen H. Rusckowski
Stephen H. Rusckowski
Chairman, Chief Executive Officer and
President



 EX-32.2 6 dgx03312021ex322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. § 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, the undersigned certifies that, to the best of my knowledge, the Quarterly Report on Form 10-Q for the period ended March 31, 2021 of Quest Diagnostics Incorporated, as being filed with the Securities and Exchange Commission concurrently herewith, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. § 78m or 78o(d)) and that the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Quest Diagnostics Incorporated.
Dated:April 23, 2021/s/ Mark J. Guinan
Mark J. Guinan
Executive Vice President and
Chief Financial Officer



 EX-101.SCH 7 dgx-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2104103 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2107104 - Disclosure - BUSINESS ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 2108105 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - FAIR VALUE MEASUREMENTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2112106 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedules) (Details) link:presentationLink link:calculationLink link:definitionLink 2116107 - Disclosure - FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 2317304 - Disclosure - FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2418406 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2419407 - Disclosure - FINANCIAL INSTRUMENTS (Balance Sheets) (Details) link:presentationLink link:calculationLink link:definitionLink 2420408 - Disclosure - FINANCIAL INSTRUMENTS (Income Statement) (Details) link:presentationLink link:calculationLink link:definitionLink 2121108 - Disclosure - STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 2422409 - Disclosure - STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details) link:presentationLink link:calculationLink link:definitionLink 2123109 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA link:presentationLink link:calculationLink link:definitionLink 2324305 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables) link:presentationLink link:calculationLink link:definitionLink 2425410 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Details) link:presentationLink link:calculationLink link:definitionLink 2126110 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2427411 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2128111 - Disclosure - BUSINESS SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 2329306 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2430412 - Disclosure - BUSINESS SEGMENT INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 2131112 - Disclosure - RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 2432413 - Disclosure - RELATED PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 2133113 - Disclosure - REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES link:presentationLink link:calculationLink link:definitionLink 2334307 - Disclosure - REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Tables) link:presentationLink link:calculationLink link:definitionLink 2435414 - Disclosure - REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Details) link:presentationLink link:calculationLink link:definitionLink 2136114 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 2437415 - Disclosure - SUBSEQUENT EVENT (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 dgx-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 dgx-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 dgx-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Reissuance of shares for employee benefit plan Stock Issued During Period, Shares, Treasury Stock Reissued Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Other income (expense), net Other Nonoperating Income (Expense) COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Related Party [Axis] Related Party [Axis] Treasury Stock, at Cost Treasury Stock [Member] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Customer-related intangibles Customer Relationships [Member] Leases: Lease, Cost [Abstract] Available-for-sale debt securities Debt Securities, Available-for-sale Total operating costs and expenses, net Costs and Expenses Segments [Axis] Segments [Axis] Equity Components [Axis] Equity Components [Axis] Class action lawsuits Loss Contingency, Pending Claims, Number Routine clinical testing services Routine clinical testing services [Member] Routine clinical testing services Minimum Minimum [Member] Significant Unobservable Inputs, Level 3 Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Impairment of equity method investment Equity Method Investment, Other than Temporary Impairment Excludes general and professional liability claims Excludes general and professional liability claims [Member] Excludes general and professional liability claims [Member] Current portion of long-term operating lease liabilities Operating Lease, Liability, Current Gene-based and esoteric testing services Gene-based and esoteric testing services [Member] Gene-based and esoteric testing services [Member] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Supplemental Cash Flow and Other Data Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Self-insurance reserves Malpractice Loss Contingency, Accrual, Undiscounted Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Less: Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Distributions to noncontrolling interest partners Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders FINANCIAL INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Fair Value Entity Interactive Data Current Entity Interactive Data Current Security Exchange Name Security Exchange Name FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Intangible assets, net Total intangible assets, Net Intangible Assets, Net (Excluding Goodwill) STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Stockholders' Equity Note Disclosure [Text Block] Remainder of 2021 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Operating income Total operating income Operating Income (Loss) Total Amortizing Intangible Assets Total Amortizing Intangible Assets [Member] Total Amortizing Intangible Assets [Member] Total current liabilities Liabilities, Current Additional paid-in capital Additional Paid in Capital, Common Stock Cash surrender value of life insurance policies Cash Surrender Value, Fair Value Disclosure Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Derivative [Table] Derivative [Table] Business Acquisition [Line Items] Business Acquisition [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current UMass Joint Venture UMass Joint Venture [Member] UMass Joint Venture [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Commitments and contingencies Commitments and Contingencies Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Purchases of treasury stock Payments for Repurchase of Common Stock Assets Assets [Abstract] Net income Net Income (Loss), Excluding Redeemable Noncontrolling Interest Net Income (Loss), Excluding Redeemable Noncontrolling Interest Less: Cash acquired Cash Acquired from Acquisition Accounting Policies [Abstract] Accounting Policies [Abstract] Intangible assets, Cost Intangible Assets, Gross (Excluding Goodwill) Other accounts receivable, related parties Other Accounts Receivable, Related Parties Other Accounts Receivable, Related Parties Issuance of common stock under benefit plans Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Entity Address, State or Province Entity Address, State or Province Net amount of deferred gains and losses on cash flow hedges that is expected to be reclassified within the next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Dividends paid Payments of Ordinary Dividends, Common Stock Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Retained earnings Retained Earnings (Accumulated Deficit) Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable, net of allowance for credit losses of $29 and $28 as of March 31, 2021 and December 31, 2020, respectively Accounts Receivable, after Allowance for Credit Loss, Current Purchases of treasury stock, shares Purchases of treasury stock- shares Treasury Stock, Shares, Acquired Income taxes paid Income Taxes Paid Stockholders' equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Long-term debt Long-term Debt and Lease Obligation Entity Address, Postal Zip Code Entity Address, Postal Zip Code Percentage of net revenues Percentage of Net Revenues Percentage of Net Revenues Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Goodwill Goodwill, Balance at beginning of period Goodwill, Balance at end of period Goodwill Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Transition Report Document Transition Report Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Other liabilities Other Liabilities, Noncurrent Increase in investments and other assets Payments for (Proceeds from) Other Investing Activities Operating costs and expenses and other operating income: Cost of Revenue [Abstract] Capitated Capitated [Member] Capitated [Member] Income taxes payable Increase (Decrease) in Income Taxes Payable Liability Class [Axis] Liability Class [Axis] Fair value of assets acquired Fair Value of Assets Acquired Other income (expense): Nonoperating Income (Expense) [Abstract] Dividends per common share Common Stock, Dividends, Per Share, Declared Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Significant Other Observable Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Consideration Disposal Group, Including Discontinued Operation, Consideration Document Quarterly Report Document Quarterly Report Inventories Inventory, Net Changes in Goodwill, Net Schedule of Goodwill [Table Text Block] Net revenues Total net revenues Revenue from Contract with Customer, Excluding Assessed Tax Measurement Frequency [Domain] Measurement Frequency [Domain] Receivables Accounts Receivable, Related Parties Total Assets, Fair Value Disclosure Fair value of liabilities assumed Liabilities Assumed Business Acquisition [Axis] Business Acquisition [Axis] Subsequent Event [Line Items] Subsequent Event [Line Items] Government Payers Government Payers [Member] Government Payers [Member] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Statement [Line Items] Statement [Line Items] Credit Facility [Domain] Credit Facility [Domain] Additional amount authorized Stock Repurchase Program, Additional Amount Authorized Stock Repurchase Program, Additional Amount Authorized Future Amortization Expense Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Diluted (in Shares) Weighted average common shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Letter of Credit Letter of Credit [Member] Scenario, Forecast Forecast [Member] Basic(in dollars per share) Earnings Per Share, Basic Earnings per share attributable to Quest Diagnostics’ common stockholders: Earnings Per Share, Basic and Diluted [Abstract] Entity File Number Entity File Number Statement [Table] Statement [Table] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Statistical Measurement [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Fair value of debt Debt Instrument, Fair Value Disclosure Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Senior Unsecured Revolving Credit Facility Senior unsecured revolving credit facility [Member] Senior unsecured revolving credit facility [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt [Table Text Block] Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt [Table Text Block] Business Combinations [Abstract] Business Combinations [Abstract] Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2021 and December 31, 2020; 217 shares issued as of both March 31, 2021 and December 31, 2020 Common Stock, Value, Issued Long-term Debt Long-term Debt [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Entity Small Business Entity Small Business Document Fiscal Year Focus Document Fiscal Year Focus Other operating expense, net Other Operating Income (Expense), Net 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Percent of ownership interest sold Equity Method Investment, Ownership Percent Disposed Of Equity Method Investment, Ownership Percent Disposed Of Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Current portion of long-term debt Long-term Debt, Current Maturities Entity Current Reporting Status Entity Current Reporting Status Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Cost of services Cost of Revenue Selling, general and administrative Selling, General and Administrative Expenses [Member] Interest income Interest and Dividend Income, Operating Adjustments to goodwill Goodwill, Period Increase (Decrease) Goodwill [Roll Forward] Goodwill [Roll Forward] Amendment Flag Amendment Flag Subsequent Event [Table] Subsequent Event [Table] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Healthcare Insurers Healthcare Insurers [Member] Healthcare Insurers [Member] Accounts Receivable Disaggregation Accounts Receivable Disaggregation [Table Text Block] Accounts Receivable Disaggregation [Table Text Block] Amounts attributable to Quest Diagnostics’ common stockholders: Income Amounts Attributable to Parent, Disclosures [Abstract] Balance, Value Balance, Value Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Litigation reserves Estimated Litigation Liability Repayments of debt Repayments of Debt Q2 Solutions Q2 Solutions [Member] Q2 Solutions Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Distributions to noncontrolling interest partners Payments of Ordinary Dividends, Noncontrolling Interest Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Segment Reporting [Abstract] Segment Reporting [Abstract] Intangible Assets Not Subject to Amortization - Other Unclassified Indefinite-lived Intangible Assets [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Net accounts receivable Percentage of Net Accounts Receivable Percentage of Net Accounts Receivable Related Party Transaction [Line Items] Related Party Transaction [Line Items] Accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Total Quest Diagnostics stockholders' equity Stockholders' Equity Attributable to Parent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] DESCRIPTION OF BUSINESS Nature of Operations [Text Block] Derivatives designated as hedging instruments Derivative, Gain (Loss) on Derivative, Net Total liabilities and stockholders' equity Liabilities and Equity All other services All other services [Member] All other services [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] SUPPLEMENTAL CASH FLOW & OTHER DATA Cash Flow, Supplemental Disclosures [Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accounts payable associated with capital expenditures Capital Expenditures Incurred but Not yet Paid Derivative Financial Instruments Derivatives, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town SUBSEQUENT EVENTS Subsequent Events [Text Block] Patients Patients [Member] Patients [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Hedging Relationship [Axis] Hedging Relationship [Axis] Segments [Domain] Segments [Domain] Stock options and performance share units Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Distributions to noncontrolling interest partners Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table] Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table] Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table] Other, net Other Noncash Income (Expense) Hedge Accounting Basis Adjustment Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-lived Intangible Assets [Axis] Weighted Average Amortization Period Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Net change in available-for-sale debt securities, net of taxes OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Property, plant and equipment, net Property, Plant and Equipment, Net 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Selling, general and administrative Selling, General and Administrative Expense Entity Tax Identification Number Entity Tax Identification Number Deferred compensation liabilities Deferred Compensation Liability, Classified, Noncurrent Amortization of intangible assets Amortization expense Amortization of Intangible Assets Net income attributable to Quest Diagnostics Net income attributable to Quest Diagnostics Net Income (Loss) Attributable to Parent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other assets Other Assets, Noncurrent Other comprehensive loss Other comprehensive loss, net of taxes Other Comprehensive Income (Loss), Net of Tax DS Businesses DS Businesses [Member] DS Businesses [Member] Intangible Assets Not Subject to Amortization - Tradenames Trade Names [Member] Description of Business (Abstract) Description of Business (Abstract) Description of Business (Abstract) BUSINESS SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Total assets Assets Related Party Transactions Related Party Transactions Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Scenario [Axis] Scenario [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Less: Comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Weighted average common shares outstanding: Earnings Per Share [Abstract] General corporate activities Corporate Segment [Member] Title of 12(b) Security Title of 12(b) Security DIS business Diagnostic Information Services Business [Member] Diagnostic Information Services Business [Member] Total Finite-Lived Intangible Assets, Net Accounts payable, related parties Accounts Payable, Related Parties Subsequent Event Type [Axis] Subsequent Event Type [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Quest Diagnostics stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Equity Attributable to Parent [Abstract] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Fiscal Period Focus Document Fiscal Period Focus Interest expense Interest Expense Finite-Lived and Indefinite-lived Intangible Assets [Line Items] Finite-Lived and Indefinite-lived Intangible Assets [Line Items] Finite-Lived and Indefinite-lived Intangible Assets [Line Items] Depreciation and amortization Depreciation and amortization expense Depreciation, Depletion and Amortization Ownership percentage by noncontrolling owners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Other Other Intangible Assets [Member] Product and Service [Axis] Product and Service [Axis] Earnings available to Quest Diagnostics’ common stockholders – basic and diluted Net Income (Loss) Available to Common Stockholders, Diluted Finite-Lived and Indefinite-lived Intangible Assets [Table] Finite-Lived and Indefinite-lived Intangible Assets [Table] Finite-Lived and Indefinite-lived Intangible Assets [Table] Fee-for-service Fee-for-service [Member] Fee-for-service [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] All other operating segments Other Segments [Member] Entity Filer Category Entity Filer Category Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Technology Unpatented Technology [Member] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Client Payers Client Payers [Member] Client Payers [Member] Quoted Prices in Active Markets for Identical Assets / Liabilities, Level 1 Fair Value, Inputs, Level 1 [Member] Secured Receivables Credit Facility Secured Debt [Member] Other assets and liabilities, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Interest expense, net Interest expense, net Interest Income (Expense), Net Fair Value Hedging Fair Value Hedging [Member] Purchases of treasury stock Purchases of treasury stock, value Treasury Stock, Value, Acquired, Cost Method Exercise of stock options, shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Related Party Transactions [Abstract] Related Party Transactions [Abstract] Net change in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Schedule of Revenues by Major Service Schedule of Revenues by Major Service [Table Text Block] Schedule of Revenues by Major Service BUSINESS ACQUISITIONS Business Combination Disclosure [Text Block] Total non-operating expense, net Non-operating expense, net Nonoperating Income (Expense) Hedging Relationship [Domain] Hedging Relationship [Domain] Balance, shares Balance, shares Common Stock, Shares, Outstanding Investments in equity method investees Equity Method Investments Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Hedged items (Long-term debt) Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Revolving Credit Facility Revolving Credit Facility [Member] Basic (in Shares) Weighted average common shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic Schedule of Fair Value Hedge Accounting on the Statement of Operations Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Events [Abstract] Subsequent Events [Abstract] Ownership [Axis] Ownership [Axis] Treasury stock (in shares) Treasury Stock, Shares Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Redeemable Non-controlling Interest [Abstract] Increase (Decrease) in Temporary Equity [Roll Forward] Subsequent Event Subsequent Event [Member] Net income Temporary Equity, Net Income Cash Flow Hedging Cash Flow Hedging [Member] Letters of credit outstanding, amount Letters of Credit Outstanding, Amount Loss Contingencies [Table] Loss Contingencies [Table] Ownership [Domain] Ownership [Domain] Business acquisitions, net of cash acquired Business acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Common stock, shares authorized (in shares) Common Stock, Shares Authorized Percentage of interests acquired Business Acquisition, Percentage of Voting Interests Acquired Stock options and performance share units Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Exercise of stock options Proceeds from Stock Options Exercised REVENUE RECOGITION AND ALLOWANCE FOR CREDIT LOSSES Revenue from Contract with Customer [Text Block] Dividends payable Dividends Payable Provision for credit losses Contract with Customer, Asset, Credit Loss Expense (Reversal) Summary of Segment Reporting Information by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total stockholders' equity Balance, value Balance, value Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Leased assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Income tax expense Income Tax Expense (Benefit) Less: Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Gain on sale of investment, before tax Equity Method Investment, Realized Gain (Loss) on Disposal Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Diluted (in dollars per share) Earnings Per Share, Diluted Local Phone Number Local Phone Number Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Use Of Estimates Use of Estimates, Policy [Policy Text Block] Derivative [Line Items] Derivative [Line Items] Depreciation expense Depreciation Entity Address, Address Line One Entity Address, Address Line One Non-compete agreements Noncompete Agreements [Member] Share repurchase authorization remaining available Stock Repurchase Program, Remaining Authorized Repurchase Amount Entity Emerging Growth Company Entity Emerging Growth Company Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Subsegments [Domain] Subsegments [Domain] Comprehensive income attributable to Quest Diagnostics Comprehensive Income (Loss), Net of Tax, Attributable to Parent Deferred income tax (benefit) provision Deferred Income Tax Expense (Benefit) Income from related party recognized Related Party Transaction, Other Revenues from Transactions with Related Party Fair value of net assets acquired Fair value of net assets acquired Fair value of net assets acquired Dividends received Proceeds from Dividends Received Credit facility capacity Line of Credit Facility, Maximum Borrowing Capacity Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Scenario [Domain] Scenario [Domain] Intangible assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Capital expenditures Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Non-controlling Interests Noncontrolling Interest [Member] Document Period End Date Document Period End Date Fair Value, Measurement Inputs Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Dividends declared Dividends, Common Stock, Cash Retained Earnings Retained Earnings [Member] GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Equity in earnings of equity method investees, net of taxes Income (Loss) from Equity Method Investments Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Income before income taxes and equity in earnings of equity method investees Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest COVID-19 Testing Services COVID-19 Testing Services [Member] COVID-19 Testing Services Trading Symbol Trading Symbol Revenues Revenue from Related Parties Trading securities Debt Securities, Trading, and Equity Securities, FV-NI Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] MACL Mid America Clinical Laboratories, LLC (MACL) [Member] Mid America Clinical Laboratories, LLC (MACL) Treasury stock, at cost; 86 and 84 shares as of March 31, 2021 and December 31, 2020, respectively Treasury Stock, Value Other financing activities, net Proceeds from (Payments for) Other Financing Activities Employee payroll tax withholdings on stock issued under stock-based compensation plans Payment, Tax Withholding, Share-based Payment Arrangement Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items] Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items] [Line Items] for Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table] EARNINGS (LOSS) PER SHARE Earnings Per Share [Text Block] Cover [Abstract] Cover [Abstract] Goodwill acquired during the period Goodwill, Acquired During Period Redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Carrying Amount Entity Shell Company Entity Shell Company Anatomic pathology testing services Anatomic pathology testing services [Member] Anatomic pathology testing services [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Recurring Basis Fair Value, Recurring [Member] Equity Method Investee Equity Method Investee [Member] Intangible Assets Excluding Goodwill Intangible Assets Disclosure [Text Block] New Accounting Standards to be Adopted New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Subsegments [Axis] Subsegments [Axis] EX-101.PRE 11 dgx-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 dgx-20210331_htm.xml IDEA: XBRL DOCUMENT 0001022079 2021-01-01 2021-03-31 0001022079 2021-04-15 0001022079 2020-01-01 2020-03-31 0001022079 2021-03-31 0001022079 2020-12-31 0001022079 2019-12-31 0001022079 2020-03-31 0001022079 us-gaap:CommonStockMember 2020-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001022079 us-gaap:RetainedEarningsMember 2020-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001022079 us-gaap:TreasuryStockMember 2020-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2020-12-31 0001022079 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001022079 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001022079 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001022079 us-gaap:CommonStockMember 2021-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001022079 us-gaap:RetainedEarningsMember 2021-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001022079 us-gaap:TreasuryStockMember 2021-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2021-03-31 0001022079 us-gaap:CommonStockMember 2019-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001022079 us-gaap:RetainedEarningsMember 2019-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001022079 us-gaap:TreasuryStockMember 2019-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2019-12-31 0001022079 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001022079 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001022079 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001022079 us-gaap:CommonStockMember 2020-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001022079 us-gaap:RetainedEarningsMember 2020-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001022079 us-gaap:TreasuryStockMember 2020-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2020-03-31 0001022079 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001022079 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001022079 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001022079 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001022079 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001022079 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001022079 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001022079 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001022079 dgx:UMassJointVentureMember 2015-07-01 0001022079 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-03-31 0001022079 2020-01-01 2020-12-31 0001022079 dgx:MidAmericaClinicalLaboratoriesLLCMACLMember 2020-12-31 0001022079 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-03-31 0001022079 us-gaap:CustomerRelationshipsMember 2021-03-31 0001022079 us-gaap:CustomerRelationshipsMember 2020-12-31 0001022079 us-gaap:NoncompeteAgreementsMember 2021-01-01 2021-03-31 0001022079 us-gaap:NoncompeteAgreementsMember 2021-03-31 0001022079 us-gaap:NoncompeteAgreementsMember 2020-12-31 0001022079 us-gaap:UnpatentedTechnologyMember 2021-01-01 2021-03-31 0001022079 us-gaap:UnpatentedTechnologyMember 2021-03-31 0001022079 us-gaap:UnpatentedTechnologyMember 2020-12-31 0001022079 us-gaap:OtherIntangibleAssetsMember 2021-01-01 2021-03-31 0001022079 us-gaap:OtherIntangibleAssetsMember 2021-03-31 0001022079 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0001022079 dgx:TotalAmortizingIntangibleAssetsMember 2021-01-01 2021-03-31 0001022079 dgx:TotalAmortizingIntangibleAssetsMember 2021-03-31 0001022079 dgx:TotalAmortizingIntangibleAssetsMember 2020-12-31 0001022079 us-gaap:TradeNamesMember 2021-03-31 0001022079 us-gaap:TradeNamesMember 2020-12-31 0001022079 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2021-03-31 0001022079 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2020-12-31 0001022079 us-gaap:CashFlowHedgingMember 2020-12-31 0001022079 us-gaap:CashFlowHedgingMember 2021-03-31 0001022079 us-gaap:LongTermDebtMember us-gaap:FairValueHedgingMember 2021-03-31 0001022079 us-gaap:LongTermDebtMember us-gaap:FairValueHedgingMember 2020-12-31 0001022079 us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-03-31 0001022079 us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0001022079 us-gaap:FairValueHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-03-31 0001022079 us-gaap:FairValueHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0001022079 2020-04-01 2020-06-30 0001022079 2020-07-01 2020-09-30 0001022079 2020-10-01 2020-12-31 0001022079 2021-03-01 2021-03-31 0001022079 2021-02-01 2021-02-28 0001022079 us-gaap:LetterOfCreditMember us-gaap:SecuredDebtMember 2021-03-31 0001022079 us-gaap:SecuredDebtMember 2021-03-31 0001022079 us-gaap:LetterOfCreditMember us-gaap:RevolvingCreditFacilityMember 2021-03-31 0001022079 dgx:SeniorunsecuredrevolvingcreditfacilityMember 2021-03-31 0001022079 2020-10-31 0001022079 dgx:ExcludesgeneralandprofessionalliabilityclaimsMember 2021-03-31 0001022079 dgx:ExcludesgeneralandprofessionalliabilityclaimsMember 2020-12-31 0001022079 srt:MinimumMember dgx:DiagnosticInformationServicesBusinessMember 2020-01-01 2020-03-31 0001022079 srt:MinimumMember dgx:DiagnosticInformationServicesBusinessMember 2021-01-01 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2021-01-01 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2020-01-01 2020-03-31 0001022079 us-gaap:AllOtherSegmentsMember 2021-01-01 2021-03-31 0001022079 us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0001022079 us-gaap:CorporateMember 2021-01-01 2021-03-31 0001022079 us-gaap:CorporateMember 2020-01-01 2020-03-31 0001022079 dgx:RoutineclinicaltestingservicesMember 2021-01-01 2021-03-31 0001022079 dgx:RoutineclinicaltestingservicesMember 2020-01-01 2020-03-31 0001022079 dgx:COVID19TestingServicesMember 2021-01-01 2021-03-31 0001022079 dgx:COVID19TestingServicesMember 2020-01-01 2020-03-31 0001022079 dgx:GenebasedandesoterictestingservicesMember 2021-01-01 2021-03-31 0001022079 dgx:GenebasedandesoterictestingservicesMember 2020-01-01 2020-03-31 0001022079 dgx:AnatomicpathologytestingservicesMember 2021-01-01 2021-03-31 0001022079 dgx:AnatomicpathologytestingservicesMember 2020-01-01 2020-03-31 0001022079 dgx:AllotherservicesMember 2021-01-01 2021-03-31 0001022079 dgx:AllotherservicesMember 2020-01-01 2020-03-31 0001022079 us-gaap:EquityMethodInvesteeMember 2021-01-01 2021-03-31 0001022079 us-gaap:EquityMethodInvesteeMember 2020-01-01 2020-03-31 0001022079 us-gaap:EquityMethodInvesteeMember 2021-03-31 0001022079 us-gaap:EquityMethodInvesteeMember 2020-12-31 0001022079 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EquityMethodInvesteeMember 2021-01-01 2021-03-31 0001022079 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EquityMethodInvesteeMember 2020-01-01 2020-03-31 0001022079 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:EquityMethodInvesteeMember 2021-03-31 0001022079 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:EquityMethodInvesteeMember 2020-12-31 0001022079 dgx:FeeforserviceMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2021-01-01 2021-03-31 0001022079 dgx:FeeforserviceMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2020-01-01 2020-03-31 0001022079 dgx:CapitatedMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2021-01-01 2021-03-31 0001022079 dgx:CapitatedMember dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2020-01-01 2020-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2021-01-01 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2020-01-01 2020-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:GovernmentPayersMember 2021-01-01 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:GovernmentPayersMember 2020-01-01 2020-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2021-01-01 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2020-01-01 2020-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:PatientsMember 2021-01-01 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:PatientsMember 2020-01-01 2020-03-31 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2021-01-01 2021-03-31 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2020-01-01 2020-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:HealthcareInsurersMember 2020-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:GovernmentPayersMember 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:GovernmentPayersMember 2020-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:ClientPayersMember 2020-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:PatientsMember 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember dgx:PatientsMember 2020-12-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2021-03-31 0001022079 dgx:DiagnosticInformationServicesBusinessMember 2020-12-31 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2021-03-31 0001022079 us-gaap:AllOtherSegmentsMember dgx:DSBusinessesMember 2020-12-31 0001022079 dgx:Q2SolutionsMember us-gaap:SubsequentEventMember 2021-04-01 0001022079 srt:ScenarioForecastMember dgx:Q2SolutionsMember 2021-04-01 2021-06-30 shares iso4217:USD iso4217:USD shares pure dgx:claim 0001022079 --12-31 2021 Q1 false 10-Q true 2021-03-31 false 001-12215 Quest Diagnostics Inc DE 16-1387862 500 Plaza Drive Secaucus, NJ 07094 (973) 520-2700 Common Stock, $0.01 Par Value DGX NYSE Yes Yes Large Accelerated Filer false false false 130638109 2720000000 1822000000 1626000000 1270000000 407000000 347000000 27000000 25000000 0 -5000000 2060000000 1647000000 660000000 175000000 -38000000 -41000000 4000000 -16000000 -34000000 -57000000 626000000 118000000 153000000 26000000 17000000 14000000 490000000 106000000 21000000 7000000 469000000 99000000 3.52 0.74 3.46 0.73 133000000 134000000 135000000 135000000 490000000 106000000 -3000000 -19000000 -7000000 0 -10000000 -19000000 480000000 87000000 21000000 7000000 459000000 80000000 1230000000 1158000000 29000000 28000000 1382000000 1520000000 223000000 223000000 164000000 157000000 2999000000 3058000000 1624000000 1627000000 600000000 604000000 6870000000 6873000000 1141000000 1167000000 527000000 521000000 170000000 176000000 13931000000 14026000000 1559000000 1633000000 2000000 2000000 146000000 141000000 1707000000 1776000000 4010000000 4013000000 503000000 499000000 842000000 847000000 79000000 82000000 0.01 0.01 600000000 600000000 217000000 217000000 2000000 2000000 2824000000 2841000000 9690000000 9303000000 -31000000 -21000000 86000000 84000000 5740000000 5366000000 6745000000 6759000000 45000000 50000000 6790000000 6809000000 13931000000 14026000000 490000000 106000000 101000000 85000000 2000000 7000000 -17000000 14000000 18000000 14000000 2000000 2000000 -138000000 -85000000 -164000000 -47000000 163000000 -3000000 -2000000 12000000 731000000 247000000 0 108000000 86000000 83000000 7000000 15000000 -93000000 -206000000 1000000 801000000 410000000 75000000 17000000 80000000 21000000 13000000 75000000 71000000 29000000 7000000 -47000000 -4000000 -566000000 -891000000 72000000 -850000000 1158000000 1192000000 1230000000 342000000 133000000 2000000 2841000000 9303000000 -21000000 -5366000000 50000000 6809000000 82000000 469000000 17000000 486000000 4000000 -10000000 -10000000 82000000 82000000 22000000 22000000 7000000 -29000000 34000000 5000000 18000000 18000000 1000000 3000000 14000000 17000000 9000000 12000000 21000000 3000000 410000000 410000000 131000000 2000000 2824000000 9690000000 -31000000 -5740000000 45000000 6790000000 79000000 133000000 2000000 2722000000 8174000000 -39000000 -5218000000 46000000 5687000000 76000000 99000000 6000000 105000000 1000000 -19000000 -19000000 76000000 76000000 6000000 6000000 1000000 3000000 3000000 6000000 14000000 14000000 2000000 12000000 68000000 80000000 13000000 13000000 1000000 75000000 75000000 134000000 2000000 2738000000 8197000000 -58000000 -5222000000 46000000 5703000000 76000000 DESCRIPTION OF BUSINESS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">    </span></div>    Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") empower people to take action to improve health outcomes.  The Company uses its extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.  The Company's diagnostic information services business ("DIS") provides information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The Company provides services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, accountable care organizations ("ACOs"), and direct contract entities ("DCEs"). The Company offers the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers and phlebotomists in physician offices and the Company's connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals. The Company is the world's leading provider of diagnostic information services. The Company provides interpretive consultation with one of the largest medical and scientific staffs in the industry. The Company's Diagnostic Solutions businesses ("DS") are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2020 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2020, but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The accounting policies of the Company are the same as those set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    A novel strain of coronavirus (“COVID-19”) continues to spread and severely impact the economy of the United States and other countries around the world. The Company's testing volume and revenues have been materially impacted by the COVID-19 pandemic, including periods of decline in testing volume in the Company's base business (which excludes COVID-19 testing) compared to historical 2019 levels and periods of significant demand for COVID-19 testing. As a result, operating results for the three months ended March 31, 2021 may not be indicative of the results that may be expected for the full year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    Earnings Per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    New Accounting Standards to be Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In March 2020, the Financial Accounting Standards Board issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The pronouncement is effective immediately and can be applied through December 31, 2022. The adoption of this standard is not expected to have a material impact on the Company’s consolidated results of operations, financial position or cash flows.</span></div> The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2020 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2020, but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities. In March 2020, the Financial Accounting Standards Board issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The pronouncement is effective immediately and can be applied through December 31, 2022. The adoption of this standard is not expected to have a material impact on the Company’s consolidated results of operations, financial position or cash flows. EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Quest Diagnostics’ common stockholders:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Earnings allocated to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to Quest Diagnostics’ common stockholders – basic and diluted</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding – basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding – diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to Quest Diagnostics’ common stockholders:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.46 </span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73 </span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Quest Diagnostics’ common stockholders:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Earnings allocated to participating securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings available to Quest Diagnostics’ common stockholders – basic and diluted</span></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding – basic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding – diluted</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share attributable to Quest Diagnostics’ common stockholders:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.46 </span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73 </span></td><td style="border-bottom:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 469000000 99000000 1000000 0 468000000 99000000 133000000 134000000 2000000 1000000 135000000 135000000 3.52 0.74 3.46 0.73 The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and performance share units</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 1000000 2000000 BUSINESS ACQUISITIONS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2021, the Company entered into a definitive agreement to acquire the outreach laboratory services business of Mercy Health, which serves providers and patients in Arkansas, Kansas, Missouri and Oklahoma. The transaction, which is expected to close in mid-2021, remains subject to customary closing conditions.</span>    For details regarding the Company's 2020 acquisitions, see Note 6 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K. FAIR VALUE MEASUREMENTS <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets/Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    A detailed description regarding the Company's fair value measurements is contained in Note 7 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan. A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities. The trading securities are classified within Level 1 of the fair value hierarchy because the changes in the fair value of these securities are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs. A corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation. The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.</span></div><div style="padding-right:72pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program. A participant's deferrals, together with Company matching credits, are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's available-for-sale debt securities are measured at fair value based on estimated future cash flows. These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable, including cash flow projections. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. As of March 31, 2021, the redeemable noncontrolling interest was presented at its fair value. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long term growth rates, and a discount rate commensurate with economic risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the three months ended March 31, 2021, the Company recorded an $8 million impairment charge, which is included in equity in earnings of equity method investees, net of taxes, in order to adjust to fair value an investment that is accounted for under the equity method of accounting. Following the impairment charge, the carrying value of the investment is not material. The fair value measurement was classified within Level 3 of the fair value hierarchy as it was based on significant inputs that are not observable, including cash flow projections.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. As of March 31, 2021 and December 31, 2020, the fair value of the Company’s debt was estimated at $4.4 billion and $4.6 billion, respectively. Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.</span></div> The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:<div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.216%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets/Liabilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redeemable noncontrolling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 71000000 71000000 0 0 52000000 0 52000000 0 2000000 0 0 2000000 125000000 71000000 52000000 2000000 132000000 0 132000000 0 79000000 0 79000000 67000000 67000000 0 0 50000000 0 50000000 0 12000000 0 0 12000000 129000000 67000000 50000000 12000000 126000000 0 126000000 0 82000000 0 82000000 0.189 8000000 4400000000 4600000000 GOODWILL AND INTANGIBLE ASSETS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The changes in goodwill for the three months ended March 31, 2021 and for the year ended December 31, 2020 were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:57.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,619 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,870 </span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873 </span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Principally all of the Company’s goodwill as of March 31, 2021 and December 31, 2020 was associated with its DIS business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For the three months ended March 31, 2021, adjustments to goodwill primarily related to foreign currency translation. For the year ended December 31, 2020, goodwill acquired was principally associated with the acquisitions of Blueprint Genetics Oy, Memorial Hermann Diagnostic Laboratories, the outreach laboratory division of Memorial Hermann Health System; and the remaining 56% interest in Mid America Clinical Laboratories, LLC (see Note 6 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K). For the year ended December 31, 2020, adjustments to goodwill primarily related to foreign currency translation.     </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Intangible assets as of March 31, 2021 and December 31, 2020 consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.727%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Amortization<br/>Period <br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizing intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(638)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2021 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.935%"><tr><td style="width:1.0%"/><td style="width:72.828%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> The changes in goodwill for the three months ended March 31, 2021 and for the year ended December 31, 2020 were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.906%"><tr><td style="width:1.0%"/><td style="width:57.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,619 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,870 </span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,873 </span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6873000000 6619000000 0 247000000 -3000000 7000000 6870000000 6873000000 0.56 Intangible assets as of March 31, 2021 and December 31, 2020 consisted of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.727%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Amortization<br/>Period <br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortizing intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer-related</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(638)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> P17Y 1481000000 659000000 822000000 1479000000 638000000 841000000 P9Y 3000000 2000000 1000000 3000000 2000000 1000000 P15Y 140000000 68000000 72000000 141000000 65000000 76000000 P5Y 108000000 98000000 10000000 108000000 95000000 13000000 P17Y 1732000000 827000000 905000000 1731000000 800000000 931000000 235000000 235000000 235000000 235000000 1000000 1000000 1000000 1000000 1968000000 827000000 1141000000 1967000000 800000000 1167000000 The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2021 is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:40.935%"><tr><td style="width:1.0%"/><td style="width:72.828%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 74000000 98000000 96000000 93000000 92000000 86000000 366000000 905000000 FINANCIAL INSTRUMENTS     The Company uses derivative financial instruments to manage its exposure to market risks for changes in interest rates and, from time to time, foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Derivatives – Cash Flow Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The total net loss, net of taxes, recognized in accumulated other comprehensive loss, related to the Company's cash flow hedges was $1 million as of both March 31, 2021 and December 31, 2020. The net amount of deferred losses on cash flow hedges that is expected to be reclassified from accumulated other comprehensive loss into interest expense, net within the next twelve months is $1 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Derivatives – Fair Value Hedges </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2021 and December 31, 2020, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"/><td style="width:18.810%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hedge Accounting Basis Adjustment (a)</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) As of both March 31, 2021 and December 31, 2020, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the three months ended March 31, 2021 and 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total for line item in which the effects of fair value hedges are recorded</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (loss) on fair value hedging relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items (Long-term debt)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span></div>    A detailed description regarding the Company's use of derivative financial instruments is contained in Note 15 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K. The Company uses derivative financial instruments to manage its exposure to market risks for changes in interest rates and, from time to time, foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.</span></div> 1000000 1000000 1000000 As of March 31, 2021 and December 31, 2020, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:<div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"/><td style="width:18.810%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hedge Accounting Basis Adjustment (a)</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) As of both March 31, 2021 and December 31, 2020, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.</span></div> 48000000 51000000 The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the three months ended March 31, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total for line item in which the effects of fair value hedges are recorded</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain (loss) on fair value hedging relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged items (Long-term debt)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 4000000 -16000000 0 -69000000 0 69000000 STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST<div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Accumulated Other Comprehensive Loss by Component</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) includes: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign currency translation adjustments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 7); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax on available-for-sale debt securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For the three months ended March 31, 2021 and 2020, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material. Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes. </span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Program</span></div><div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the first quarter of 2021, the Company's Board of Directors declared a quarterly cash dividend of $0.62 per common share. During each of the four quarters of 2020, the Company's Board of Directors declared a quarterly cash dividend of $0.56 per common share. </span></div><div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In each of February and March 2021, the Company's Board of Directors increased the size of its share repurchase program by $1 billion. As of March 31, 2021, $2.5 billion remained available under the Company’s share repurchase authorization. The share repurchase authorization has no set expiration or termination date.</span></div><div style="text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchases</span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For the three months ended March 31, 2021, the Company repurchased 3.4 million shares of its common stock for $410 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For the three months ended March 31, 2020, the Company repurchased 0.7 million shares of its common stock for $75 million.</span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shares Reissued from Treasury Stock</span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's practice has been to issue shares related to its Employee Stock Purchase Plan ("ESPP") and its stock-based compensation program from shares of its common stock held in treasury or by issuing new shares of its common stock. In January 2021, the Company began to issue shares related to its ESPP and stock-based compensation program solely from common stock held in treasury. For the three months ended March 31, 2021 and 2020, the Company reissued 0.6 million shares and 1.1 million shares, respectively from treasury stock. For details regarding the Company's stock ownership and compensation plans, see Note 17 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    Redeemable Noncontrolling Interest</span></div><div style="text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts. Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value. As of March 31, 2021 and December 31, 2020, the redeemable noncontrolling interest was presented at its fair value. For further information regarding the fair value of the redeemable noncontrolling interest, see Note 5.</span></div> 0.62 0.56 0.56 0.56 0.56 1000000000 1000000000 2500000000 3400000 410000000 700000 75000000 600000 1100000 0.189 SUPPLEMENTAL CASH FLOW AND OTHER DATA<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Supplemental cash flow and other data for the three months ended March 31, 2021 and 2020 was as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with capital expenditures</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Businesses acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for new operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> Supplemental cash flow and other data for the three months ended March 31, 2021 and 2020 was as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable associated with capital expenditures</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Businesses acquired:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of net assets acquired</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased assets obtained in exchange for new operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 74000000 60000000 27000000 25000000 101000000 85000000 38000000 42000000 0 1000000 -38000000 -41000000 32000000 48000000 7000000 18000000 30000000 11000000 82000000 75000000 0 131000000 0 20000000 0 111000000 0 3000000 0 108000000 36000000 32000000 COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Letters of Credit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company can issue letters of credit totaling $100 million under its $600 million secured receivables credit facility and $150 million under its $750 million senior unsecured revolving credit facility. For further discussion regarding the Company's secured receivables credit facility and senior unsecured revolving credit facility, see Note 13 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In support of its risk management program, to ensure the Company’s performance or payment to third parties, $70 million in letters of credit under the secured receivables credit facility were outstanding as of March 31, 2021. The letters of credit primarily represent collateral for current and future automobile liability and workers’ compensation loss payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Lease Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company remains subject to contingent obligations under certain real estate leases, including leases that were entered into by certain predecessor companies of a subsidiary prior to the Company's acquisition of the subsidiary. No liability has been recorded for any of these potential contingent obligations. For further details, see Note 18 to the audited consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Legal Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues. The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">401(k) Plan Lawsuit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">    In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company’s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. In October 2020, the court consolidated the two lawsuits under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">In re: Quest Diagnostics ERISA Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and plaintiffs filed a consolidated amended complaint. The Company plans to vigorously defend this matter and has filed a motion to dismiss the complaint.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AMCA Data Security Incident</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">    On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (“AMCA”) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019 (the “AMCA Data Security Incident”). Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360. AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019. AMCA’s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included. Neither Optum360’s nor the Company’s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories’ customers was also affected. Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws. The bankruptcy proceeding has been dismissed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident. The U.S. Judicial Panel on Multidistrict Litigation transferred the cases still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey. In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident. In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss is pending. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In addition, certain federal and state governmental authorities are investigating, or otherwise seeking information and/or documents from the Company related to the AMCA Data Security Incident and related matters, including the Office for Civil Rights of the U.S. Department of Health and Human Services, Attorneys General offices from numerous states and the District of Columbia, and certain U.S. senators.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Legal Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services. These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The federal or state governments may bring claims based on the Company's current practices, which it believes are lawful. In addition, certain federal and state statutes, including the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers. The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing practices based on the qui tam provisions of the Civil False Claims Act or other federal and state statutes, regulations or other laws. The Company understands that there may be other pending qui tam claims brought by former employees or other "whistle blowers" as to which the Company cannot determine the extent of any potential liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    These matters are in different stages. Some of these matters are in their early stages. Matters may involve responding to and cooperating with various government investigations and related subpoenas. As of March 31, 2021, the Company does not believe that material losses related to legal matters are probable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Reserves for legal matters totaled $2 million and $1 million as of March 31, 2021 and December 31, 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for General and Professional Liability Claims</span></div>    As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims. These suits could involve claims for substantial damages. Any professional liability litigation could also have an adverse impact on the Company's client base and reputation. The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures. The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims. Reserves for such matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience. Such reserves totaled $142 million and $138 million as of March 31, 2021 and December 31, 2020, respectively. Management believes that established reserves and present insurance coverage are sufficient to cover currently estimated exposures. 100000000 600000000 150000000 750000000 70000000 2 2 2000000 1000000 142000000 138000000 BUSINESS SEGMENT INFORMATION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, ACOs and DCEs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for greater than 95% of net revenues in 2021 and 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2021, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.</span></div><div style="text-indent:29.25pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table is a summary of segment information for the three months ended March 31, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,643 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues </span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings (loss):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-operating expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes and equity in earnings of equity method investees</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of equity method investees, net of taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Net revenues by major service were as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routine clinical testing services</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gene-based and esoteric (including advanced diagnostics) testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anatomic pathology testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.95 0.95 The following table is a summary of segment information for the three months ended March 31, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net revenues:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,643 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,744 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues </span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings (loss):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DIS business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other operating segments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-operating expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before income taxes and equity in earnings of equity method investees</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity in earnings of equity method investees, net of taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Quest Diagnostics</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 2643000000 1744000000 77000000 78000000 2720000000 1822000000 712000000 205000000 9000000 9000000 -61000000 -39000000 660000000 175000000 -34000000 -57000000 626000000 118000000 153000000 26000000 17000000 14000000 490000000 106000000 21000000 7000000 469000000 99000000 Net revenues by major service were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Routine clinical testing services</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gene-based and esoteric (including advanced diagnostics) testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anatomic pathology testing services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,720 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1032000000 945000000 828000000 24000000 653000000 641000000 130000000 134000000 77000000 78000000 2720000000 1822000000 RELATED PARTIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture (see Note 14), a diagnostic information services joint venture, and an investment in a fund that purchases strategic holdings in private companies in the healthcare industry. During the three months ended March 31, 2021 and 2020, the Company recognized net revenues of $5 million and $9 million, respectively, associated with diagnostic information services provided to its equity method investees. As of March 31, 2021 and December 31, 2020, there was $5 million and $3 million, respectively, of accounts receivable from equity method investees related to such services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the three months ended March 31, 2021 and 2020, the Company recognized income of $3 million and $4 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. As of March 31, 2021 and December 31, 2020, there was $1 million and $3 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of both March 31, 2021 and December 31, 2020 included $1 million due to equity method investees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the three months ended March 31, 2021 and 2020, the Company received dividends from its equity method investees of $16 million and $5 million, respectively.</span></div> 5000000 9000000 5000000 3000000 3000000 4000000 1000000 3000000 1000000 1000000 16000000 5000000 REVENUE RECOGNITION<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DIS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Net revenues in the Company’s DIS business accounted for over 95% of the Company’s total net revenues for the three months ended March 31, 2021 and 2020 and are primarily comprised of a high volume of relatively low-dollar transactions. The DIS business, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered. The Company estimates the amount of consideration it expects to be entitled to receive from customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions. The portfolios determined using the portfolio approach consist of the following groups of customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For further details regarding revenue recognition in the Company's DIS business, see Note 3 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The approximate percentage of net revenue by type of customer was as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitated</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total healthcare insurers</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The approximate percentage of net accounts receivable by type of customer was as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Insurers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client Payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accounts receivable</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.95 0.95 The approximate percentage of net revenue by type of customer was as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare insurers:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitated</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total healthcare insurers</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0.38 0.34 0.02 0.03 0.40 0.37 0.10 0.14 0.35 0.33 0.12 0.12 0.97 0.96 0.03 0.04 1 1 The approximate percentage of net accounts receivable by type of customer was as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Insurers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Client Payers</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients (including coinsurance and deductible responsibilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total DIS</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accounts receivable</span></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 0.33 0.34 0.07 0.06 0.43 0.46 0.13 0.11 0.96 0.97 0.04 0.03 1 1 SUBSEQUENT EVENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On April 1, 2021, the Company sold its 40% ownership interest in Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solutions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solutions"), its clinical trials central laboratory services joint venture, to IQVIA Holdings, Inc. ("IQVIA"), its joint venture partner for $760 million in an all-cash transaction. Prior to the transaction, the Company accounted for its minority interest as an equity method investment. As a result of the transaction, the Company expects to record a pre-tax gain during the second quarter of 2021 of approximately $310 million. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Under a multi-year agreement, the Company will remain the strategic preferred laboratory provider for Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Solutions' clients, providing a range of complementary lab testing capabilities to augment Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Solutions' core offerings and extend its industry leading suite of services.</span></div> 0.40 760000000 310000000 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2021
Apr. 15, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-12215  
Entity Registrant Name Quest Diagnostics Inc  
Entity Central Index Key 0001022079  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 16-1387862  
Entity Address, Address Line One 500 Plaza Drive  
Entity Address, City or Town Secaucus,  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07094  
City Area Code (973)  
Local Phone Number 520-2700  
Title of 12(b) Security Common Stock, $0.01 Par Value  
Trading Symbol DGX  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   130,638,109
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Net revenues $ 2,720 $ 1,822
Operating costs and expenses and other operating income:    
Cost of services 1,626 1,270
Selling, general and administrative 407 347
Amortization of intangible assets 27 25
Other operating expense, net 0 5
Total operating costs and expenses, net 2,060 1,647
Operating income 660 175
Other income (expense):    
Interest expense, net (38) (41)
Other income (expense), net 4 (16)
Total non-operating expense, net (34) (57)
Income before income taxes and equity in earnings of equity method investees 626 118
Income tax expense (153) (26)
Equity in earnings of equity method investees, net of taxes 17 14
Net income 490 106
Less: Net income attributable to noncontrolling interests 21 7
Net income attributable to Quest Diagnostics $ 469 $ 99
Earnings per share attributable to Quest Diagnostics’ common stockholders:    
Basic(in dollars per share) $ 3.52 $ 0.74
Diluted (in dollars per share) $ 3.46 $ 0.73
Weighted average common shares outstanding:    
Basic (in Shares) 133 134
Diluted (in Shares) 135 135
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Statement of Comprehensive Income [Abstract]    
Net income $ 490 $ 106
Other comprehensive loss:    
Foreign currency translation adjustment (3) (19)
Net change in available-for-sale debt securities, net of taxes (7) 0
Other comprehensive loss (10) (19)
Comprehensive income 480 87
Less: Comprehensive income attributable to noncontrolling interests 21 7
Comprehensive income attributable to Quest Diagnostics $ 459 $ 80
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Assets    
Cash and cash equivalents $ 1,230 $ 1,158
Accounts receivable, net of allowance for credit losses of $29 and $28 as of March 31, 2021 and December 31, 2020, respectively 1,382 1,520
Inventories 223 223
Prepaid expenses and other current assets 164 157
Total current assets 2,999 3,058
Property, plant and equipment, net 1,624 1,627
Operating lease right-of-use assets 600 604
Goodwill 6,870 6,873
Intangible assets, net 1,141 1,167
Investments in equity method investees 527 521
Other assets 170 176
Total assets 13,931 14,026
Liabilities and Stockholders' Equity    
Accounts payable and accrued expenses 1,559 1,633
Current portion of long-term debt 2 2
Current portion of long-term operating lease liabilities 146 141
Total current liabilities 1,707 1,776
Long-term debt 4,010 4,013
Long-term operating lease liabilities 503 499
Other liabilities 842 847
Commitments and contingencies
Redeemable noncontrolling interest 79 82
Quest Diagnostics stockholders’ equity:    
Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2021 and December 31, 2020; 217 shares issued as of both March 31, 2021 and December 31, 2020 2 2
Additional paid-in capital 2,824 2,841
Retained earnings 9,690 9,303
Accumulated other comprehensive loss (31) (21)
Treasury stock, at cost; 86 and 84 shares as of March 31, 2021 and December 31, 2020, respectively (5,740) (5,366)
Total Quest Diagnostics stockholders' equity 6,745 6,759
Noncontrolling interests 45 50
Total stockholders' equity 6,790 6,809
Total liabilities and stockholders' equity $ 13,931 $ 14,026
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
shares in Millions, $ in Millions
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 29 $ 28
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 600 600
Common stock, shares issued (in shares) 217 217
Treasury stock (in shares) 86 84
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net income $ 490 $ 106
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 101 85
Provision for credit losses 2 7
Deferred income tax (benefit) provision (17) 14
Stock-based compensation expense 18 14
Other, net (2) (2)
Changes in operating assets and liabilities:    
Accounts receivable 138 85
Accounts payable and accrued expenses (164) (47)
Income taxes payable 163 (3)
Other assets and liabilities, net 2 (12)
Net cash provided by operating activities 731 247
Cash flows from investing activities:    
Business acquisitions, net of cash acquired 0 (108)
Capital expenditures (86) (83)
Increase in investments and other assets (7) (15)
Net cash used in investing activities (93) (206)
Cash flows from financing activities:    
Repayments of debt (1) (801)
Purchases of treasury stock (410) (75)
Exercise of stock options 17 80
Employee payroll tax withholdings on stock issued under stock-based compensation plans (21) (13)
Dividends paid (75) (71)
Distributions to noncontrolling interest partners (29) (7)
Other financing activities, net (47) (4)
Net cash used in financing activities (566) (891)
Net change in cash and cash equivalents and restricted cash 72 (850)
Cash and cash equivalents and restricted cash, beginning of period 1,158 1,192
Cash and cash equivalents and restricted cash, end of period $ 1,230 $ 342
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury Stock, at Cost
Non-controlling Interests
Balance, shares at Dec. 31, 2019   133.0          
Balance, value at Dec. 31, 2019 $ 5,687 $ 2 $ 2,722 $ 8,174 $ (39) $ (5,218) $ 46
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 105     99     6
Other comprehensive loss, net of taxes (19)       (19)    
Dividends declared (76)     (76)      
Distributions to noncontrolling interest partners (6)           (6)
Issuance of common stock under benefit plans 6   3     3  
Stock-based compensation expense 14   14        
Exercise of stock options, shares   2.0          
Exercise of stock options 80   12     $ 68  
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans (13)   (13)        
Purchases of treasury stock, shares   (1.0)       (0.7)  
Purchases of treasury stock (75)         $ (75)  
Balance, shares at Mar. 31, 2020   134.0          
Balance, value at Mar. 31, 2020 5,703 $ 2 2,738 8,197 (58) (5,222) 46
Balance, Value at Dec. 31, 2019 76            
Redeemable Non-controlling Interest [Abstract]              
Net income 1            
Distributions to noncontrolling interest partners (1)            
Balance, Value at Mar. 31, 2020 76            
Balance, shares at Dec. 31, 2020   133.0          
Balance, value at Dec. 31, 2020 6,809 $ 2 2,841 9,303 (21) (5,366) 50
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 486     469     17
Other comprehensive loss, net of taxes (10)       (10)    
Dividends declared (82)     (82)      
Distributions to noncontrolling interest partners (22)           (22)
Issuance of common stock under benefit plans 5   (29)     34  
Stock-based compensation expense 18   18        
Exercise of stock options, shares   1.0          
Exercise of stock options 17   3     14  
Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans (21)   (9)     $ (12)  
Purchases of treasury stock, shares   (3.0)       (3.4)  
Purchases of treasury stock (410)         $ (410)  
Balance, shares at Mar. 31, 2021   131.0          
Balance, value at Mar. 31, 2021 6,790 $ 2 $ 2,824 $ 9,690 $ (31) $ (5,740) $ 45
Balance, Value at Dec. 31, 2020 82            
Redeemable Non-controlling Interest [Abstract]              
Net income 4            
Distributions to noncontrolling interest partners (7)            
Balance, Value at Mar. 31, 2021 $ 79            
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.1
DESCRIPTION OF BUSINESS
 3 Months Ended
Mar. 31, 2021
Description of Business (Abstract)  
DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
    
    Background
    
    Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") empower people to take action to improve health outcomes.  The Company uses its extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management.  The Company's diagnostic information services business ("DIS") provides information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The Company provides services to a broad range of customers, including patients, clinicians, hospitals, independent delivery networks ("IDNs"), health plans, employers, accountable care organizations ("ACOs"), and direct contract entities ("DCEs"). The Company offers the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, patient service centers and phlebotomists in physician offices and the Company's connectivity resources, including call centers and mobile paramedics, nurses and other health and wellness professionals. The Company is the world's leading provider of diagnostic information services. The Company provides interpretive consultation with one of the largest medical and scientific staffs in the industry. The Company's Diagnostic Solutions businesses ("DS") are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    Basis of Presentation
    
    The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2020 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2020, but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”).

    The accounting policies of the Company are the same as those set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K.

    A novel strain of coronavirus (“COVID-19”) continues to spread and severely impact the economy of the United States and other countries around the world. The Company's testing volume and revenues have been materially impacted by the COVID-19 pandemic, including periods of decline in testing volume in the Company's base business (which excludes COVID-19 testing) compared to historical 2019 levels and periods of significant demand for COVID-19 testing. As a result, operating results for the three months ended March 31, 2021 may not be indicative of the results that may be expected for the full year.

    Use of Estimates
    
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

    Earnings Per Share

    The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings
allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.

    New Accounting Standards to be Adopted

    In March 2020, the Financial Accounting Standards Board issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The pronouncement is effective immediately and can be applied through December 31, 2022. The adoption of this standard is not expected to have a material impact on the Company’s consolidated results of operations, financial position or cash flows.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.1
EARNINGS PER SHARE
 3 Months Ended
Mar. 31, 2021
Earnings Per Share, Basic and Diluted [Abstract]  
EARNINGS (LOSS) PER SHARE EARNINGS PER SHARE
    The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
Three Months Ended March 31,
 20212020
Amounts attributable to Quest Diagnostics’ common stockholders:  
Net income attributable to Quest Diagnostics$469 $99 
Less: Earnings allocated to participating securities1 — 
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted
$468 $99 
Weighted average common shares outstanding – basic133 134 
Effect of dilutive securities:  
Stock options and performance share units2 1 
Weighted average common shares outstanding – diluted135 135 
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic$3.52 $0.74 
Diluted$3.46 $0.73 
    
    The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
Three Months Ended March 31,
20212020
Stock options and performance share units1 2 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.1
BUSINESS ACQUISITIONS
 3 Months Ended
Mar. 31, 2021
Business Combinations [Abstract]  
BUSINESS ACQUISITIONS BUSINESS ACQUISITIONS    On March 6, 2021, the Company entered into a definitive agreement to acquire the outreach laboratory services business of Mercy Health, which serves providers and patients in Arkansas, Kansas, Missouri and Oklahoma. The transaction, which is expected to close in mid-2021, remains subject to customary closing conditions.    For details regarding the Company's 2020 acquisitions, see Note 6 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.1
FAIR VALUE MEASUREMENTS
 3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
    Assets and Liabilities Measured at Fair Value on a Recurring Basis

    The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:
Basis of Fair Value Measurements
Quoted Prices in Active Markets for Identical Assets/LiabilitiesSignificant Other Observable InputsSignificant Unobservable Inputs
March 31, 2021TotalLevel 1Level 2Level 3
Assets:    
Trading securities$71 $71 $— $— 
Cash surrender value of life insurance policies52 — 52 — 
Available-for-sale debt securities2 — — 2 
Total$125 $71 $52 $2 
Liabilities:    
Deferred compensation liabilities$132 $— $132 $— 
Redeemable noncontrolling interest$79 $— $— $79 
Basis of Fair Value Measurements
December 31, 2020TotalLevel 1Level 2Level 3
Assets:       
Trading securities$67 $67 $— $— 
Cash surrender value of life insurance policies50 — 50 — 
Available-for-sale debt securities12 — — 12 
Total$129 $67 $50 $12 
Liabilities:    
Deferred compensation liabilities$126 $— $126 $— 
Redeemable noncontrolling interest$82 $— $— $82 
    
    A detailed description regarding the Company's fair value measurements is contained in Note 7 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.    
    The Company offers certain employees the opportunity to participate in a non-qualified supplemental deferred compensation plan. A participant's deferrals, together with Company matching credits, are invested in a variety of participant-directed stock and bond mutual funds that are classified as trading securities. The trading securities are classified within Level 1 of the fair value hierarchy because the changes in the fair value of these securities are measured using quoted prices in active markets based on the market price per unit multiplied by the number of units held, exclusive of any transaction costs. A corresponding adjustment for changes in fair value of the trading securities is also reflected in the changes in fair value of the deferred compensation obligation. The deferred compensation liabilities are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the trading securities.

    The Company offers certain employees the opportunity to participate in a non-qualified deferred compensation program. A participant's deferrals, together with Company matching credits, are “invested” at the direction of the employee in a hypothetical portfolio of investments which are tracked by an administrator. The Company purchases life insurance policies, with the Company named as beneficiary of the policies, for the purpose of funding the program's liability. Changes in the cash surrender value of the life insurance policies are based upon earnings and changes in the value of the underlying investments. Changes in the fair value of the deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash surrender value and the deferred compensation obligation are classified within Level 2 of the fair value hierarchy because their inputs are derived principally from observable market data by correlation to the hypothetical investments. Deferrals under the plan currently may only be made by participants who made deferrals under the plan in 2017.

    The Company's available-for-sale debt securities are measured at fair value based on estimated future cash flows. These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable, including cash flow projections.
        
    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass Memorial Medical Center ("UMass") on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. As of March 31, 2021, the redeemable noncontrolling interest was presented at its fair value. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy because the fair value is based on a discounted cash flow analysis that takes into account, among other items, the joint venture's expected future cash flows, long term growth rates, and a discount rate commensurate with economic risk.

    During the three months ended March 31, 2021, the Company recorded an $8 million impairment charge, which is included in equity in earnings of equity method investees, net of taxes, in order to adjust to fair value an investment that is accounted for under the equity method of accounting. Following the impairment charge, the carrying value of the investment is not material. The fair value measurement was classified within Level 3 of the fair value hierarchy as it was based on significant inputs that are not observable, including cash flow projections.
    
    The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses approximate fair value based on the short maturities of these instruments. As of March 31, 2021 and December 31, 2020, the fair value of the Company’s debt was estimated at $4.4 billion and $4.6 billion, respectively. Principally all of the Company's debt is classified within Level 1 of the fair value hierarchy because the fair value of the debt is estimated based on rates currently offered to the Company with identical terms and maturities, using quoted active market prices and yields, taking into account the underlying terms of the debt instruments.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.1
GOODWILL AND INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
    The changes in goodwill for the three months ended March 31, 2021 and for the year ended December 31, 2020 were as follows:
March 31, 2021December 31, 2020
Balance, beginning of period$6,873 $6,619 
Goodwill acquired during the period— 247 
Adjustments to goodwill(3)7 
Balance, end of period$6,870 $6,873 
    
    Principally all of the Company’s goodwill as of March 31, 2021 and December 31, 2020 was associated with its DIS business.

    For the three months ended March 31, 2021, adjustments to goodwill primarily related to foreign currency translation. For the year ended December 31, 2020, goodwill acquired was principally associated with the acquisitions of Blueprint Genetics Oy, Memorial Hermann Diagnostic Laboratories, the outreach laboratory division of Memorial Hermann Health System; and the remaining 56% interest in Mid America Clinical Laboratories, LLC (see Note 6 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K). For the year ended December 31, 2020, adjustments to goodwill primarily related to foreign currency translation.     

    Intangible assets as of March 31, 2021 and December 31, 2020 consisted of the following:
Weighted
Average
Amortization
Period
(in years)		March 31, 2021December 31, 2020
CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
Amortizing intangible assets:      
Customer-related17$1,481 $(659)$822 $1,479 $(638)$841 
Non-compete agreements93 (2)1 3 (2)1 
Technology15140 (68)72 141 (65)76 
Other5108 (98)10 108 (95)13 
Total171,732 (827)905 1,731 (800)931 
Intangible assets not subject to amortization:     
Trade names 235 — 235 235 — 235 
Other 1 — 1 1 — 1 
Total intangible assets$1,968 $(827)$1,141 $1,967 $(800)$1,167 
    
    The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2021 is as follows:
Year Ending December 31, 
Remainder of 2021$74 
202298 
202396 
202493 
202592 
202686 
Thereafter366 
Total$905 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.1
FINANCIAL INSTRUMENTS
 3 Months Ended
Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS     The Company uses derivative financial instruments to manage its exposure to market risks for changes in interest rates and, from time to time, foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral.
    Interest Rate Risk
    
    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements.

    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.

    Interest Rate Derivatives – Cash Flow Hedges

    From time to time, the Company has entered into various interest rate lock agreements and forward-starting interest rate swap agreements to hedge part of the Company's interest rate exposure associated with the variability in future cash flows attributable to changes in interest rates.

    The total net loss, net of taxes, recognized in accumulated other comprehensive loss, related to the Company's cash flow hedges was $1 million as of both March 31, 2021 and December 31, 2020. The net amount of deferred losses on cash flow hedges that is expected to be reclassified from accumulated other comprehensive loss into interest expense, net within the next twelve months is $1 million.

    Interest Rate Derivatives – Fair Value Hedges

    Historically, the Company has entered into various fixed-to-variable interest rate swap agreements in order to convert a portion of the Company's long-term debt into variable interest rate debt. All such fixed-to-variable interest rate swap agreements have been terminated and proceeds from the terminations have been reflected as basis adjustments to the hedged debt instruments and are being amortized as a reduction of interest expense, net over the remaining terms of such debt instruments.

    As of March 31, 2021 and December 31, 2020, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:
Hedge Accounting Basis Adjustment (a)
Balance Sheet ClassificationMarch 31, 2021December 31, 2020
Long-term debt$48 $51 

(a) As of both March 31, 2021 and December 31, 2020, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.
    The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
20212020
Other income (expense), netOther income (expense), net
Total for line item in which the effects of fair value hedges are recorded$4 $(16)
Gain (loss) on fair value hedging relationships:
Hedged items (Long-term debt)$— $(69)
Derivatives designated as hedging instruments$— $69 
    
    A detailed description regarding the Company's use of derivative financial instruments is contained in Note 15 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.1
STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
 3 Months Ended
Mar. 31, 2021
Stockholders' Equity Attributable to Parent [Abstract]  
STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST
    
    Stockholders' Equity    

    Changes in Accumulated Other Comprehensive Loss by Component

    Comprehensive income (loss) includes:

•Foreign currency translation adjustments;
•Net deferred gains (losses) on cash flow hedges, which represent deferred gains (losses), net of tax, on interest rate-related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 7); and
•Net changes in available-for-sale debt securities, which represent unrealized holding gains (losses), net of tax on available-for-sale debt securities.

    For the three months ended March 31, 2021 and 2020, the tax effects related to the deferred gains (losses) on cash flow hedges and net changes in available-for-sale debt securities were not material. Foreign currency translation adjustments related to indefinite investments in non-U.S. subsidiaries are not adjusted for income taxes.

    Dividend Program
    
    During the first quarter of 2021, the Company's Board of Directors declared a quarterly cash dividend of $0.62 per common share. During each of the four quarters of 2020, the Company's Board of Directors declared a quarterly cash dividend of $0.56 per common share.
    
    Share Repurchase Program
    
    In each of February and March 2021, the Company's Board of Directors increased the size of its share repurchase program by $1 billion. As of March 31, 2021, $2.5 billion remained available under the Company’s share repurchase authorization. The share repurchase authorization has no set expiration or termination date.
        
    Share Repurchases

    For the three months ended March 31, 2021, the Company repurchased 3.4 million shares of its common stock for $410 million.
    For the three months ended March 31, 2020, the Company repurchased 0.7 million shares of its common stock for $75 million.

    Shares Reissued from Treasury Stock

    The Company's practice has been to issue shares related to its Employee Stock Purchase Plan ("ESPP") and its stock-based compensation program from shares of its common stock held in treasury or by issuing new shares of its common stock. In January 2021, the Company began to issue shares related to its ESPP and stock-based compensation program solely from common stock held in treasury. For the three months ended March 31, 2021 and 2020, the Company reissued 0.6 million shares and 1.1 million shares, respectively from treasury stock. For details regarding the Company's stock ownership and compensation plans, see Note 17 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.    

    Redeemable Noncontrolling Interest

    In connection with the sale of an 18.9% noncontrolling interest in a subsidiary to UMass on July 1, 2015, the Company granted UMass the right to require the Company to purchase all of its interest in the subsidiary at fair value commencing July 1, 2020. The subsidiary performs diagnostic information services in a defined territory within the state of Massachusetts. Since the redemption of the noncontrolling interest is outside of the Company's control, it has been presented outside of stockholders' equity at the greater of its carrying amount or its fair value. As of March 31, 2021 and December 31, 2020, the redeemable noncontrolling interest was presented at its fair value. For further information regarding the fair value of the redeemable noncontrolling interest, see Note 5.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.1
SUPPLEMENTAL CASH FLOW & OTHER DATA
 3 Months Ended
Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]  
SUPPLEMENTAL CASH FLOW & OTHER DATA SUPPLEMENTAL CASH FLOW AND OTHER DATA
    Supplemental cash flow and other data for the three months ended March 31, 2021 and 2020 was as follows:
Three Months Ended March 31,
20212020
Depreciation expense$74 $60 
Amortization expense27 25 
Depreciation and amortization expense$101 $85 
Interest expense$(38)$(42)
Interest income— 1 
Interest expense, net$(38)$(41)
Interest paid$32 $48 
Income taxes paid$7 $18 
Accounts payable associated with capital expenditures$30 $11 
Dividends payable$82 $75 
Businesses acquired:  
Fair value of assets acquired$— $131 
Fair value of liabilities assumed— (20)
Fair value of net assets acquired— 111 
Less: Cash acquired— 3 
Business acquisitions, net of cash acquired$— $108 
Leases:
Leased assets obtained in exchange for new operating lease liabilities$36 $32 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
    Letters of Credit

    The Company can issue letters of credit totaling $100 million under its $600 million secured receivables credit facility and $150 million under its $750 million senior unsecured revolving credit facility. For further discussion regarding the Company's secured receivables credit facility and senior unsecured revolving credit facility, see Note 13 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.
    
    In support of its risk management program, to ensure the Company’s performance or payment to third parties, $70 million in letters of credit under the secured receivables credit facility were outstanding as of March 31, 2021. The letters of credit primarily represent collateral for current and future automobile liability and workers’ compensation loss payments.

    Contingent Lease Obligations
    
    The Company remains subject to contingent obligations under certain real estate leases, including leases that were entered into by certain predecessor companies of a subsidiary prior to the Company's acquisition of the subsidiary. No liability has been recorded for any of these potential contingent obligations. For further details, see Note 18 to the audited consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K.

    Certain Legal Matters

    The Company may incur losses associated with these proceedings and investigations, but it is not possible to estimate the amount of loss or range of loss, if any, that might result from adverse judgments, settlements, fines, penalties, or other resolution of these proceedings and investigations based on the stage of these proceedings and investigations, the absence of specific allegations as to alleged damages, the uncertainty as to the certification of a class or classes and the size of any certified class, if applicable, and/or the lack of resolution of significant factual and legal issues. The Company has insurance coverage rights in place (limited in amount; subject to deductible) for certain potential costs and liabilities related to these proceedings and investigations.

401(k) Plan Lawsuit
    
    In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Company’s 401(k) plan. The complaint alleges, among other things, that the fiduciaries of the 401(k) plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. In October 2020, the court consolidated the two lawsuits under the caption In re: Quest Diagnostics ERISA Litigation and plaintiffs filed a consolidated amended complaint. The Company plans to vigorously defend this matter and has filed a motion to dismiss the complaint.

AMCA Data Security Incident

    On June 3, 2019, the Company reported that Retrieval-Masters Creditors Bureau, Inc./American Medical Collection Agency (“AMCA”) had informed the Company and Optum360 LLC that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019 (the “AMCA Data Security Incident”). Optum360 provides revenue management services to the Company, and AMCA provided debt collection services to Optum360. AMCA first informed the Company of the AMCA Data Security Incident on May 14, 2019. AMCA’s affected system included financial information (e.g., credit card numbers and bank account information), medical information and other personal information (e.g., social security numbers). Test results were not included. Neither Optum360’s nor the Company’s systems or databases were involved in the incident. AMCA also informed the Company that information pertaining to other laboratories’ customers was also affected. Following announcement of the AMCA Data Security Incident, AMCA sought protection under the U.S. bankruptcy laws. The bankruptcy proceeding has been dismissed.

    Numerous putative class action lawsuits were filed against the Company related to the AMCA Data Security Incident. The U.S. Judicial Panel on Multidistrict Litigation transferred the cases still pending to, and consolidated them for pre-trial proceedings in, the U.S. District Court for New Jersey. In November 2019, the plaintiffs in the multidistrict proceeding filed a consolidated putative class action complaint against the Company and Optum360 that named additional individuals as plaintiffs and that asserted a variety of common law and statutory claims in connection with the AMCA Data Security Incident. In January 2020, the Company moved to dismiss the consolidated complaint; the motion to dismiss is pending.

    In addition, certain federal and state governmental authorities are investigating, or otherwise seeking information and/or documents from the Company related to the AMCA Data Security Incident and related matters, including the Office for Civil Rights of the U.S. Department of Health and Human Services, Attorneys General offices from numerous states and the District of Columbia, and certain U.S. senators.
    Other Legal Matters

    In the normal course of business, the Company has been named, from time to time, as a defendant in various legal actions, including arbitrations, class actions and other litigation, arising in connection with the Company's activities as a provider of diagnostic testing, information and services. These actions could involve claims for substantial compensatory and/or punitive damages or claims for indeterminate amounts of damages, and could have an adverse impact on the Company's client base and reputation.

    The Company is also involved, from time to time, in other reviews, investigations and proceedings by governmental agencies regarding the Company's business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief.

    The federal or state governments may bring claims based on the Company's current practices, which it believes are lawful. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of government or private payers. The Company is aware of lawsuits, and from time to time has received subpoenas, related to billing practices based on the qui tam provisions of the Civil False Claims Act or other federal and state statutes, regulations or other laws. The Company understands that there may be other pending qui tam claims brought by former employees or other "whistle blowers" as to which the Company cannot determine the extent of any potential liability.

    Management cannot predict the outcome of such matters. Although management does not anticipate that the ultimate outcome of such matters will have a material adverse effect on the Company's financial condition, given the high degree of judgment involved in establishing loss estimates related to these types of matters, the outcome of such matters may be material to the Company's consolidated results of operations or cash flows in the period in which the impact of such matters is determined or paid.

    These matters are in different stages. Some of these matters are in their early stages. Matters may involve responding to and cooperating with various government investigations and related subpoenas. As of March 31, 2021, the Company does not believe that material losses related to legal matters are probable.

    Reserves for legal matters totaled $2 million and $1 million as of March 31, 2021 and December 31, 2020, respectively.

    Reserves for General and Professional Liability Claims
    As a general matter, providers of clinical testing services may be subject to lawsuits alleging negligence or other similar legal claims. These suits could involve claims for substantial damages. Any professional liability litigation could also have an adverse impact on the Company's client base and reputation. The Company maintains various liability insurance coverages for, among other things, claims that could result from providing, or failing to provide, clinical testing services, including inaccurate testing results, and other exposures. The Company's insurance coverage limits its maximum exposure on individual claims; however, the Company is essentially self-insured for a significant portion of these claims. Reserves for such matters, including those associated with both asserted and incurred but not reported claims, are established on an undiscounted basis by considering actuarially determined losses based upon the Company's historical and projected loss experience. Such reserves totaled $142 million and $138 million as of March 31, 2021 and December 31, 2020, respectively. Management believes that established reserves and present insurance coverage are sufficient to cover currently estimated exposures.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.1
BUSINESS SEGMENT INFORMATION
 3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
BUSINESS SEGMENT INFORMATION BUSINESS SEGMENT INFORMATION
    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, ACOs and DCEs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for greater than 95% of net revenues in 2021 and 2020.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.
        
    As of March 31, 2021, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.

    The following table is a summary of segment information for the three months ended March 31, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended March 31,
20212020
Net revenues:  
DIS business$2,643 $1,744 
All other operating segments77 78 
Total net revenues $2,720 $1,822 
Operating earnings (loss):  
DIS business$712 $205 
All other operating segments9 9 
General corporate activities(61)(39)
Total operating income660 175 
Non-operating expense, net(34)(57)
Income before income taxes and equity in earnings of equity method investees626 118 
Income tax expense(153)(26)
Equity in earnings of equity method investees, net of taxes17 14 
Net income490 106 
Less: Net income attributable to noncontrolling interests21 7 
Net income attributable to Quest Diagnostics$469 $99 
    Net revenues by major service were as follows:

Three Months Ended March 31,
20212020
Routine clinical testing services$1,032 $945 
COVID-19 testing services828 24 
Gene-based and esoteric (including advanced diagnostics) testing services653 641 
Anatomic pathology testing services130 134 
All other77 78 
Total net revenues$2,720 $1,822 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.1
RELATED PARTIES
 3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions RELATED PARTIES
    The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture (see Note 14), a diagnostic information services joint venture, and an investment in a fund that purchases strategic holdings in private companies in the healthcare industry. During the three months ended March 31, 2021 and 2020, the Company recognized net revenues of $5 million and $9 million, respectively, associated with diagnostic information services provided to its equity method investees. As of March 31, 2021 and December 31, 2020, there was $5 million and $3 million, respectively, of accounts receivable from equity method investees related to such services.

    During the three months ended March 31, 2021 and 2020, the Company recognized income of $3 million and $4 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. As of March 31, 2021 and December 31, 2020, there was $1 million and $3 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of both March 31, 2021 and December 31, 2020 included $1 million due to equity method investees.

    During the three months ended March 31, 2021 and 2020, the Company received dividends from its equity method investees of $16 million and $5 million, respectively.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.1
REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES
 3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGITION AND ALLOWANCE FOR CREDIT LOSSES REVENUE RECOGNITION
    DIS

    Net revenues in the Company’s DIS business accounted for over 95% of the Company’s total net revenues for the three months ended March 31, 2021 and 2020 and are primarily comprised of a high volume of relatively low-dollar transactions. The DIS business, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered. The Company estimates the amount of consideration it expects to be entitled to receive from customer groups in exchange for providing services using the portfolio approach. These estimates include the impact of contractual allowances (including payer denials), and patient price concessions. The portfolios determined using the portfolio approach consist of the following groups of customers: healthcare insurers, government payers (Medicare and Medicaid programs), client payers and patients.

    For further details regarding revenue recognition in the Company's DIS business, see Note 3 to the audited consolidated financial statements in the Company's 2020 Annual Report on Form 10-K.

    DS
    The Company’s DS businesses primarily satisfy their performance obligations and recognize revenues when delivery has occurred or services have been rendered.

    The approximate percentage of net revenue by type of customer was as follows:
    
Three Months Ended March 31,
20212020
Healthcare insurers:
Fee-for-service38 %34 %
Capitated2 3 
Total healthcare insurers40 37 
Government payers10 14 
Client payers35 33 
Patients12 12 
Total DIS97 96 
DS3 4 
Net revenues100 %100 %
    
    The approximate percentage of net accounts receivable by type of customer was as follows:
March 31, 2021December 31, 2020
Healthcare Insurers33 %34 %
Government Payers7 6 
Client Payers43 46 
Patients (including coinsurance and deductible responsibilities)13 11 
Total DIS96 97 
DS4 3 
Net accounts receivable100 %100 %
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.1
SUBSEQUENT EVENT
 3 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
    On April 1, 2021, the Company sold its 40% ownership interest in Q2 Solutions® ("Q2 Solutions"), its clinical trials central laboratory services joint venture, to IQVIA Holdings, Inc. ("IQVIA"), its joint venture partner for $760 million in an all-cash transaction. Prior to the transaction, the Company accounted for its minority interest as an equity method investment. As a result of the transaction, the Company expects to record a pre-tax gain during the second quarter of 2021 of approximately $310 million.

    Under a multi-year agreement, the Company will remain the strategic preferred laboratory provider for Q2 Solutions' clients, providing a range of complementary lab testing capabilities to augment Q2 Solutions' core offerings and extend its industry leading suite of services.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation The interim unaudited consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, comprehensive income, financial condition, cash flows and stockholders' equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the full year. These interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s 2020 Annual Report on Form 10-K. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2020, but does not include all the disclosures required by accounting principles generally accepted in the United States (“GAAP”).
Use Of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Earnings Per Share The Company's unvested restricted stock units that contain non-forfeitable rights to dividends are participating securities and, therefore, are included in the earnings allocation in computing earnings per share using the two-class method. Basic earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding. Diluted earnings per common share is calculated by dividing net income attributable to Quest Diagnostics, adjusted for earnings allocated to participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan and its Amended and Restated Non-Employee Director Long-Term Incentive Plan. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities.
New Accounting Standards to be Adopted In March 2020, the Financial Accounting Standards Board issued a new accounting standard which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform due to the risk of cessation of the London Interbank Offered Rate ("LIBOR"). The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The pronouncement is effective immediately and can be applied through December 31, 2022. The adoption of this standard is not expected to have a material impact on the Company’s consolidated results of operations, financial position or cash flows.
Derivative Financial Instruments The Company uses derivative financial instruments to manage its exposure to market risks for changes in interest rates and, from time to time, foreign currencies. This strategy includes the use of interest rate swap agreements, forward-starting interest rate swap agreements, interest rate lock agreements and foreign currency forward contracts to manage its exposure to movements in interest and currency rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. These policies prohibit holding or issuing derivative financial instruments for speculative purposes. The Company does not enter into derivative financial instruments that contain credit-risk-related contingent features or requirements to post collateral.
    Interest Rate Risk
    
    The Company is exposed to interest rate risk on its cash and cash equivalents and its debt obligations. Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company's debt obligations consist of fixed-rate and variable-rate debt instruments. The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. In order to achieve this objective, the Company has historically entered into interest rate swap agreements.

    Interest rate swaps involve the periodic exchange of payments without the exchange of underlying principal or notional amounts. Net settlements between the counterparties are recognized as an adjustment to interest expense, net.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.1
EARNINGS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2021
Earnings Per Share, Basic and Diluted [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
Three Months Ended March 31,
 20212020
Amounts attributable to Quest Diagnostics’ common stockholders:  
Net income attributable to Quest Diagnostics$469 $99 
Less: Earnings allocated to participating securities1 — 
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted
$468 $99 
Weighted average common shares outstanding – basic133 134 
Effect of dilutive securities:  
Stock options and performance share units2 1 
Weighted average common shares outstanding – diluted135 135 
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic$3.52 $0.74 
Diluted$3.46 $0.73 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
Three Months Ended March 31,
20212020
Stock options and performance share units1 2 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.1
FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value, Measurement Inputs The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:
Basis of Fair Value Measurements
Quoted Prices in Active Markets for Identical Assets/LiabilitiesSignificant Other Observable InputsSignificant Unobservable Inputs
March 31, 2021TotalLevel 1Level 2Level 3
Assets:    
Trading securities$71 $71 $— $— 
Cash surrender value of life insurance policies52 — 52 — 
Available-for-sale debt securities2 — — 2 
Total$125 $71 $52 $2 
Liabilities:    
Deferred compensation liabilities$132 $— $132 $— 
Redeemable noncontrolling interest$79 $— $— $79 
Basis of Fair Value Measurements
December 31, 2020TotalLevel 1Level 2Level 3
Assets:       
Trading securities$67 $67 $— $— 
Cash surrender value of life insurance policies50 — 50 — 
Available-for-sale debt securities12 — — 12 
Total$129 $67 $50 $12 
Liabilities:    
Deferred compensation liabilities$126 $— $126 $— 
Redeemable noncontrolling interest$82 $— $— $82 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in Goodwill, Net The changes in goodwill for the three months ended March 31, 2021 and for the year ended December 31, 2020 were as follows:
March 31, 2021December 31, 2020
Balance, beginning of period$6,873 $6,619 
Goodwill acquired during the period— 247 
Adjustments to goodwill(3)7 
Balance, end of period$6,870 $6,873 
Intangible Assets Excluding Goodwill Intangible assets as of March 31, 2021 and December 31, 2020 consisted of the following:
Weighted
Average
Amortization
Period
(in years)		March 31, 2021December 31, 2020
CostAccumulated
Amortization		NetCostAccumulated
Amortization		Net
Amortizing intangible assets:      
Customer-related17$1,481 $(659)$822 $1,479 $(638)$841 
Non-compete agreements93 (2)1 3 (2)1 
Technology15140 (68)72 141 (65)76 
Other5108 (98)10 108 (95)13 
Total171,732 (827)905 1,731 (800)931 
Intangible assets not subject to amortization:     
Trade names 235 — 235 235 — 235 
Other 1 — 1 1 — 1 
Total intangible assets$1,968 $(827)$1,141 $1,967 $(800)$1,167 
Future Amortization Expense Intangible Assets The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2021 is as follows:
Year Ending December 31, 
Remainder of 2021$74 
202298 
202396 
202493 
202592 
202686 
Thereafter366 
Total$905 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.1
FINANCIAL INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt As of March 31, 2021 and December 31, 2020, the following amounts were recorded on the consolidated balance sheets related to cumulative basis adjustments for fair value hedges included in the carrying amount of long-term debt:
Hedge Accounting Basis Adjustment (a)
Balance Sheet ClassificationMarch 31, 2021December 31, 2020
Long-term debt$48 $51 

(a) As of both March 31, 2021 and December 31, 2020, the entire balance is associated with remaining unamortized hedging adjustments on discontinued relationships.
Schedule of Fair Value Hedge Accounting on the Statement of Operations The following table presents the effect of fair value hedge accounting on the consolidated statements of operations for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
20212020
Other income (expense), netOther income (expense), net
Total for line item in which the effects of fair value hedges are recorded$4 $(16)
Gain (loss) on fair value hedging relationships:
Hedged items (Long-term debt)$— $(69)
Derivatives designated as hedging instruments$— $69 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.1
SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables)
 3 Months Ended
Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow and Other Data Supplemental cash flow and other data for the three months ended March 31, 2021 and 2020 was as follows:
Three Months Ended March 31,
20212020
Depreciation expense$74 $60 
Amortization expense27 25 
Depreciation and amortization expense$101 $85 
Interest expense$(38)$(42)
Interest income— 1 
Interest expense, net$(38)$(41)
Interest paid$32 $48 
Income taxes paid$7 $18 
Accounts payable associated with capital expenditures$30 $11 
Dividends payable$82 $75 
Businesses acquired:  
Fair value of assets acquired$— $131 
Fair value of liabilities assumed— (20)
Fair value of net assets acquired— 111 
Less: Cash acquired— 3 
Business acquisitions, net of cash acquired$— $108 
Leases:
Leased assets obtained in exchange for new operating lease liabilities$36 $32 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.1
BUSINESS SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Summary of Segment Reporting Information by Segment The following table is a summary of segment information for the three months ended March 31, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2020 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended March 31,
20212020
Net revenues:  
DIS business$2,643 $1,744 
All other operating segments77 78 
Total net revenues $2,720 $1,822 
Operating earnings (loss):  
DIS business$712 $205 
All other operating segments9 9 
General corporate activities(61)(39)
Total operating income660 175 
Non-operating expense, net(34)(57)
Income before income taxes and equity in earnings of equity method investees626 118 
Income tax expense(153)(26)
Equity in earnings of equity method investees, net of taxes17 14 
Net income490 106 
Less: Net income attributable to noncontrolling interests21 7 
Net income attributable to Quest Diagnostics$469 $99 
Schedule of Revenues by Major Service Net revenues by major service were as follows:
Three Months Ended March 31,
20212020
Routine clinical testing services$1,032 $945 
COVID-19 testing services828 24 
Gene-based and esoteric (including advanced diagnostics) testing services653 641 
Anatomic pathology testing services130 134 
All other77 78 
Total net revenues$2,720 $1,822 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.1
REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Tables)
 3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue The approximate percentage of net revenue by type of customer was as follows:
    
Three Months Ended March 31,
20212020
Healthcare insurers:
Fee-for-service38 %34 %
Capitated2 3 
Total healthcare insurers40 37 
Government payers10 14 
Client payers35 33 
Patients12 12 
Total DIS97 96 
DS3 4 
Net revenues100 %100 %
Accounts Receivable Disaggregation The approximate percentage of net accounts receivable by type of customer was as follows:
March 31, 2021December 31, 2020
Healthcare Insurers33 %34 %
Government Payers7 6 
Client Payers43 46 
Patients (including coinsurance and deductible responsibilities)13 11 
Total DIS96 97 
DS4 3 
Net accounts receivable100 %100 %
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.1
EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Amounts attributable to Quest Diagnostics’ common stockholders:    
Net income attributable to Quest Diagnostics $ 469 $ 99
Less: Earnings allocated to participating securities 1 0
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted $ 468 $ 99
Weighted average common shares outstanding - basic 133 134
Stock options and performance share units 2 1
Weighted average common shares outstanding - diluted 135 135
Basic(in dollars per share) $ 3.52 $ 0.74
Diluted (in dollars per share) $ 3.46 $ 0.73
Stock options and performance share units 1 2
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.1
FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details) - Recurring Basis - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Trading securities $ 71 $ 67
Cash surrender value of life insurance policies 52 50
Available-for-sale debt securities 2 12
Total 125 129
Deferred compensation liabilities 132 126
Redeemable noncontrolling interest 79 82
Quoted Prices in Active Markets for Identical Assets / Liabilities, Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Trading securities 71 67
Cash surrender value of life insurance policies 0 0
Available-for-sale debt securities 0 0
Total 71 67
Deferred compensation liabilities 0 0
Redeemable noncontrolling interest 0 0
Significant Other Observable Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Trading securities 0 0
Cash surrender value of life insurance policies 52 50
Available-for-sale debt securities 0 0
Total 52 50
Deferred compensation liabilities 132 126
Significant Unobservable Inputs, Level 3    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Trading securities 0 0
Cash surrender value of life insurance policies 0 0
Available-for-sale debt securities 2 12
Total 2 12
Deferred compensation liabilities 0 0
Redeemable noncontrolling interest $ 79 $ 82
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.1
FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Jul. 01, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Fair value of debt $ 4,400 $ 4,600  
Fair Value, Inputs, Level 3      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Impairment of equity method investment $ 8    
UMass Joint Venture      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Ownership percentage by noncontrolling owners     18.90%
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.1
GOODWILL AND INTANGIBLE ASSETS (Goodwill) (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Goodwill [Roll Forward]    
Goodwill, Balance at beginning of period $ 6,873 $ 6,619
Goodwill acquired during the period 0 247
Adjustments to goodwill (3) 7
Goodwill, Balance at end of period $ 6,870 $ 6,873
MACL    
Business Acquisition [Line Items]    
Percentage of interests acquired   56.00%
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.1
GOODWILL AND INTANGIBLE ASSETS (Schedules) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Finite-Lived and Indefinite-lived Intangible Assets [Line Items]      
Intangible assets, Cost $ 1,968   $ 1,967
Intangible assets, Accumulated Amortization (827)   (800)
Total intangible assets, Net 1,141   1,167
Amortization expense 27 $ 25  
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]      
Remainder of 2021 74    
2022 98    
2023 96    
2024 93    
2025 92    
2026 86    
Thereafter 366    
Total 905    
Intangible Assets Not Subject to Amortization - Tradenames      
Finite-Lived and Indefinite-lived Intangible Assets [Line Items]      
Intangible assets, Cost 235   235
Total intangible assets, Net 235   235
Intangible Assets Not Subject to Amortization - Other      
Finite-Lived and Indefinite-lived Intangible Assets [Line Items]      
Intangible assets, Cost 1   1
Total intangible assets, Net $ 1   1
Customer-related intangibles      
Finite-Lived and Indefinite-lived Intangible Assets [Line Items]      
Weighted Average Amortization Period 17 years    
Intangible assets, Cost $ 1,481   1,479
Intangible assets, Accumulated Amortization (659)   (638)
Total intangible assets, Net $ 822   841
Non-compete agreements      
Finite-Lived and Indefinite-lived Intangible Assets [Line Items]      
Weighted Average Amortization Period 9 years    
Intangible assets, Cost $ 3   3
Intangible assets, Accumulated Amortization (2)   (2)
Total intangible assets, Net $ 1   1
Technology      
Finite-Lived and Indefinite-lived Intangible Assets [Line Items]      
Weighted Average Amortization Period 15 years    
Intangible assets, Cost $ 140   141
Intangible assets, Accumulated Amortization (68)   (65)
Total intangible assets, Net $ 72   76
Other      
Finite-Lived and Indefinite-lived Intangible Assets [Line Items]      
Weighted Average Amortization Period 5 years    
Intangible assets, Cost $ 108   108
Intangible assets, Accumulated Amortization (98)   (95)
Total intangible assets, Net $ 10   13
Total Amortizing Intangible Assets      
Finite-Lived and Indefinite-lived Intangible Assets [Line Items]      
Weighted Average Amortization Period 17 years    
Intangible assets, Cost $ 1,732   1,731
Intangible assets, Accumulated Amortization (827)   (800)
Total intangible assets, Net $ 905   $ 931
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.1
FINANCIAL INSTRUMENTS (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Derivative [Line Items]    
Accumulated other comprehensive loss $ (31) $ (21)
Net amount of deferred gains and losses on cash flow hedges that is expected to be reclassified within the next 12 months 1  
Cash Flow Hedging    
Derivative [Line Items]    
Accumulated other comprehensive loss $ 1 $ 1
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.1
FINANCIAL INSTRUMENTS (Balance Sheets) (Details) - USD ($)
$ in Millions
Mar. 31, 2021
Dec. 31, 2020
Long-term Debt | Fair Value Hedging    
Derivative [Line Items]    
Hedge Accounting Basis Adjustment $ 48 $ 51
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.1
FINANCIAL INSTRUMENTS (Income Statement) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Derivative [Line Items]    
Other income (expense), net $ 4 $ (16)
Other Nonoperating Income (Expense)    
Derivative [Line Items]    
Hedged items (Long-term debt) 0 (69)
Other Nonoperating Income (Expense) | Fair Value Hedging    
Derivative [Line Items]    
Derivatives designated as hedging instruments $ 0 $ 69
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.1
STOCKHOLDERS’ EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details) - USD ($)
$ / shares in Units, shares in Millions
 1 Months Ended 3 Months Ended
Mar. 31, 2021
Feb. 28, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Jul. 01, 2015
Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]                
Dividends per common share     $ 0.62 $ 0.56 $ 0.56 $ 0.56 $ 0.56  
Additional amount authorized $ 1,000,000,000 $ 1,000,000,000            
Share repurchase authorization remaining available $ 2,500,000,000   $ 2,500,000,000          
Purchases of treasury stock, value     $ 410,000,000       $ 75,000,000  
Reissuance of shares for employee benefit plan     0.6       1.1  
UMass Joint Venture                
Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]                
Ownership percentage by noncontrolling owners               18.90%
Treasury Stock, at Cost                
Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]                
Purchases of treasury stock- shares     3.4       0.7  
Purchases of treasury stock, value     $ 410,000,000       $ 75,000,000  
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.1
SUPPLEMENTAL CASH FLOW & OTHER DATA (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Supplemental Cash Flow Elements [Abstract]    
Depreciation expense $ 74 $ 60
Amortization expense 27 25
Depreciation and amortization expense 101 85
Interest expense (38) (42)
Interest income 0 1
Interest expense, net (38) (41)
Interest paid 32 48
Income taxes paid 7 18
Accounts payable associated with capital expenditures 30 11
Dividends payable 82 75
Fair value of assets acquired 0 131
Fair value of liabilities assumed 0 (20)
Fair value of net assets acquired 0 111
Less: Cash acquired 0 3
Business acquisitions, net of cash acquired 0 108
Leases:    
Leased assets obtained in exchange for new operating lease liabilities $ 36 $ 32
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.1
COMMITMENTS AND CONTINGENCIES (Details)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
claim
Oct. 31, 2020
claim
Debt Instrument [Line Items]      
Self-insurance reserves $ 142,000,000 $ 138,000,000  
Class action lawsuits | claim   2 2
Secured Receivables Credit Facility      
Debt Instrument [Line Items]      
Credit facility capacity 600,000,000    
Letters of credit outstanding, amount 70,000,000    
Secured Receivables Credit Facility | Letter of Credit      
Debt Instrument [Line Items]      
Credit facility capacity 100,000,000    
Revolving Credit Facility | Letter of Credit      
Debt Instrument [Line Items]      
Credit facility capacity 150,000,000    
Senior Unsecured Revolving Credit Facility      
Debt Instrument [Line Items]      
Remaining borrowing capacity 750,000,000    
Excludes general and professional liability claims      
Loss Contingencies [Line Items]      
Litigation reserves $ 2,000,000 $ 1,000,000  
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.1
BUSINESS SEGMENT INFORMATION (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting Information [Line Items]    
Percentage of net revenues 100.00% 100.00%
Total net revenues $ 2,720 $ 1,822
Total operating income 660 175
Non-operating expense, net (34) (57)
Income before income taxes and equity in earnings of equity method investees 626 118
Income tax expense (153) (26)
Equity in earnings of equity method investees, net of taxes 17 14
Net income 490 106
Less: Net income attributable to noncontrolling interests 21 7
Net income attributable to Quest Diagnostics 469 99
Routine clinical testing services    
Segment Reporting Information [Line Items]    
Total net revenues 1,032 945
COVID-19 Testing Services    
Segment Reporting Information [Line Items]    
Total net revenues 828 24
Gene-based and esoteric testing services    
Segment Reporting Information [Line Items]    
Total net revenues 653 641
Anatomic pathology testing services    
Segment Reporting Information [Line Items]    
Total net revenues 130 134
All other services    
Segment Reporting Information [Line Items]    
Total net revenues $ 77 $ 78
DIS business    
Segment Reporting Information [Line Items]    
Percentage of net revenues 97.00% 96.00%
Total net revenues $ 2,643 $ 1,744
Total operating income $ 712 $ 205
DIS business | Minimum    
Segment Reporting Information [Line Items]    
Percentage of net revenues 95.00% 95.00%
All other operating segments    
Segment Reporting Information [Line Items]    
Total net revenues $ 77 $ 78
Total operating income 9 9
General corporate activities    
Segment Reporting Information [Line Items]    
Total operating income $ (61) $ (39)
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.1
RELATED PARTIES (Details) - Equity Method Investee - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Related Party Transaction [Line Items]      
Revenues $ 5 $ 9  
Receivables 5   $ 3
Accounts payable, related parties 1   1
Dividends received 16 5  
Prepaid expenses and other current assets      
Related Party Transaction [Line Items]      
Other accounts receivable, related parties 1   $ 3
Selling, general and administrative      
Related Party Transaction [Line Items]      
Income from related party recognized $ 3 $ 4  
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.1
REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Details)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Segment Reporting Information [Line Items]      
Percentage of net revenues 100.00% 100.00%  
Net accounts receivable 100.00%   100.00%
DIS business      
Segment Reporting Information [Line Items]      
Percentage of net revenues 97.00% 96.00%  
Net accounts receivable 96.00%   97.00%
DIS business | Healthcare Insurers      
Segment Reporting Information [Line Items]      
Percentage of net revenues 40.00% 37.00%  
Net accounts receivable 33.00%   34.00%
DIS business | Healthcare Insurers | Fee-for-service      
Segment Reporting Information [Line Items]      
Percentage of net revenues 38.00% 34.00%  
DIS business | Healthcare Insurers | Capitated      
Segment Reporting Information [Line Items]      
Percentage of net revenues 2.00% 3.00%  
DIS business | Government Payers      
Segment Reporting Information [Line Items]      
Percentage of net revenues 10.00% 14.00%  
Net accounts receivable 7.00%   6.00%
DIS business | Client Payers      
Segment Reporting Information [Line Items]      
Percentage of net revenues 35.00% 33.00%  
Net accounts receivable 43.00%   46.00%
DIS business | Patients      
Segment Reporting Information [Line Items]      
Percentage of net revenues 12.00% 12.00%  
Net accounts receivable 13.00%   11.00%
DIS business | Minimum      
Segment Reporting Information [Line Items]      
Percentage of net revenues 95.00% 95.00%  
All other operating segments | DS Businesses      
Segment Reporting Information [Line Items]      
Percentage of net revenues 3.00% 4.00%  
Net accounts receivable 4.00%   3.00%
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.1
SUBSEQUENT EVENT (Details) - Q2 Solutions - USD ($)
$ in Millions
 3 Months Ended
Jun. 30, 2021
Apr. 01, 2021
Scenario, Forecast    
Subsequent Event [Line Items]    
Gain on sale of investment, before tax $ 310  
Subsequent Event    
Subsequent Event [Line Items]    
Percent of ownership interest sold   40.00%
Consideration   $ 760
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 148 291 1 false 50 0 false 5 false false R1.htm 0001001 - Document - Cover Page Sheet http://questdiagnostics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 1006007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 7 false false R8.htm 2101101 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS DESCRIPTION OF BUSINESS Notes 8 false false R9.htm 2102102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2104103 - Disclosure - EARNINGS PER SHARE Sheet http://questdiagnostics.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 10 false false R11.htm 2107104 - Disclosure - BUSINESS ACQUISITIONS Sheet http://questdiagnostics.com/role/BUSINESSACQUISITIONS BUSINESS ACQUISITIONS Notes 11 false false R12.htm 2108105 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 2112106 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 13 false false R14.htm 2116107 - Disclosure - FINANCIAL INSTRUMENTS Sheet http://questdiagnostics.com/role/FINANCIALINSTRUMENTS FINANCIAL INSTRUMENTS Notes 14 false false R15.htm 2121108 - Disclosure - STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Sheet http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST Notes 15 false false R16.htm 2123109 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA Sheet http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATA SUPPLEMENTAL CASH FLOW & OTHER DATA Notes 16 false false R17.htm 2126110 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 2128111 - Disclosure - BUSINESS SEGMENT INFORMATION Sheet http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION BUSINESS SEGMENT INFORMATION Notes 18 false false R19.htm 2131112 - Disclosure - RELATED PARTIES Sheet http://questdiagnostics.com/role/RELATEDPARTIES RELATED PARTIES Notes 19 false false R20.htm 2133113 - Disclosure - REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES Sheet http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSES REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES Notes 20 false false R21.htm 2136114 - Disclosure - SUBSEQUENT EVENT Sheet http://questdiagnostics.com/role/SUBSEQUENTEVENT SUBSEQUENT EVENT Notes 21 false false R22.htm 2203201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 2305301 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://questdiagnostics.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://questdiagnostics.com/role/EARNINGSPERSHARE 23 false false R24.htm 2309302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS 24 false false R25.htm 2313303 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS 25 false false R26.htm 2317304 - Disclosure - FINANCIAL INSTRUMENTS (Tables) Sheet http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables FINANCIAL INSTRUMENTS (Tables) Tables http://questdiagnostics.com/role/FINANCIALINSTRUMENTS 26 false false R27.htm 2324305 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables) Sheet http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATATables SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables) Tables http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATA 27 false false R28.htm 2329306 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables) Sheet http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables BUSINESS SEGMENT INFORMATION (Tables) Tables http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION 28 false false R29.htm 2334307 - Disclosure - REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Tables) Sheet http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESTables REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Tables) Tables http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSES 29 false false R30.htm 2406401 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://questdiagnostics.com/role/EARNINGSPERSHAREDetails EARNINGS PER SHARE (Details) Details http://questdiagnostics.com/role/EARNINGSPERSHARETables 30 false false R31.htm 2410402 - Disclosure - FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details) Sheet http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details) Details http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables 31 false false R32.htm 2411403 - Disclosure - FAIR VALUE MEASUREMENTS (Narrative) (Details) Sheet http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails FAIR VALUE MEASUREMENTS (Narrative) (Details) Details http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables 32 false false R33.htm 2414404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Goodwill) (Details) Sheet http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails GOODWILL AND INTANGIBLE ASSETS (Goodwill) (Details) Details http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables 33 false false R34.htm 2415405 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedules) (Details) Sheet http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails GOODWILL AND INTANGIBLE ASSETS (Schedules) (Details) Details http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables 34 false false R35.htm 2418406 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details) Sheet http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails FINANCIAL INSTRUMENTS (Narrative) (Details) Details http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables 35 false false R36.htm 2419407 - Disclosure - FINANCIAL INSTRUMENTS (Balance Sheets) (Details) Sheet http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails FINANCIAL INSTRUMENTS (Balance Sheets) (Details) Details http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables 36 false false R37.htm 2420408 - Disclosure - FINANCIAL INSTRUMENTS (Income Statement) (Details) Sheet http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails FINANCIAL INSTRUMENTS (Income Statement) (Details) Details http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables 37 false false R38.htm 2422409 - Disclosure - STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details) Sheet http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails STOCKHOLDERS??? EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details) Details http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST 38 false false R39.htm 2425410 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Details) Sheet http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails SUPPLEMENTAL CASH FLOW & OTHER DATA (Details) Details http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATATables 39 false false R40.htm 2427411 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES 40 false false R41.htm 2430412 - Disclosure - BUSINESS SEGMENT INFORMATION (Details) Sheet http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails BUSINESS SEGMENT INFORMATION (Details) Details http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables 41 false false R42.htm 2432413 - Disclosure - RELATED PARTIES (Details) Sheet http://questdiagnostics.com/role/RELATEDPARTIESDetails RELATED PARTIES (Details) Details http://questdiagnostics.com/role/RELATEDPARTIES 42 false false R43.htm 2435414 - Disclosure - REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Details) Sheet http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Details) Details http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESTables 43 false false R44.htm 2437415 - Disclosure - SUBSEQUENT EVENT (Details) Sheet http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails SUBSEQUENT EVENT (Details) Details http://questdiagnostics.com/role/SUBSEQUENTEVENT 44 false false All Reports Book All Reports dgx-20210331.htm dgx-20210331.xsd dgx-20210331_cal.xml dgx-20210331_def.xml dgx-20210331_lab.xml dgx-20210331_pre.xml dgx03312021ex101.htm dgx03312021ex311.htm dgx03312021ex312.htm dgx03312021ex321.htm dgx03312021ex322.htm http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dgx-20210331.htm": { "axisCustom": 0, "axisStandard": 21, "contextCount": 148, "dts": { "calculationLink": { "local": [ "dgx-20210331_cal.xml" ] }, "definitionLink": { "local": [ "dgx-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "dgx-20210331.htm" ] }, "labelLink": { "local": [ "dgx-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "dgx-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "dgx-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 377, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 11, "keyStandard": 280, "memberCustom": 19, "memberStandard": 31, "nsprefix": "dgx", "nsuri": "http://questdiagnostics.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://questdiagnostics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - EARNINGS PER SHARE", "role": "http://questdiagnostics.com/role/EARNINGSPERSHARE", "shortName": "EARNINGS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107104 - Disclosure - BUSINESS ACQUISITIONS", "role": "http://questdiagnostics.com/role/BUSINESSACQUISITIONS", "shortName": "BUSINESS ACQUISITIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108105 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112106 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "role": "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116107 - Disclosure - FINANCIAL INSTRUMENTS", "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121108 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "role": "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST", "shortName": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123109 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA", "role": "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATA", "shortName": "SUPPLEMENTAL CASH FLOW & OTHER DATA", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126110 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128111 - Disclosure - BUSINESS SEGMENT INFORMATION", "role": "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION", "shortName": "BUSINESS SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131112 - Disclosure - RELATED PARTIES", "role": "http://questdiagnostics.com/role/RELATEDPARTIES", "shortName": "RELATED PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133113 - Disclosure - REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES", "role": "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSES", "shortName": "REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136114 - Disclosure - SUBSEQUENT EVENT", "role": "http://questdiagnostics.com/role/SUBSEQUENTEVENT", "shortName": "SUBSEQUENT EVENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - EARNINGS PER SHARE (Tables)", "role": "http://questdiagnostics.com/role/EARNINGSPERSHARETables", "shortName": "EARNINGS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "role": "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dgx:ScheduleofDebtInstrumentFairValueBasisAdjustmentAttributabletoHedgedDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317304 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dgx:ScheduleofDebtInstrumentFairValueBasisAdjustmentAttributabletoHedgedDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324305 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables)", "role": "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATATables", "shortName": "SUPPLEMENTAL CASH FLOW & OTHER DATA (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329306 - Disclosure - BUSINESS SEGMENT INFORMATION (Tables)", "role": "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables", "shortName": "BUSINESS SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334307 - Disclosure - REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Tables)", "role": "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESTables", "shortName": "REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - EARNINGS PER SHARE (Details)", "role": "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails", "shortName": "EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i0ed43c43b5ff493e9231f461d2f7f59b_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details)", "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails", "shortName": "FAIR VALUE MEASUREMENTS (Recognized Assets and Liabilities at Fair Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i0ed43c43b5ff493e9231f461d2f7f59b_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - FAIR VALUE MEASUREMENTS (Narrative) (Details)", "role": "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "shortName": "FAIR VALUE MEASUREMENTS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i71eadae108864617a48c288ee03da704_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414404 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Goodwill) (Details)", "role": "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Goodwill) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i9adbe4d9a49f4d73b4e4e499c1602647_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Schedules) (Details)", "role": "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Schedules) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418406 - Disclosure - FINANCIAL INSTRUMENTS (Narrative) (Details)", "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "shortName": "FINANCIAL INSTRUMENTS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i823a17c2df114f629409d133576bca9e_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419407 - Disclosure - FINANCIAL INSTRUMENTS (Balance Sheets) (Details)", "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "shortName": "FINANCIAL INSTRUMENTS (Balance Sheets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i823a17c2df114f629409d133576bca9e_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420408 - Disclosure - FINANCIAL INSTRUMENTS (Income Statement) (Details)", "role": "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails", "shortName": "FINANCIAL INSTRUMENTS (Income Statement) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i4276aed117b24b4684c477c58a926e2f_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422409 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details)", "role": "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails", "shortName": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425410 - Disclosure - SUPPLEMENTAL CASH FLOW & OTHER DATA (Details)", "role": "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails", "shortName": "SUPPLEMENTAL CASH FLOW & OTHER DATA (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MalpracticeLossContingencyAccrualUndiscounted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427411 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:MalpracticeLossContingencyAccrualUndiscounted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "dgx:PercentageofNetRevenues", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430412 - Disclosure - BUSINESS SEGMENT INFORMATION (Details)", "role": "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "shortName": "BUSINESS SEGMENT INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie9e62f1f9ce94456b1cd2a528dd83efc_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i5cdb593684214c31b69e5e0f14a1dd79_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432413 - Disclosure - RELATED PARTIES (Details)", "role": "http://questdiagnostics.com/role/RELATEDPARTIESDetails", "shortName": "RELATED PARTIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i5cdb593684214c31b69e5e0f14a1dd79_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "dgx:PercentageofNetRevenues", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435414 - Disclosure - REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Details)", "role": "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails", "shortName": "REVENUE RECOGNITION AND ALLOWANCE FOR CREDIT LOSSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "INF", "lang": "en-US", "name": "dgx:PercentageofNetAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ic411e7e9465f4d0ca07e2fc70dfc9403_D20210401-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437415 - Disclosure - SUBSEQUENT EVENT (Details)", "role": "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails", "shortName": "SUBSEQUENT EVENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ic411e7e9465f4d0ca07e2fc70dfc9403_D20210401-20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie648c1d0f7124826ab1f231505fef1e4_I20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetCreditLossExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie4f49c664e464e75a6577f2c5dbd5d00_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "ie4f49c664e464e75a6577f2c5dbd5d00_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS", "role": "http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dgx-20210331.htm", "contextRef": "i8dbed4e81ed14963b472f052115ee891_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 50, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dgx_AccountsReceivableDisaggregationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable Disaggregation [Table Text Block]", "label": "Accounts Receivable Disaggregation [Table Text Block]", "terseLabel": "Accounts Receivable Disaggregation" } } }, "localname": "AccountsReceivableDisaggregationTableTextBlock", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESTables" ], "xbrltype": "textBlockItemType" }, "dgx_AllotherservicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All other services [Member]", "label": "All other services [Member]", "terseLabel": "All other services" } } }, "localname": "AllotherservicesMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "dgx_AnatomicpathologytestingservicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anatomic pathology testing services [Member]", "label": "Anatomic pathology testing services [Member]", "terseLabel": "Anatomic pathology testing services" } } }, "localname": "AnatomicpathologytestingservicesMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "dgx_COVID19TestingServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19 Testing Services", "label": "COVID-19 Testing Services [Member]", "terseLabel": "COVID-19 Testing Services" } } }, "localname": "COVID19TestingServicesMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "dgx_CapitatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitated [Member]", "label": "Capitated [Member]", "terseLabel": "Capitated" } } }, "localname": "CapitatedMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "dgx_ClientPayersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Client Payers [Member]", "label": "Client Payers [Member]", "terseLabel": "Client Payers" } } }, "localname": "ClientPayersMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "dgx_DSBusinessesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DS Businesses [Member]", "label": "DS Businesses [Member]", "terseLabel": "DS Businesses" } } }, "localname": "DSBusinessesMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "dgx_DescriptionOfBusinessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of Business (Abstract)", "label": "Description of Business (Abstract)", "terseLabel": "Description of Business (Abstract)" } } }, "localname": "DescriptionOfBusinessAbstract", "nsuri": "http://questdiagnostics.com/20210331", "xbrltype": "stringItemType" }, "dgx_DiagnosticInformationServicesBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostic Information Services Business [Member]", "label": "Diagnostic Information Services Business [Member]", "terseLabel": "DIS business" } } }, "localname": "DiagnosticInformationServicesBusinessMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "dgx_EquityMethodInvestmentOwnershipPercentDisposedOf": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment, Ownership Percent Disposed Of", "label": "Equity Method Investment, Ownership Percent Disposed Of", "terseLabel": "Percent of ownership interest sold" } } }, "localname": "EquityMethodInvestmentOwnershipPercentDisposedOf", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "percentItemType" }, "dgx_ExcludesgeneralandprofessionalliabilityclaimsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Excludes general and professional liability claims [Member]", "label": "Excludes general and professional liability claims [Member]", "terseLabel": "Excludes general and professional liability claims" } } }, "localname": "ExcludesgeneralandprofessionalliabilityclaimsMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "dgx_FairValueOfNetAssetsAcquired": { "auth_ref": [], "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of net assets acquired", "label": "Fair value of net assets acquired", "totalLabel": "Fair value of net assets acquired" } } }, "localname": "FairValueOfNetAssetsAcquired", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "dgx_FeeforserviceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fee-for-service [Member]", "label": "Fee-for-service [Member]", "terseLabel": "Fee-for-service" } } }, "localname": "FeeforserviceMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finite-Lived and Indefinite-lived Intangible Assets [Line Items]", "label": "Finite-Lived and Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived and Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "stringItemType" }, "dgx_FiniteLivedAndIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finite-Lived and Indefinite-lived Intangible Assets [Table]", "label": "Finite-Lived and Indefinite-lived Intangible Assets [Table]", "terseLabel": "Finite-Lived and Indefinite-lived Intangible Assets [Table]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "stringItemType" }, "dgx_GenebasedandesoterictestingservicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gene-based and esoteric testing services [Member]", "label": "Gene-based and esoteric testing services [Member]", "terseLabel": "Gene-based and esoteric testing services" } } }, "localname": "GenebasedandesoterictestingservicesMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "dgx_GovernmentPayersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government Payers [Member]", "label": "Government Payers [Member]", "terseLabel": "Government Payers" } } }, "localname": "GovernmentPayersMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "dgx_HealthcareInsurersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare Insurers [Member]", "label": "Healthcare Insurers [Member]", "terseLabel": "Healthcare Insurers" } } }, "localname": "HealthcareInsurersMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "dgx_MidAmericaClinicalLaboratoriesLLCMACLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mid America Clinical Laboratories, LLC (MACL)", "label": "Mid America Clinical Laboratories, LLC (MACL) [Member]", "terseLabel": "MACL" } } }, "localname": "MidAmericaClinicalLaboratoriesLLCMACLMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "domainItemType" }, "dgx_NetIncomeLossExcludingRedeemableNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Income (Loss), Excluding Redeemable Noncontrolling Interest", "label": "Net Income (Loss), Excluding Redeemable Noncontrolling Interest", "terseLabel": "Net income" } } }, "localname": "NetIncomeLossExcludingRedeemableNoncontrollingInterest", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "dgx_OtherAccountsReceivableRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Accounts Receivable, Related Parties", "label": "Other Accounts Receivable, Related Parties", "terseLabel": "Other accounts receivable, related parties" } } }, "localname": "OtherAccountsReceivableRelatedParties", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "monetaryItemType" }, "dgx_PatientsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patients [Member]", "label": "Patients [Member]", "terseLabel": "Patients" } } }, "localname": "PatientsMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "dgx_PercentageofNetAccountsReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Net Accounts Receivable", "label": "Percentage of Net Accounts Receivable", "terseLabel": "Net accounts receivable" } } }, "localname": "PercentageofNetAccountsReceivable", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "percentItemType" }, "dgx_PercentageofNetRevenues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Net Revenues", "label": "Percentage of Net Revenues", "terseLabel": "Percentage of net revenues" } } }, "localname": "PercentageofNetRevenues", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "percentItemType" }, "dgx_Q2SolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Q2 Solutions", "label": "Q2 Solutions [Member]", "terseLabel": "Q2 Solutions" } } }, "localname": "Q2SolutionsMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "domainItemType" }, "dgx_RoutineclinicaltestingservicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Routine clinical testing services", "label": "Routine clinical testing services [Member]", "terseLabel": "Routine clinical testing services" } } }, "localname": "RoutineclinicaltestingservicesMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "dgx_ScheduleOfRevenuesByMajorServiceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Revenues by Major Service", "label": "Schedule of Revenues by Major Service [Table Text Block]", "terseLabel": "Schedule of Revenues by Major Service" } } }, "localname": "ScheduleOfRevenuesByMajorServiceTableTextBlock", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "dgx_ScheduleofDebtInstrumentFairValueBasisAdjustmentAttributabletoHedgedDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt [Table Text Block]", "label": "Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt [Table Text Block]", "terseLabel": "Schedule of Debt Instrument Fair Value Basis Adjustment Attributable to Hedged Debt" } } }, "localname": "ScheduleofDebtInstrumentFairValueBasisAdjustmentAttributabletoHedgedDebtTableTextBlock", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "dgx_ScheduleofStockholdersEquityandRedeemableNoncontrollingInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table]", "label": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]", "terseLabel": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Line Items]" } } }, "localname": "ScheduleofStockholdersEquityandRedeemableNoncontrollingInterestLineItems", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "stringItemType" }, "dgx_ScheduleofStockholdersEquityandRedeemableNoncontrollingInterestTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table]", "label": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table]", "terseLabel": "Schedule of Stockholders' Equity and Redeemable Noncontrolling Interest [Table]" } } }, "localname": "ScheduleofStockholdersEquityandRedeemableNoncontrollingInterestTable", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "stringItemType" }, "dgx_SeniorunsecuredrevolvingcreditfacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior unsecured revolving credit facility [Member]", "label": "Senior unsecured revolving credit facility [Member]", "terseLabel": "Senior Unsecured Revolving Credit Facility" } } }, "localname": "SeniorunsecuredrevolvingcreditfacilityMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "dgx_StockRepurchaseProgramAdditionalAmountAuthorized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Repurchase Program, Additional Amount Authorized", "label": "Stock Repurchase Program, Additional Amount Authorized", "terseLabel": "Additional amount authorized" } } }, "localname": "StockRepurchaseProgramAdditionalAmountAuthorized", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "monetaryItemType" }, "dgx_TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders", "label": "Temporary equity, Noncontrolling interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distributions to noncontrolling interest partners" } } }, "localname": "TemporaryequityNoncontrollinginterestDecreasefromDistributionstoNoncontrollingInterestHolders", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "dgx_TotalAmortizingIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Amortizing Intangible Assets [Member]", "label": "Total Amortizing Intangible Assets [Member]", "terseLabel": "Total Amortizing Intangible Assets" } } }, "localname": "TotalAmortizingIntangibleAssetsMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "domainItemType" }, "dgx_UMassJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UMass Joint Venture [Member]", "label": "UMass Joint Venture [Member]", "terseLabel": "UMass Joint Venture" } } }, "localname": "UMassJointVentureMember", "nsuri": "http://questdiagnostics.com/20210331", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r275", "r278", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r454", "r456" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r178", "r260", "r262", "r399", "r453", "r455" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r178", "r260", "r262", "r399", "r453", "r455" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r264", "r275", "r278", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r454", "r456" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r264", "r275", "r278", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r454", "r456" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Scenario, Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r225", "r276", "r387" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r104", "r380", "r420", "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts Payable, Related Parties", "terseLabel": "Accounts payable, related parties" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r15", "r183", "r184" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for credit losses of $29 and $28 as of March 31, 2021 and December 31, 2020, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedParties": { "auth_ref": [ "r14", "r100", "r380", "r382", "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.", "label": "Accounts Receivable, Related Parties", "terseLabel": "Receivables" } } }, "localname": "AccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r18", "r44", "r45", "r46", "r437", "r461", "r462" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r43", "r46", "r47", "r108", "r109", "r110", "r318", "r457", "r458" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r108", "r109", "r110", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Shares to cover employee payroll tax withholdings on stock issued under stock-based compensation plans" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r279", "r280", "r289", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r148", "r165", "r166", "r167", "r168", "r170" ], "lang": { "en-us": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All other operating segments" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r22", "r185", "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r87", "r203", "r210" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "order": 2.0, "parentTag": "us-gaap_DepreciationDepletionAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails", "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Stock options and performance share units" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r98", "r160", "r167", "r174", "r192", "r313", "r319", "r358", "r415", "r435" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r39", "r98", "r192", "r313", "r319", "r358" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r346" ], "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r187", "r188", "r196", "r419" ], "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "verboseLabel": "Available-for-sale debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r331", "r334" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r274", "r277" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r274", "r277", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "BUSINESS ACQUISITIONS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSACQUISITIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r91", "r92", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accounts payable associated with capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "verboseLabel": "Less: Cash acquired" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r25", "r89" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]", "terseLabel": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r83", "r89", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r83", "r359" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Net amount of deferred gains and losses on cash flow hedges that is expected to be reclassified within the next 12 months" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "SUPPLEMENTAL CASH FLOW & OTHER DATA" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATA" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashSurrenderValueFairValueDisclosure": { "auth_ref": [], "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of the amount that could be realized under a life insurance contract or contracts owned by the entity, commonly known as corporate-owned life insurance (COLI) or bank-owned life insurance (BOLI).", "label": "Cash Surrender Value, Fair Value Disclosure", "terseLabel": "Cash surrender value of life insurance policies" } } }, "localname": "CashSurrenderValueFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "terseLabel": "Hedged items (Long-term debt)" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r33", "r224", "r421", "r443" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r221", "r222", "r223", "r232" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends per common share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r108", "r109" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r240" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2021 and December 31, 2020; 217 shares issued as of both March 31, 2021 and December 31, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r50", "r52", "r53", "r61", "r428", "r450" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to Quest Diagnostics" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r50", "r52", "r60", "r311", "r312", "r323", "r427", "r449" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Comprehensive income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r50", "r52", "r59", "r310", "r323", "r426", "r448" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetCreditLossExpense": { "auth_ref": [ "r195", "r249", "r259" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Credit Loss Expense (Reversal)", "terseLabel": "Provision for credit losses" } } }, "localname": "ContractWithCustomerAssetCreditLossExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateMember": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.", "label": "Corporate Segment [Member]", "terseLabel": "General corporate activities" } } }, "localname": "CorporateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r67", "r98", "r192", "r358" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of services" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Operating costs and expenses and other operating income:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r65" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating costs and expenses, net" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "verboseLabel": "Customer-related intangibles" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r31", "r102", "r241", "r242", "r243", "r244", "r369", "r370", "r372", "r434" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation liabilities" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r87", "r99", "r292", "r296", "r297", "r298" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income tax (benefit) provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r87", "r215" ], "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "order": 1.0, "parentTag": "us-gaap_DepreciationDepletionAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r87", "r155" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Derivatives designated as hedging instruments" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "FINANCIAL INSTRUMENTS" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r329", "r332", "r337" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r324", "r325", "r326", "r329", "r330", "r335", "r337", "r339", "r341", "r343" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r96", "r105", "r324", "r325", "r329", "r330", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r274", "r277" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r9", "r11", "r416", "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Weighted average common shares outstanding:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r62", "r113", "r114", "r115", "r116", "r117", "r121", "r123", "r129", "r130", "r131", "r135", "r136", "r429", "r451" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Basic(in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Earnings per share attributable to Quest Diagnostics\u2019 common stockholders:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r62", "r113", "r114", "r115", "r116", "r117", "r123", "r129", "r130", "r131", "r135", "r136", "r429", "r451" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r96", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r132", "r133", "r134", "r137" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r108", "r109", "r110", "r112", "r118", "r120", "r138", "r193", "r240", "r245", "r285", "r286", "r287", "r293", "r294", "r360", "r361", "r362", "r363", "r364", "r366", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvesteeMember": { "auth_ref": [ "r189", "r403", "r405", "r407", "r409", "r411", "r413" ], "lang": { "en-us": { "role": { "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.", "label": "Equity Method Investee [Member]", "terseLabel": "Equity Method Investee" } } }, "localname": "EquityMethodInvesteeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.", "label": "Equity Method Investment, Other than Temporary Impairment", "terseLabel": "Impairment of equity method investment" } } }, "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "auth_ref": [ "r63", "r64", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "terseLabel": "Gain on sale of investment, before tax" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r26", "r161", "r191" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Investments in equity method investees" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r346", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r347", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r346", "r347", "r348", "r349", "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedging" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r265", "r266", "r271", "r273", "r347", "r389" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets / Liabilities, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r265", "r266", "r271", "r273", "r347", "r390" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r347", "r391" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3", "verboseLabel": "Significant Unobservable Inputs, Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value, Measurement Inputs" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r351", "r353" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfAssetsAcquired": { "auth_ref": [ "r91", "r92", "r93" ], "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "order": 1.0, "parentTag": "dgx_FairValueOfNetAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of assets acquired in noncash investing or financing activities.", "label": "Fair Value of Assets Acquired", "terseLabel": "Fair value of assets acquired" } } }, "localname": "FairValueOfAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Weighted Average Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r209" ], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Intangible assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r211" ], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Remainder of 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r211" ], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": 7.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r211" ], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r211" ], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r211" ], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r204", "r206", "r209", "r213", "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r204", "r208" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r209", "r400" ], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r197", "r198", "r414" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Balance at end of period", "periodStartLabel": "Goodwill, Balance at beginning of period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS", "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired during the period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Adjustments to goodwill" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "terseLabel": "Hedge Accounting Basis Adjustment" } } }, "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]", "terseLabel": "Amounts attributable to Quest Diagnostics\u2019 common stockholders:" } } }, "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r103", "r160", "r166", "r170", "r173", "r176" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes and equity in earnings of equity method investees" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r56", "r87", "r157", "r191", "r423", "r445" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Equity in earnings of equity method investees, net of taxes" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r274", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails", "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails", "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r119", "r120", "r158", "r291", "r295", "r299", "r452" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r84", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r86" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r86" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r86" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r86" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Redeemable Non-controlling Interest [Abstract]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r124", "r125", "r126", "r131" ], "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Stock options and performance share units" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r205", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r205", "r212" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets Excluding Goodwill" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Intangible assets, Cost" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r202", "r207" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Total intangible assets, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS", "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDividendIncomeOperating": { "auth_ref": [ "r430" ], "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "order": 2.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.", "label": "Interest and Dividend Income, Operating", "terseLabel": "Interest income" } } }, "localname": "InterestAndDividendIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r55", "r154", "r368", "r371", "r432" ], "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "order": 1.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r431" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest expense, net", "totalLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r38" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "verboseLabel": "Leases:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding, amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r98", "r192", "r358", "r418", "r440" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAssumed1": { "auth_ref": [ "r91", "r92", "r93" ], "calculation": { "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails": { "order": 2.0, "parentTag": "dgx_FairValueOfNetAssetsAcquired", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.", "label": "Liabilities Assumed", "negatedTerseLabel": "Fair value of liabilities assumed" } } }, "localname": "LiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r30", "r98", "r192", "r314", "r319", "r320", "r358" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r33", "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Litigation reserves" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r10" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt [Member]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSBalanceSheetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r31", "r235" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Class action lawsuits" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MalpracticeLossContingencyAccrualUndiscounted": { "auth_ref": [ "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period.", "label": "Malpractice Loss Contingency, Accrual, Undiscounted", "terseLabel": "Self-insurance reserves" } } }, "localname": "MalpracticeLossContingencyAccrualUndiscounted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r37", "r98", "r192", "r358", "r417", "r439" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedLabel": "Distributions to noncontrolling interest partners" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership percentage by noncontrolling owners" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r139", "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "DESCRIPTION OF BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/DESCRIPTIONOFBUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r83", "r85", "r88" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r48", "r51", "r57", "r88", "r98", "r111", "r113", "r114", "r115", "r116", "r119", "r120", "r127", "r160", "r166", "r170", "r173", "r176", "r192", "r358", "r424", "r446" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income attributable to Quest Diagnostics", "totalLabel": "Net income attributable to Quest Diagnostics" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r48", "r51", "r119", "r120", "r316", "r322" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: Net income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r122", "r128", "r131" ], "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Earnings available to Quest Diagnostics\u2019 common stockholders \u2013 basic and diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Standards to be Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-compete agreements" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r108", "r109", "r110", "r245", "r308" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Non-operating expense, net", "totalLabel": "Total non-operating expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r160", "r166", "r170", "r173", "r176" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income", "verboseLabel": "Total operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r374" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r374" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r373" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r41", "r42", "r44" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Net change in available-for-sale debt securities, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r40" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r49", "r52", "r54", "r58", "r240", "r360", "r365", "r366", "r425", "r447" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive loss", "verboseLabel": "Other comprehensive loss, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r88" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "verboseLabel": "Other Nonoperating Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSIncomeStatementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedTerseLabel": "Other operating expense, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": { "auth_ref": [ "r128" ], "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted", "terseLabel": "Less: Earnings allocated to participating securities" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r72", "r75", "r106" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Increase in investments and other assets" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r78" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r78" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "auth_ref": [ "r78" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "negatedLabel": "Distributions to noncontrolling interest partners" } } }, "localname": "PaymentsOfDividendsMinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Employee payroll tax withholdings on stock issued under stock-based compensation plans" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r73" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Business acquisitions, net of cash acquired", "terseLabel": "Business acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r74" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r23", "r24" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDividendsReceived": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Dividends received on equity and other investments during the current period.", "label": "Proceeds from Dividends Received", "terseLabel": "Dividends received" } } }, "localname": "ProceedsFromDividendsReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r77", "r80", "r106" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r76", "r284" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r48", "r51", "r82", "r98", "r111", "r119", "r120", "r160", "r166", "r170", "r173", "r176", "r192", "r310", "r315", "r317", "r322", "r323", "r358", "r433" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r8", "r216", "r442" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "auth_ref": [ "r236", "r237", "r238", "r239" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "terseLabel": "Redeemable noncontrolling interest" } } }, "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": { "auth_ref": [ "r236", "r237", "r238", "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value", "terseLabel": "Redeemable noncontrolling interest" } } }, "localname": "RedeemableNoncontrollingInterestEquityFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r272", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "Related Party Transaction, Other Revenues from Transactions with Related Party", "terseLabel": "Income from related party recognized" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r272", "r379", "r382", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r377", "r378", "r380", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r79" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r245", "r288", "r438", "r460", "r462" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r108", "r109", "r110", "r112", "r118", "r120", "r193", "r285", "r286", "r287", "r293", "r294", "r457", "r459" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r151", "r152", "r165", "r171", "r172", "r178", "r179", "r181", "r258", "r260", "r399" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenues", "verboseLabel": "Total net revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r261", "r263" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE RECOGITION AND ALLOWANCE FOR CREDIT LOSSES" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSES" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r66", "r463" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenues" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "verboseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r375", "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Supplemental Cash Flow and Other Data" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUPPLEMENTALCASHFLOWOTHERDATATables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/EARNINGSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of Fair Value Hedge Accounting on the Statement of Operations" } } }, "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FINANCIALINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r200", "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Changes in Goodwill, Net" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r101", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r160", "r163", "r169", "r200" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r160", "r163", "r169", "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Summary of Segment Reporting Information by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Future Amortization Expense Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Receivables Credit Facility" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r148", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r165", "r166", "r167", "r168", "r170", "r171", "r172", "r173", "r174", "r176", "r181", "r453" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r148", "r149", "r150", "r160", "r164", "r170", "r174", "r175", "r176", "r177", "r178", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "BUSINESS SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/RELATEDPARTIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r86" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r148", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r165", "r166", "r167", "r168", "r170", "r171", "r172", "r173", "r174", "r176", "r181", "r200", "r218", "r219", "r220", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/BUSINESSSEGMENTINFORMATIONDetails", "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r36", "r108", "r109", "r110", "r112", "r118", "r120", "r138", "r193", "r240", "r245", "r285", "r286", "r287", "r293", "r294", "r360", "r361", "r362", "r363", "r364", "r366", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r108", "r109", "r110", "r138", "r399" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r240", "r245", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "auth_ref": [ "r13", "r240", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Shares, Treasury Stock Reissued", "terseLabel": "Reissuance of shares for employee benefit plan" } } }, "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r12", "r13", "r245", "r281", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under benefit plans" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r36", "r240", "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Share repurchase authorization remaining available" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r19", "r20", "r98", "r186", "r192", "r358" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Quest Diagnostics stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Quest Diagnostics stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r98", "r108", "r109", "r110", "r112", "r118", "r192", "r193", "r245", "r285", "r286", "r287", "r293", "r294", "r308", "r309", "r321", "r358", "r360", "r361", "r366", "r458", "r459" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance, value", "periodStartLabel": "Balance, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS", "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r97", "r245", "r248" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY AND REDEEMABLE NONCONTROLLING INTEREST" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTEREST" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/REVENUERECOGNITIONANDALLOWANCEFORCREDITLOSSESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r367", "r386" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r367", "r386" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r367", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r367", "r386" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://questdiagnostics.com/role/SUBSEQUENTEVENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r385", "r388" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUBSEQUENTEVENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "auth_ref": [ "r34", "r98", "r192", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "periodEndLabel": "Balance, Value", "periodStartLabel": "Balance, Value" } } }, "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "terseLabel": "Net income" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "verboseLabel": "Intangible Assets Not Subject to Amortization - Tradenames" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r422" ], "calculation": { "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Trading securities" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/FAIRVALUEMEASUREMENTSRecognizedAssetsandLiabilitiesatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r35", "r246" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock, at Cost" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r35", "r246" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r13", "r240", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Purchases of treasury stock, shares", "terseLabel": "Purchases of treasury stock- shares" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r35", "r246", "r247" ], "calculation": { "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 86 and 84 shares as of March 31, 2021 and December 31, 2020, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r240", "r245", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Purchases of treasury stock", "terseLabel": "Purchases of treasury stock, value" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://questdiagnostics.com/role/STOCKHOLDERSEQUITYANDREDEEMABLENONCONTROLLINGINTERESTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Costs of contractual or legal rights meeting the criteria for capitalization as intangible assets apart from goodwill, which have indefinite life and that are not otherwise specified in the taxonomy.", "label": "Unclassified Indefinite-lived Intangible Assets [Member]", "terseLabel": "Intangible Assets Not Subject to Amortization - Other" } } }, "localname": "UnclassifiedIndefinitelivedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnpatentedTechnologyMember": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Technology-based innovations or scientific advances that have not been patented.", "label": "Unpatented Technology [Member]", "terseLabel": "Technology" } } }, "localname": "UnpatentedTechnologyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/GOODWILLANDINTANGIBLEASSETSSchedulesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r140", "r141", "r142", "r143", "r144", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use Of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r122", "r131" ], "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in Shares)", "totalLabel": "Weighted average common shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r121", "r131" ], "calculation": { "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in Shares)", "verboseLabel": "Weighted average common shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://questdiagnostics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://questdiagnostics.com/role/EARNINGSPERSHAREDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=121548190&loc=d3e32787-111569" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r384": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r388": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.1-5)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r464": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r466": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r467": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r468": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r469": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 63 0001022079-21-000070-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001022079-21-000070-xbrl.zip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Ŋ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end